0000950170-23-058838.txt : 20231103 0000950170-23-058838.hdr.sgml : 20231103 20231103161534 ACCESSION NUMBER: 0000950170-23-058838 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231103 DATE AS OF CHANGE: 20231103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 231376523 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 10-Q 1 cue-20230930.htm 10-Q 10-Q
false--12-310001645460Q3http://fasb.org/us-gaap/2023#LicenseMemberhttp://fasb.org/us-gaap/2023#LicenseMemberhttp://fasb.org/us-gaap/2023#CostsAndExpenseshttp://fasb.org/us-gaap/2023#CostsAndExpenseshttp://fasb.org/us-gaap/2023#LicenseMemberhttp://fasb.org/us-gaap/2023#LicenseMember0001645460us-gaap:CommonStockMember2022-01-012022-09-300001645460us-gaap:StockOptionMember2023-07-012023-09-300001645460us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001645460cue:SiliconValleyBankMembercue:TermLoanAgreementMember2023-09-300001645460cue:OnoCollaborationAndOptionAgreementMember2023-02-220001645460us-gaap:RetainedEarningsMember2023-01-012023-09-3000016454602023-01-012023-09-300001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2021-11-232021-11-230001645460us-gaap:AdditionalPaidInCapitalMember2023-06-300001645460us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001645460us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001645460cue:ComputerAndOfficeEquipmentMember2023-09-300001645460us-gaap:RetainedEarningsMember2021-12-310001645460cue:OnoCollaborationAndOptionAgreementMember2023-01-012023-09-300001645460cue:WarrantTrancheTwoMember2023-09-300001645460cue:WarrantTrancheOneMember2022-06-150001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2023-01-012023-09-300001645460cue:EinsteinMembercue:EinsteinLicenseAndServiceAgreementMember2019-06-012019-06-300001645460cue:TwentyOneErieLaboratoryAndOfficeLeaseMember2023-07-012023-09-300001645460cue:WarrantIssuedNovemberSixteenTwoThousandTwentyTwoMember2022-12-310001645460srt:MaximumMembercue:OnoCollaborationAndOptionAgreementMember2023-09-300001645460us-gaap:EquipmentMemberus-gaap:OtherIncomeMember2023-01-012023-09-300001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2018-11-060001645460srt:MinimumMember2022-01-012022-09-300001645460us-gaap:CommonStockMember2023-09-300001645460us-gaap:StockOptionMember2022-01-012022-09-300001645460us-gaap:EquipmentMember2023-01-012023-09-300001645460cue:OperatingLeaseAgreementMember2022-12-310001645460us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001645460us-gaap:AdditionalPaidInCapitalMember2023-09-300001645460us-gaap:RetainedEarningsMember2023-06-300001645460cue:AdditionalLaboratoryLeaseFourthAmendmentMember2022-01-012022-03-310001645460cue:OnoCollaborationAndOptionAgreementMember2023-07-012023-09-300001645460cue:TransactionExpenseMembercue:Agreement2Member2021-10-012023-09-300001645460cue:WarrantTrancheOneMember2023-09-300001645460us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-3000016454602021-12-310001645460us-gaap:AccountingStandardsUpdate201602Member2022-12-310001645460us-gaap:CommonStockMember2021-12-310001645460us-gaap:ComputerEquipmentMember2022-12-310001645460us-gaap:FairValueMeasurementsRecurringMember2022-12-310001645460us-gaap:ComputerEquipmentMember2023-09-300001645460cue:SiliconValleyBankMembersrt:MaximumMembercue:TermLoanAgreementMember2023-09-300001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2022-07-012022-09-300001645460us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001645460us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001645460cue:LicenseAgreementForPatentRightsMember2022-07-012022-09-300001645460cue:TransactionExpenseMembercue:JefferiesLlcMember2023-09-300001645460us-gaap:StockOptionMember2022-07-012022-09-300001645460us-gaap:AccountingStandardsUpdate201602Member2023-09-300001645460us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001645460us-gaap:AdditionalPaidInCapitalMember2022-09-300001645460cue:TwentyOneErieLaboratoryAndOfficeLeaseMember2023-01-012023-09-300001645460srt:MaximumMembercue:JefferiesLlcMember2023-01-012023-09-300001645460us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001645460cue:SiliconValleyBankMembercue:TermLoanAgreementMember2023-01-012023-09-300001645460cue:LicenseAgreementForPatentRightsMember2023-01-012023-09-300001645460srt:MaximumMembercue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2018-11-060001645460us-gaap:RetainedEarningsMember2022-07-012022-09-300001645460cue:LicenseAgreementForPatentRightsMember2022-01-012022-09-3000016454602023-07-012023-09-300001645460us-gaap:CertificatesOfDepositMember2023-09-300001645460cue:PreFundedWarrantsMember2022-11-160001645460us-gaap:CommonStockMember2023-01-012023-09-300001645460stpr:MA2022-03-280001645460us-gaap:RetainedEarningsMember2022-09-3000016454602022-09-300001645460srt:MaximumMember2022-01-012022-09-3000016454602022-01-012022-09-300001645460us-gaap:CommonStockMember2023-07-012023-09-300001645460us-gaap:EquipmentMember2022-12-310001645460us-gaap:EquipmentMember2023-09-300001645460us-gaap:RestrictedStockUnitsRSUMember2019-10-030001645460us-gaap:AdditionalPaidInCapitalMember2022-12-310001645460cue:WarrantTrancheTwoMember2017-12-270001645460us-gaap:TrademarksMember2023-01-012023-09-300001645460cue:EinsteinMembercue:EinsteinLicenseAndServiceAgreementMember2018-01-012018-12-310001645460us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001645460us-gaap:EquipmentMember2022-09-300001645460us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001645460us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001645460us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001645460us-gaap:TrademarksMember2022-07-012022-09-300001645460us-gaap:CommonStockMember2022-06-300001645460us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001645460srt:MaximumMember2023-01-012023-09-300001645460us-gaap:CommonStockMember2022-09-3000016454602021-11-232021-11-230001645460us-gaap:WarrantMember2023-01-012023-09-300001645460cue:FortyGOfficeAndAdditionalLaboratoryMember2023-09-300001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001645460cue:PreFundedWarrantsMember2022-11-162022-11-160001645460cue:WarrantTrancheThreeMember2023-01-012023-09-300001645460us-gaap:LeaseholdImprovementsMember2022-12-310001645460us-gaap:TrademarksMember2023-07-012023-09-300001645460us-gaap:FurnitureAndFixturesMember2023-09-300001645460us-gaap:StockOptionMember2023-01-012023-09-3000016454602022-01-012022-12-310001645460us-gaap:CommonStockMember2022-12-310001645460cue:PreFundedWarrantsMember2022-01-012022-12-310001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001645460cue:SiliconValleyBankMember2024-02-152024-02-150001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2019-05-162019-05-160001645460us-gaap:RestrictedStockUnitsRSUMembercue:March2020AwardedAndGrantedMember2020-03-012020-03-310001645460cue:AlbertEinsteinCollegeOfMedicineMembercue:EinsteinLicenseAndServiceAgreementMember2023-01-012023-09-300001645460cue:OnoCollaborationAndOptionAgreementMember2022-07-012022-09-300001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2020-12-072020-12-070001645460cue:CommonStockOptionsMember2023-01-012023-09-300001645460us-gaap:FurnitureAndFixturesMember2022-12-310001645460us-gaap:RetainedEarningsMember2022-12-310001645460cue:TransactionExpenseMembercue:JefferiesLlcMember2023-07-012023-09-3000016454602023-09-300001645460us-gaap:LicenseAgreementTermsMember2023-09-300001645460us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-3000016454602023-06-300001645460cue:OperatingLeaseAgreementMember2023-09-300001645460us-gaap:LeaseholdImprovementsMember2023-09-300001645460cue:EinsteinMembercue:EinsteinLicenseAndServiceAgreementMember2023-01-012023-09-3000016454602022-12-310001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2023-07-012023-09-300001645460cue:TransactionExpenseMembercue:Agreement2Member2023-01-012023-09-3000016454602023-11-010001645460cue:TransactionExpenseMembercue:Agreement2Member2023-07-012023-09-300001645460cue:FortyGOfficeAndAdditionalLaboratoryMember2022-12-310001645460cue:EinsteinMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2023-09-300001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001645460us-gaap:CommonStockMember2023-06-300001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001645460cue:EinsteinMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2022-12-310001645460us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001645460cue:February2020AwardedAndGrantedMemberus-gaap:RestrictedStockUnitsRSUMember2020-02-052020-02-050001645460us-gaap:RetainedEarningsMember2023-09-300001645460cue:FirstAmendmentMemberus-gaap:LicenseAgreementTermsMember2023-09-300001645460us-gaap:USTreasurySecuritiesMember2022-12-310001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001645460cue:LGChemLifeSciencesMembercue:CollaborationAgreementWithLGChemLifeSciencesMember2022-01-012022-09-300001645460cue:LicenseAgreementForPatentRightsMember2015-12-310001645460srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2023-09-3000016454602020-12-072020-12-070001645460cue:BostonMembercue:OperatingLeaseAgreementForAdditionalLaboratorySpaceMember2022-05-310001645460us-gaap:AdditionalPaidInCapitalMember2022-06-300001645460cue:SiliconValleyBankMember2025-02-152025-02-150001645460srt:MinimumMember2023-01-012023-09-300001645460us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001645460us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001645460us-gaap:FairValueMeasurementsRecurringMember2023-09-300001645460cue:EinsteinMembercue:EinsteinLicenseAndServiceAgreementMember2020-12-012020-12-310001645460us-gaap:RestrictedStockUnitsRSUMember2020-08-210001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001645460cue:SiliconValleyBankMember2022-02-152022-02-150001645460us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001645460cue:SiliconValleyBankMembercue:TrancheALoanMember2023-01-012023-09-300001645460cue:WarrantIssuedNovemberSixteenTwoThousandTwentyTwoMember2023-09-300001645460us-gaap:RetainedEarningsMember2022-01-012022-09-300001645460cue:BostonMembercue:OperatingLeaseAgreementForAdditionalLaboratorySpaceMember2023-09-300001645460us-gaap:EquipmentMember2022-01-012022-09-300001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001645460us-gaap:LicenseAgreementTermsMember2022-03-280001645460cue:WarrantIssuedNovemberSixteenTwoThousandTwentyTwoMember2023-01-012023-09-300001645460us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001645460us-gaap:EquipmentMemberus-gaap:OtherIncomeMember2022-01-012022-09-300001645460cue:OnoCollaborationAndOptionAgreementMember2023-09-300001645460cue:LabSpaceLeaseMember2023-01-012023-09-300001645460cue:TransactionExpenseMember2023-01-012023-09-300001645460cue:WarrantTrancheOneMember2015-06-150001645460cue:LicenseAgreementForPatentRightsMember2023-07-012023-09-300001645460srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2023-09-300001645460us-gaap:RetainedEarningsMember2023-07-012023-09-300001645460us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001645460cue:SiliconValleyBankMembercue:TermLoanAgreementMember2022-02-150001645460cue:PreFundedWarrantsMember2023-01-012023-09-300001645460us-gaap:CertificatesOfDepositMember2022-12-310001645460cue:LaboratoryEquipmentMember2023-09-3000016454602022-06-3000016454602019-05-162019-05-160001645460us-gaap:TrademarksMember2022-01-012022-09-300001645460cue:OnoCollaborationAndOptionAgreementMember2022-01-012022-09-300001645460us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001645460us-gaap:RetainedEarningsMember2022-06-300001645460us-gaap:CommonStockMember2022-07-012022-09-300001645460us-gaap:AdditionalPaidInCapitalMember2021-12-310001645460cue:SiliconValleyBankMembersrt:MinimumMembercue:TermLoanAgreementMember2023-01-012023-09-300001645460us-gaap:RestrictedStockUnitsRSUMember2019-10-022019-10-030001645460cue:WarrantTrancheTwoMember2022-12-260001645460cue:LabSpaceLeaseMember2023-09-300001645460us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001645460cue:CommonStockOptionsMember2022-01-012022-09-300001645460us-gaap:WarrantMember2022-01-012022-09-3000016454602022-07-012022-09-300001645460us-gaap:LicenseAgreementTermsMember2022-05-03cue:Tranchexbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USDcue:SupportingTechnology

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-38327

 

Cue Biopharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

47-3324577

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

40 Guest Street

Boston, Massachusetts

 

 

02135

(Address of principal executive offices)

 

(Zip Code)

 

(617) 949-2680

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

CUE

Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

 

 

 

 

 

 

 

Non-accelerated filer

 

Smaller reporting company

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

As of November 1, 2023, the registrant had 45,123,281 shares of Common Stock ($0.001 par value per share) outstanding.

 

 

 


 

CUE BIOPHARMA, INC.

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION

 

 

Item 1. Financial Statements

6

 

Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022

6

 

Consolidated Statements of Operations and Other Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 (Unaudited)

7

 

Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022 (Unaudited)

8

 

Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2023 and 2022 (Unaudited)

9

 

Notes to the Consolidated Financial Statements

10

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

43

 

Item 4. Controls and Procedures

43

PART II. OTHER INFORMATION

 

 

Item 1. Legal Proceedings

44

 

Item 1A. Risk Factors

44

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

44

 

Item 3. Defaults Upon Senior Securities

44

 

Item 4. Mine Safety Disclosures

44

 

Item 5. Other Information

44

 

Item 6. Exhibits

45

 

2


 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

the initiation, timing, progress and results of our ongoing and planned preclinical studies and clinical trials and our research and development programs;

 

our estimates regarding expenses, future revenue, capital requirements and need for additional financing;

 

our expectations regarding our ability to fund our projected operating requirements with our existing cash resources and the period in which we expect that such cash resources will enable us to fund such operating requirements;

 

our plans to develop our drug product candidates;

 

the timing of and our ability to submit applications for, and to obtain and maintain regulatory approvals for, our drug product candidates;

 

the potential advantages of our drug product candidates;

 

the rate and degree of market acceptance and clinical utility of our drug product candidates, if approved;

 

our estimates regarding the potential market opportunity for our drug product candidates;

 

our commercialization, marketing and manufacturing capabilities and strategy;

 

our intellectual property position;

 

our ability to identify additional products, drug product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;

 

the impact of government laws and regulations;

 

our competitive position;

 

developments relating to our competitors and our industry; and

 

our ability to maintain and establish collaborations or obtain additional funding.

 

3


 

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include the factors discussed below under the heading “Risk Factor Summary,” and the risk factors detailed further in Item 1A., “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2022.

This report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates. All of the market data used in this report involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our drug product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

Any forward-looking statement made by us in this Quarterly Report on Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

RISK FACTOR SUMMARY

Investment in our securities involves risk. You should carefully consider the following summary of what we believe to be the principal risks facing our business, in addition to the risks described more fully in Item 1A, “Risk Factors” of Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 21, 2023 and other information included in this report. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.

If any of the following risks occurs, our business, financial condition and results of operations and future growth prospects could be materially and adversely affected, and the actual outcomes of matters as to which forward-looking statements are made in this report could be materially different from those anticipated in such forward-looking statements.

We are a clinical-stage biopharmaceutical company, have no history of generating commercial revenue, have a history of operating losses, and we may never achieve or maintain profitability.
We currently do not have, and may never develop, any FDA-approved or commercialized products.
We are substantially dependent on the success of our drug product candidates, only two of which are currently being tested in a clinical trial, and significant additional research and development and clinical testing will be required before we can potentially seek regulatory approval for or commercialize any of our drug product candidates.
We have limited experience in conducting clinical trials and no history of commercializing biologic products, which may make it difficult to evaluate the prospects for our future viability.
We plan to seek collaborations or strategic alliances. However, we may not be able to establish such relationships, and relationships we have established may not provide the expected benefits.
Our collaboration agreement with LG Chem contains exclusivity provisions that restrict our research and development activities.
We may not be successful in our efforts to identify additional drug product candidates. Due to our limited resources and access to capital, we must prioritize the development of certain drug product candidates; these decisions may prove to be wrong and may adversely affect our business.
We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.

4


 

We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug product candidates and our business could be substantially harmed.
We rely completely on third parties to manufacture our preclinical and clinical drug supplies for our drug product candidates.
If we or our licensor is unable to protect our or its intellectual property, then our financial condition, results of operations and the value of our technology and potential products could be adversely affected.
We will be subject to stringent domestic and foreign regulation in respect of any potential products. The regulatory approval processes of the FDA and other comparable regulatory authorities outside the United States are lengthy, time-consuming and inherently unpredictable. Any unfavorable regulatory action may materially and adversely affect our future financial condition and business operations.
Even if a potential therapeutic is ultimately approved by the various regulatory authorities, it may be approved only for narrow indications which may render it commercially less viable.
Even if we receive regulatory approval of our drug product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug product candidates.
We have a loan agreement that requires us to meet certain operating covenants and places restrictions on our operating and financial flexibility.

 

5


 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Cue Biopharma, Inc.

Consolidated Balance Sheets

(in thousands, except shares and per share amounts)

 

 

September 30,
2023

 

 

December 31,
2022

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

54,691

 

 

$

51,614

 

Marketable securities

 

 

 

 

 

24,675

 

Accounts receivable

 

 

1,661

 

 

 

57

 

Prepaid expenses and other current assets

 

 

1,165

 

 

 

841

 

Total current assets

 

 

57,517

 

 

 

77,187

 

Property and equipment, net

 

 

1,064

 

 

 

1,499

 

Operating lease right-of-use

 

 

7,060

 

 

 

9,203

 

Deposits

 

 

2,977

 

 

 

3,116

 

Restricted cash

 

 

150

 

 

 

150

 

Other long-term assets

 

 

120

 

 

 

128

 

Total assets

 

$

68,888

 

 

$

91,283

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,480

 

 

$

2,731

 

Accrued expenses

 

 

5,127

 

 

 

3,554

 

Research and development contract liability, current portion

 

 

2,238

 

 

 

 

Operating lease liability, current portion

 

 

3,399

 

 

 

3,300

 

Current portion of long-term debt, net

 

 

3,963

 

 

 

1,963

 

Total current liabilities

 

 

17,207

 

 

 

11,548

 

Operating lease liability, net of current portion

 

 

3,855

 

 

 

6,017

 

Long-term debt, net

 

 

5,160

 

 

 

8,035

 

Total liabilities

 

$

26,222

 

 

$

25,600

 

Commitments and contingencies (Note 10)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and
outstanding at September 30, 2023 and December 31, 2022

 

 

 

 

 

 

Common stock, $0.001 par value; 100,000,000 shares authorized; 45,123,281 and 43,042,548 shares issued and outstanding, at September 30, 2023 and December 31, 2022, respectively

 

 

45

 

 

 

43

 

Additional paid in capital

 

 

330,376

 

 

 

316,192

 

Accumulated other comprehensive loss

 

 

 

 

 

(96

)

Accumulated deficit

 

 

(287,755

)

 

 

(250,456

)

Total stockholders’ equity

 

 

42,666

 

 

 

65,683

 

Total liabilities and stockholders’ equity

 

$

68,888

 

 

$

91,283

 

 

The accompanying notes are an integral part of these consolidated financial statements.

6


 

Cue Biopharma, Inc.

Consolidated Statements of Operations and Other Comprehensive Loss

(Unaudited)

(in thousands, except shares and per share amounts)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Collaboration revenue

 

$

2,100

 

 

$

68

 

 

$

3,669

 

 

$

1,094

 

Operating expenses (income):

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

3,645

 

 

 

3,528

 

 

 

12,071

 

 

 

12,465

 

Research and development

 

 

9,874

 

 

 

7,571

 

 

 

29,915

 

 

 

27,246

 

Gain on right-of-use asset termination

 

 

 

 

 

 

 

 

 

 

 

(258

)

Total operating expenses

 

 

13,519

 

 

 

11,099

 

 

 

41,986

 

 

 

39,453

 

Loss from operations

 

 

(11,419

)

 

 

(11,031

)

 

 

(38,317

)

 

 

(38,359

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

700

 

 

 

200

 

 

 

1,756

 

 

 

296

 

Interest expense, net

 

 

(286

)

 

 

(124

)

 

 

(738

)

 

 

(355

)

Total other (expense) income

 

 

414

 

 

 

76

 

 

 

1,018

 

 

 

(59

)

Net loss

 

$

(11,005

)

 

$

(10,955

)

 

$

(37,299

)

 

$

(38,418

)

Unrealized gain (loss) from available-for-sale securities

 

 

5

 

 

 

(92

)

 

 

96

 

 

 

(92

)

Comprehensive loss

 

$

(11,000

)

 

$

(11,047

)

 

$

(37,203

)

 

$

(38,510

)

Net loss per common share – basic and diluted

 

$

(0.24

)

 

$

(0.31

)

 

$

(0.82

)

 

$

(1.11

)

Weighted average common shares outstanding –basic and diluted

 

 

46,358,555

 

 

 

35,383,430

 

 

 

45,274,124

 

 

 

34,471,499

 

 

The accompanying notes are an integral part of these consolidated financial statements.

7


 

Cue Biopharma, Inc.

Consolidated Statements of Stockholders’ Equity

(Unaudited)

(in thousands, except shares and per share amounts)

 

Three Months Ended September 30, 2023 and 2022:

 

 

 

Common Stock

 

 

Additional

 

 

Accumulated
Other

 

 

 

 

 

Total

 

 

 

Shares

 

 

Par
Value

 

 

Paid-in
Capital

 

 

Comprehensive
Income (Loss)

 

 

Accumulated
Deficit

 

 

Stockholders’
Equity

 

Balance, June 30, 2022

 

 

35,381,743

 

 

$

35

 

 

$

284,630

 

 

$

 

 

$

(224,909

)

 

$

59,756

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,064

 

 

 

 

 

 

 

 

 

2,064

 

Restricted stock awards released

 

 

6,667

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock awards withheld at vesting to cover taxes

 

 

(2,828

)

 

 

 

 

 

(9

)

 

 

 

 

 

 

 

 

(9

)

Unrealized losses from available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

(92

)

 

 

 

 

 

(92

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,955

)

 

 

(10,955

)

Balance, September 30, 2022

 

 

35,385,582

 

 

$

35

 

 

$

286,685

 

 

$

(92

)

 

$

(235,864

)

 

$

50,764

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2023

 

 

43,744,414

 

 

$

44

 

 

$

322,715

 

 

$

(5

)

 

$

(276,750

)

 

$

46,004

 

Issuance of common stock from ATM offering, net of
   sales agent commission and fees

 

 

1,378,867

 

 

 

1

 

 

 

5,588

 

 

 

 

 

 

 

 

 

5,589

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,073

 

 

 

 

 

 

 

 

 

2,073

 

Unrealized gain from available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

5

 

 

 

 

 

 

5

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,005

)

 

 

(11,005

)

Balance, September 30, 2023

 

 

45,123,281

 

 

$

45

 

 

$

330,376

 

 

$

0

 

 

$

(287,755

)

 

$

42,666

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2023 and 2022:

 

 

 

Common Stock

 

 

Additional

 

 

Accumulated
Other

 

 

 

 

 

Total

 

 

 

Shares

 

 

Par
Value

 

 

Paid-in
Capital

 

 

Comprehensive
Income (Loss)

 

 

Accumulated
Deficit

 

 

Stockholders’
Equity

 

Balance, December 31, 2021

 

 

32,202,496

 

 

$

32

 

 

$

262,906

 

 

$

-

 

 

$

(197,446

)

 

$

65,492

 

Issuance of common stock from ATM offering, net of
   sales agent commission and fees

 

 

3,117,220

 

 

 

3

 

 

 

16,595

 

 

 

 

 

 

 

 

 

16,598

 

Stock-based compensation

 

 

 

 

 

 

 

 

7,384

 

 

 

 

 

 

 

 

 

7,384

 

Issuance of common stock upon exercise of warrants, net

 

 

9,549

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock awards released

 

 

98,335

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock awards withheld at vesting to cover taxes

 

 

(42,018

)

 

 

 

 

 

(200

)

 

 

 

 

 

 

 

 

(200

)

Unrealized losses from available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

(92

)

 

 

 

 

 

(92

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(38,418

)

 

 

(38,418

)

Balance, September 30, 2022

 

 

35,385,582

 

 

$

35

 

 

$

286,685

 

 

$

(92

)

 

$

(235,864

)

 

$

50,764

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2022

 

 

43,042,548

 

 

$

43

 

 

$

316,192

 

 

$

(96

)

 

$

(250,456

)

 

$

65,683

 

Issuance of common stock from ATM offering, net of
   sales agent commission and fees

 

 

1,915,131

 

 

 

2

 

 

 

7,603

 

 

 

 

 

 

 

 

 

7,605

 

Stock-based compensation

 

 

 

 

 

 

 

 

6,108

 

 

 

 

 

 

 

 

 

6,108

 

Exercise of stock options

 

 

165,602

 

 

 

 

 

 

473

 

 

 

 

 

 

 

 

 

473

 

Unrealized gain from available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

96

 

 

 

 

 

 

96

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(37,299

)

 

 

(37,299

)

Balance, September 30, 2023

 

 

45,123,281

 

 

$

45

 

 

$

330,376

 

 

$

-

 

 

$

(287,755

)

 

$

42,666

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

8


 

Cue Biopharma, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(37,299

)

 

$

(38,418

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

443

 

 

 

719

 

Stock-based compensation

 

 

6,108

 

 

 

7,384

 

Decrease in the carrying amount of right-of-use-assets

 

 

2,142

 

 

 

507

 

Gain on right-of-use asset termination

 

 

 

 

 

(258

)

Loss (gain) on sale of property and equipment

 

 

(2

)

 

 

4

 

Amortization of premium/discount on purchased securities

 

 

(234

)

 

 

(101

)

Amortization of debt issuance costs

 

 

28

 

 

 

21

 

Accretion of final payment on term loan

 

 

98

 

 

 

76

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(1,603

)

 

 

2,347

 

Prepaid expenses and other current assets

 

 

(324

)

 

 

(846

)

Deposits

 

 

139

 

 

 

(395

)

Accounts payable

 

 

(251

)

 

 

(546

)

Accrued expenses

 

 

1,573

 

 

 

(741

)

Research and development contract liability

 

 

2,238

 

 

 

(645

)

Operating lease liability

 

 

(2,064

)

 

 

(397

)

Accrued interest

 

 

5

 

 

 

(3

)

Net cash used in operating activities

 

 

(29,003

)

 

 

(31,292

)

Cash flows from investing activities

 

 

 

 

 

 

Purchases of property and equipment

 

 

 

 

 

(170

)

Cash received from the sale of property and equipment

 

 

2

 

 

 

6

 

Redemption of short-term investments

 

 

25,000

 

 

 

 

Purchase of short-term investments

 

 

 

 

 

(29,445

)

Net cash provided by (used in) investing activities

 

 

25,002

 

 

 

(29,609

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from ATM offering, net of sales agent
   commission and fees

 

 

7,605

 

 

 

16,598

 

Proceeds from borrowings under term loan

 

 

 

 

 

10,000

 

Payment of term loan

 

 

(1,000

)

 

 

 

Proceeds from exercise of stock options

 

 

473

 

 

 

 

Payment of debt issuance costs

 

 

 

 

 

(142

)

Restricted stock awards withheld at vesting to cover taxes

 

 

 

 

 

(200

)

Net cash provided by financing activities

 

 

7,078

 

 

 

26,256

 

Net increase (decrease) in cash, cash equivalents, and restricted cash

 

 

3,077

 

 

 

(34,645

)

Cash, cash equivalents, and restricted cash at beginning of period

 

 

51,764

 

 

 

64,521

 

Cash, cash equivalents, and restricted cash at end of period

 

$

54,841

 

 

$

29,876

 

Supplemental disclosures of non-cash investing and financing activities:

 

 

 

 

 

 

Cash paid for interest

 

$

768

 

 

$

354

 

Right-of-use asset and lease liability (new lease)

 

$

 

 

$

9,057

 

Operating lease modification

 

$

 

 

$

7,119

 

 

The accompanying notes are an integral part of these consolidated financial statements.

9


 

Cue Biopharma, Inc.

Notes to Consolidated Financial Statements (Unaudited)

For the three and nine months ended September 30, 2023 and 2022

1.
Organization and Basis of Presentation

Cue Biopharma, Inc. (the "Company") is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s corporate office and research facilities are located in Boston, Massachusetts.

The Company is in the development stage and has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2023, the Company had cash and cash equivalents of approximately $54,691,000. Management believes that current cash and cash equivalents on hand at September 30, 2023 are sufficient to fund operations for at least the next twelve months from the date of issuance of these financial statements; however, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations and to fund research and development costs in order to seek approval for commercialization of its drug product candidates. The Company’s failure to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategies as this capital is necessary for the Company to perform the research and development activities required to develop and commercialize the Company’s drug product candidates in order to generate future revenue streams.

2.
Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements as of September 30, 2023, and for the three and nine months ended September 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for financial information, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp., which was incorporated in the Commonwealth of Massachusetts in December 2018. In the opinion of management, these financial statements reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2023.

Interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future periods.

 

Public Offerings

In October 2021, the Company entered into an open market sale agreement (the “October 2021 ATM Agreement”) with Jefferies LLC ("Jefferies"), as agent, to sell shares of the Company’s common stock for aggregate gross proceeds of up to $80 million, from time to time, through an at-the-market equity offering program. The October 2021 ATM Agreement will terminate upon the earliest of (a) the sale of $80 million of shares of the Company’s common stock pursuant to the October 2021 ATM Agreement or (b) the termination of the October 2021 ATM Agreement by the Company or Jefferies. During the three months ended September 30, 2023, the Company sold 1,378,867 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $5,589,000 net of commission paid, but excluding transaction expenses. During the nine months ended September 30, 2023, the Company sold 1,915,131 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $7,605,000 net of commission paid, but excluding transaction expenses. As of September 30, 2023, the Company had sold an aggregate of 5,508,538 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $31.2 million, net of commission paid, but excluding transaction expenses, since its inception.

10


 

Consolidation

The accompanying consolidated financial statements include the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp. The Company has eliminated all intercompany transactions.

 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.

Cash Concentrations

The Company maintains its cash balances with financial institutions in federally insured accounts and may periodically have cash balances in excess of insurance limits. The Company maintains its accounts with financial institutions with a high credit rating. The Company has not experienced any losses to date from our deposits with these financial institutions and believes that it is not exposed to any significant credit risk on cash.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company currently invests available cash in money market funds.

Marketable Securities

Marketable securities consist of investments with original maturities greater than ninety days and less than one year from the balance sheet date. The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are recognized and determined on a specific identification basis and are included in other comprehensive loss. Realized gains and losses are determined on a specific identification basis and are included in other income on the consolidated statement of operations and other comprehensive loss. Amortization and accretion of discounts and premiums is recorded in interest income. The Company has invested available cash in U.S. Treasury obligations.

Restricted Cash

The Company had $150,000 in restricted cash deposited with separate commercial banks to collateralize a credit card as of September 30, 2023 and December 31, 2022.

Property and Equipment

Property and equipment is recorded at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from dispositions of property and equipment are included in income and expense when realized. Amortization of leasehold improvements is provided using the straight-line method over the shorter of the lease term or the useful life of the underlying assets. Depreciation of property and equipment is provided using the straight-line method over the following estimated useful lives:

 

Laboratory equipment

 

5 years

Computer and office equipment

 

3 years

Furniture and fixtures

 

3-8 years

 

The Company recognizes depreciation and amortization expense in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on how each category of property and equipment is utilized in the Company’s business activities.

11


 

Trademark

Trademark consists of the Company’s right, title and interest to the CUE BIOLOGICS Mark, and any derivative mark incorporating CUE, throughout the world, together with all associated goodwill and common law rights appurtenant thereto, including, but not limited to, any right, title and interest in any corporate name, company name, business, name, trade name, dba, domain name, or other source identifier incorporating CUE.

The Company has classified the trademark as a component of other long-term assets, having a useful life of 15 years. The Company evaluates the status of this intangible asset for amortization and impairment at each quarter end and year end reporting date. For each of the three and nine months ended September 30, 2023 and 2022, the Company recorded approximately $3,000 and $9,000, respectively, in amortization expense on a straight-line basis.

 

Debt Issuance Costs

Debt issuance costs are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and other comprehensive loss.

Revenue Recognition

The Company recognizes collaboration revenue under certain of the Company’s license and collaboration agreements that are within the scope of Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the expected value method.

Research and Development Expenses

Research and development expenses consist primarily of compensation costs, fees paid to consultants, outside service providers and organizations (including research institutes at universities), facility costs, and development and clinical trial costs with respect to the Company’s drug product candidates.

Research and development expenses incurred under contracts are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different pattern of performance is more appropriate. Other research and development expenses are charged to operations as incurred.

Nonrefundable advance payments are recognized as an expense as the related services are performed. The Company evaluates whether it expects the services to be rendered at each quarter end and year end reporting date. If the Company does not expect the services to be rendered, the advance payment is charged to expense. Nonrefundable advance payments for research and development services are included in prepaid and other current assets on the balance sheet. To the extent that a nonrefundable advance payment is for contracted services to be performed within 12 months from the reporting date, such advance is included in current assets; otherwise, such advance is included in non-current assets.

The Company evaluates the status of its research and development agreements and contracts, and the carrying amount of the related assets and liabilities, at each quarter end and year end reporting date, and adjusts the carrying amounts and their classification on the balance sheet as appropriate.

12


 

 

Patent Expenses

The Company is the exclusive worldwide licensee of, and has patent applications pending for, numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development of one or more commercially viable drug product candidates based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal fees, filing fees and other costs are charged to general and administrative expense as incurred. For the three and nine months ended September 30, 2023, patent expenses were approximately $503,000 and $1,649,000, respectively. For the three and nine months ended September 30, 2022, patent expenses were $395,000 and $1,625,000, respectively.

Licensing Fees and Costs

Licensing fees and costs consist primarily of costs relating to the acquisition of the Company’s license agreement (the “Einstein License Agreement”) with the Albert Einstein College of Medicine (“Einstein”), including related royalties, maintenance fees, milestone payments and product development costs. Licensing fees and costs are charged to research and development expense as incurred.

Long-Lived Assets

The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs.

Leases

 

The Company accounts for leases under ASC 842, Leases, which requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases are required.

Stock-Based Compensation

The Company periodically issues stock-based awards to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values. Stock option grants, which are generally time-vested, are measured at the grant date fair value and charged to operations on a straight-line basis over the service period, which generally approximates the vesting term. The Company also grants performance-based awards periodically to officers of the Company. The Company recognizes compensation costs related to performance awards over the requisite service period if and when the Company concludes that it is probable that the performance condition will be achieved.

The fair value of stock options and restricted stock units is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading history for its common stock that approximates the expected term of the options, estimated volatility is based on the average historical volatility of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends and has no plans to do so for the foreseeable future. As permitted by Staff Accounting Bulletin No. 107, due to the Company’s limited trading history and option activity, management

13


 

utilizes the simplified method to estimate the expected term of options at the date of grant. The exercise price is determined based on the fair value of our common stock at the date of grant. The Company accounts for forfeitures as they occur.

The Company recognizes the fair value of stock-based compensation in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on the type of services provided by the recipient of the equity award.

Comprehensive Income (Loss)

Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive income (loss) includes net income (loss) as well as changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. The Company’s only element of other comprehensive income (loss) in periods presented was unrealized gain or loss on available-for-sale securities.

Earnings (Loss) Per Share

The Company’s computation of earnings (loss) per share (“EPS”) for the respective periods includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares that would result from the exercise of outstanding stock options and warrants as if they had been exercised at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Basic and diluted loss per common share is the same for all periods presented because all outstanding stock options and warrants are anti-dilutive.

Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included 1,531,440 pre-funded warrants in the denominator of basic EPS at September 30, 2023.

At September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

 

 

 

September 30,

 

 

 

2023

 

2022

 

Common stock warrants

 

 

10,719,846

 

 

789,358

 

Common stock options

 

 

7,500,480

 

 

6,268,729

 

Total

 

 

18,220,326

 

 

7,058,087

 

 

Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active exchange-traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.

14


 

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

The Company had approximately $54,691,000 in cash equivalents as of September 30, 2023. The Company had approximately $45,423,000 in cash equivalents and approximately $24,675,000 in short-term marketable securities that were measured and recorded at fair value on the Company’s balance sheet at December 31, 2022.

The carrying value of financial instruments (consisting of cash, a certificate of deposit, accounts payable, accrued compensation and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) (CECL). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The new standard is effective for annual reporting periods beginning after December 15, 2022, including interim reporting periods within each annual reporting period for smaller reporting companies. The Company adopted ASU No. 2016-13 but there was no financial impact to the Company’s consolidated financial statements for the year ended December 31, 2022 or for the nine months ended September 30, 2023.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

3.
Fair Value

The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022, and indicate the level of the fair value hierarchy utilized to determine such fair value:

 

 

 

Fair Value Measurements as of September 30, 2023

 

 

 

(in thousands)

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Fair Value

 

Cash equivalents

 

$

54,691

 

 

$

 

 

$

 

 

$

54,691

 

Marketable securities

 

 

 

 

$

 

 

 

 

 

 

 

Total

 

$

54,691

 

 

$

 

 

$

 

 

$

54,691

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements as of December 31, 2022

 

 

 

(in thousands)

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Fair Value

 

Cash equivalents

 

$

45,423

 

 

$

 

 

$

 

 

$

45,423

 

Marketable securities

 

 

 

 

 

24,675

 

 

 

 

 

 

24,675

 

Total

 

$

45,423

 

 

$

24,675

 

 

$

 

 

$

70,098

 

 

As of September 30, 2023, the Company reported approximately $54,691,000 in cash equivalents. The Company measures the cash equivalents that are invested in money market funds using Level 1 inputs for identical securities. The Company measures the fair value of marketable securities that are invested in U.S. Treasury securities using Level 2 inputs and primarily relies on quoted prices in active markets for similar marketable securities. As of December 31, 2022, the Company reported approximately $45,423,000 and $24,675,000 in cash equivalents and marketable securities, respectively. During the three and nine months ended September 30, 2023, and the year ended December 31, 2022, there were no transfers between Level 2 and Level 3.

 

15


 

4.
Marketable Securities

As of September 30, 2023, the Company had no marketable securities. The Company had marketable securities that consisted of $24,675,000 at December 31, 2022. The following table presents the Company's marketable securities at December 31, 2022:

 

 

 

December 31, 2022

 

(In thousands)

 

Amortized Cost

 

 

Gross Unrealized
Gains

 

 

Gross Unrealized
Losses

 

 

Fair Value

 

U.S. Treasury Securities

 

$

24,771

 

 

$

 

 

$

(96

)

 

$

24,675

 

 

$

24,771

 

 

$

 

 

$

(96

)

 

$

24,675

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2022, the Company's marketable securities consisted of $24,771,000 of investments that mature within 12 months and the Company recorded an unrealized loss on investments of $96,000 for the year ended December 31, 2022.

5.
Property and Equipment

Property and equipment as of September 30, 2023 and December 31, 2022 consisted of the following:

 

 

 

September 30,
2023

 

 

December 31,
2022

 

 

 

(in thousands)

 

Laboratory equipment

 

$

5,205

 

 

$

5,246

 

Furniture and fixtures

 

 

81

 

 

 

81

 

Computer and office equipment

 

 

296

 

 

 

296

 

Leasehold improvements

 

 

118

 

 

 

118

 

 

 

5,699

 

 

 

5,741

 

Less accumulated depreciation

 

 

(4,635

)

 

 

(4,242

)

Net property and equipment

 

$

1,064

 

 

$

1,499

 

 

Depreciation expense for the three months ended September 30, 2023 and 2022 was approximately $128,000 and $198,000, respectively. Depreciation expense for the nine months ended September 30, 2023 and 2022 was approximately $434,000 and $630,000, respectively. Depreciation expense for the nine months ended September 30, 2023 excludes trademark amortization expense of approximately $9,000. Depreciation expense for the nine months ended September 30, 2022 excludes trademark amortization expense of approximately $9,000, and amortization of capitalized license expenses of approximately $80,000. During the nine months ended September 30, 2023, the Company sold fully depreciated lab equipment with an acquisition cost of $41,450 and collected cash of $2,000. The Company recorded a gain on the sale of fixed assets of $2,000, which is presented in other income on the consolidated statements of operations and other comprehensive loss. During the nine months ended September 30, 2022, the Company sold furniture and fixtures with an acquisition cost of $30,000 and collected cash of $5,800. The Company recorded a loss on the sale of fixed assets of $4,300, which is presented in other income on the consolidated statements of operations and other comprehensive loss.

6.
Loan with Silicon Valley Bank

On February 15, 2022 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”), with Silicon Valley Bank, as lender (“SVB”). The Company drew $10,000,000 in term loans under the Loan Agreement (the "Term Loans") on the Closing Date. The Loan Agreement was amended in April 2023.

The Term Loans bear interest at a floating rate per annum equal to the greater of (A) the prime rate (as published in the money rates section of The Wall Street Journal) plus 2.25% and (B) 5.50%. The Term Loans were interest only from the Closing Date through June 30, 2023, after which the Company is required to pay 30 equal monthly installments of principal. At September 30, 2023, the interest rate was 10.75% based on the prime rate plus 2.25%.

The Term Loans may be prepaid in full prior to February 15, 2024 with payment of a 2.00% prepayment premium, on or after which they may be prepaid in full with payment of a 1.00% prepayment premium. Upon prepayment or repayment in full of the Term Loans, the Company will be required to pay a one-time final payment fee equal to 5.00% of the original principal amount of any funded Term Loans being repaid. This one-time final payment fee is recorded to interest expense using the effective interest method over the period of the Term Loans in the consolidated statements of operation and other comprehensive loss.

The Term Loans and related obligations under the Loan Agreement are secured by substantially all of the Company’s properties, rights and assets, except for its intellectual property which is subject to a negative pledge under the Loan Agreement.

16


 

The Loan Agreement contains customary representations, warranties, events of default and covenants, including a requirement that the Company maintain in accounts of the Company at SVB unrestricted and unencumbered cash equal to the lesser of all of the Company’s cash or $20,000,000. On March 10, 2023, SVB was closed by state regulators and the Federal Deposit Insurance Company ("FDIC") was appointed receiver for the bank. The FDIC created a successor bridge bank, Silicon Valley Bridge Bank, N.A. (“SVBB”) and all deposits of SVB were transferred to SVBB under a systemic risk exception approved by the U.S. Department of the Treasury, the Federal Reserve and the FDIC. SVBB continues to hold the Company’s Term Loans under the same existing terms and covenants which were in place with SVB.

During the three and nine months ended September 30, 2023, the Company recognized interest expense related to the Term Loans of $254,000 and $848,000, respectively, and $33,000 and $98,000, respectively, in interest expense related to accretion of the final payment. During the three and nine months ended September 30, 2022, the Company recognized interest expense related to the Term Loans of $183,000 and $354,000, respectively, and $33,000 and $76,000 in interest expense related to accretion of the final payment for the three months and nine months ended September 30, 2022, respectively.

The following tables present the aggregate maturities of long-term and current portion of debt as of September 30, 2023 (in thousands):

 

 

 

 

 

 

 

Year

Aggregate Minimum Payments

 

 

 

2023

$

 

1,000

 

 

 

2024

 

 

4,000

 

 

 

2025

 

 

4,000

 

 

 

Total maturities

$

 

9,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total long-term debt

 

 

 

$

5,000

 

Accretion of final payment

 

 

207

 

Less: unamortized debt issuance costs

 

 

 

 

(46

)

Long-term debt, net

 

$

5,160

 

 

 

 

 

 

 

Total current portion of long-term debt

 

 

 

$

4,000

 

Less: unamortized debt issuance costs

 

 

 

 

(37

)

Current portion of long-term debt, net

 

$

3,963

 

 

 

Debt Issuance Costs

Debt issuance costs are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and comprehensive loss. The Company incurred approximately $141,748 in debt issuance costs related to the Loan Agreement. For the three and nine months ended September 30, 2023, the Company recorded approximately $9,000 and $28,000, respectively, in amortization of debt issuance costs to interest expense in the consolidated statements of operations and comprehensive loss. For the three and nine months ended September 30, 2022, the Company recorded approximately $9,000 and $21,000, respectively, in amortization of debt issuance costs to interest expense in the consolidated statements of operations and comprehensive loss.

 

7. Stock-Based Compensation

17


 

Stock Option Valuation

For stock options requiring an assessment of value during the nine months ended September 30, 2023 and 2022, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:

 

 

 

September 30, 2023

Risk-free interest rate

 

3.4% - 4.16%

Expected dividend yield

 

0%

Expected volatility

 

97.03% - 110.4%

Expected life

 

5.50 to 6.25 years

 

 

 

 

 

September 30, 2022

Risk-free interest rate

 

1.53% - 2.92%

Expected dividend yield

 

0%

Expected volatility

 

92.1% - 95.7%

Expected life

 

5.50 to 6.25 years

 

A summary of stock option activity for the nine months ended September 30, 2023 is as follows:

 

 

 

Number of
Shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Life
(in Years)

 

Stock options outstanding at December 31, 2022

 

 

6,173,867

 

 

$

9.60

 

 

 

5.05

 

Granted

 

 

2,576,900

 

 

 

3.65

 

 

 

 

Exercised

 

 

(165,602

)

 

 

2.86

 

 

 

 

Cancelled

 

 

(1,084,685

)

 

 

4.78

 

 

 

 

Stock options outstanding at September 30, 2023

 

 

7,500,480

 

 

 

8.40

 

 

 

6.35

 

Stock options exercisable at September 30, 2023

 

 

4,365,960

 

 

$

10.38

 

 

 

4.54

 

 

The Company recognized approximately $2,073,000 and $6,108,000 in stock-based compensation expense during the three and nine months ended September 30, 2023, respectively, related to stock options activity. As of September 30, 2023, total unrecognized stock-based compensation expense was approximately $12,141,000, which is expected to be recognized as an operating expense in the Company’s consolidated statement of operations and other comprehensive loss over the weighted average remaining period of 2.16 years. During the three months ended September 30, 2023, the Company granted stock options to purchase 1,115,000 shares of common stock with a weighted average grant date fair value of $4.17 per share. During the nine months ended September 30, 2023, the Company granted stock options to purchase 2,576,900 shares of common stock with a weighted average grant date fair value of $3.65 per share.

 

The Company recognized approximately $2,045,000 and $6,537,000 in stock-based compensation expense during the three and nine months ended September 30, 2022, respectively, related to stock options activity. As of September 30, 2022, total unrecognized stock-based compensation expense was approximately $13,856,000, which is expected to be recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss over the weighted average remaining period of 2.13 years. During the three months ended September 30, 2022, the Company granted stock options to purchase 12,500 shares of common stock with a weighted average grant date fair value of $2.45 per share. During the nine months ended September 30, 2022, the Company granted stock options to purchase 828,500 shares of common stock with a weighted average grant date fair value of $6.99 per share.

The intrinsic value of exercisable but unexercised in-the-money stock options at September 30, 2023 was approximately $0, based on a weighted average grant date fair value of $10.38 per share on September 30, 2023.

 

Restricted Stock Units

 

On October 3, 2019, the Company granted 100,000 restricted stock units (“RSUs”) with time-based vesting conditions to an executive officer having an average grant date fair value of $7.53 per share. The RSUs vested in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter. Compensation expense is recognized on a straight-line basis.

18


 

 

On February 5, 2020, the Company granted 150,000 RSUs with time-based vesting conditions to an executive officer. One-half of the RSUs vested on September 30, 2021, and the balance vested on March 31, 2022. On March 31, 2020, the Company granted 50,000 RSUs with time-based vesting conditions to an executive officer. The RSUs vested in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter. Compensation expense is recognized on a straight-line basis.

On August 21, 2020, the Company granted 20,000 RSUs with time-based vesting conditions to an executive officer. The RSUs vest in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter, subject to the recipient’s continued service on each applicable vesting date. Compensation expense is recognized on a straight-line basis.

 

The Company recognized $0 in stock-based compensation during the three and nine months ended September 30, 2023 related to RSU activity. As of September 30, 2023, total unrecognized stock-based compensation was fully recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss. The Company recognized approximately $19,000 and $847,000 in stock-based compensation during the three and nine months ended September 30, 2022, respectively, related to RSU activity. As of September 30, 2022, total unrecognized stock-based compensation was fully recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss.


 

Stock-based Compensation

 

Stock-based compensation expense for the three and nine months ended September 30, 2023 and 2022 was included in the Company’s consolidated statements of operations and other comprehensive loss as follows:

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended September 30,

 

(in thousands)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

General and administrative

 

$

858

 

 

$

1,003

 

 

$

2,708

 

 

$

3,650

 

Research and development

 

 

1,215

 

 

 

1,061

 

 

 

3,399

 

 

 

3,734

 

Total

 

$

2,073

 

 

$

2,064

 

 

$

6,108

 

 

$

7,384

 

 

8. Warrants

The Company has one tranche of common stock warrants outstanding at September 30, 2023. The Company issued warrants exercisable for 1,500 shares of common stock on June 15, 2015 with an exercise price of $2.70 per share, which warrants expired at the end of their 7-year term on June 15, 2022. The Company issued another tranche of warrants exercisable for an aggregate of 882,071 shares of common stock with an exercise price of $9.38 per share when issued on December 27, 2017, which warrants expired at the end of their 5-year term on December 26, 2022. On November 16, 2022, the Company issued in a private placement 9,188,406 warrants with an exercise price of $3.93 and 1,531,440 pre-funded warrants.

Each tranche of warrants was evaluated under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and the Company determined that equity classification was appropriate. The Company determined equity classification for both warrants and pre-funded warrants as they do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Per ASC 815-40-25, the Company accounts for the warrants and pre-funded warrants as equity, as the Company does not provide the holder a fixed or guaranteed return.

The Company recorded cash received from 1,531,440 pre-funded warrants to additional paid in capital in the amount of $4,999,999. The Company recorded placement fees and expenses related to the sale of pre-funded warrants in the amount of $299,999 as a charge to additional paid in capital in the consolidated balance sheet at December 31, 2022.

Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included 1,531,440 pre-funded warrants in the denominator of basic EPS at September 30, 2023.

19


 

 

The following table shows common stock warrants outstanding as of September 30, 2023:

 

 

 

Warrant Issued
November 16, 2022

 

 

Total

 

Balance at December 31, 2022

 

 

10,719,846

 

 

 

10,719,846

 

Issued via cashless exercises

 

 

 

 

 

 

Withheld as payment to cover issued shares

 

 

 

 

 

 

Expired

 

 

 

 

 

 

Issued

 

 

 

 

 

 

Balance at September 30, 2023

 

 

10,719,846

 

 

 

10,719,846

 

 

 

 

9. Collaboration Revenue

The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and if, over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company’s contracts may include options to acquire additional goods and/or services.

The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front payment, and pass through costs related to research activities, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of pass through costs and milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any development, regulatory or commercial milestones or royalty revenue resulting from any of its collaboration arrangements. Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

20


 

The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis, when applicable. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.

Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. The Company measures progress toward satisfaction of the performance obligation over time as effort is expended.

Collaboration Agreement with LG Chem

On November 6, 2018, the Company entered into a collaboration agreement (the “LG Chem Collaboration Agreement”) with LG Chem Ltd. (“LG Chem”) related to the development of the Company’s Immuno-STATs focused in the field of oncology. Pursuant to the LG Chem Collaboration Agreement, the Company granted LG Chem an exclusive license to develop, manufacture and commercialize the Company’s lead product, CUE-101, as well as Immuno-STATs that target T cells against two additional cancer antigens, in certain Asian countries (collectively, the “LG Chem Territory”). On April 30, 2021, LG Chem’s option pursuant to the Global License and Collaboration Agreement entered into between the Company and LG Chem on December 18, 2019 and as amended on November 5, 2020 (the "Global License and Collaboration Agreement"), expired, and accordingly the Company no longer has any material obligations under the Global License and Collaboration Agreement. In June 2021, after ongoing discussions regarding the selection of the second of the two additional cancer antigens, LG Chem and the Company agreed to let the selection period expire without a second antigen being selected. The Company retains rights to develop and commercialize all assets included in the LG Chem Collaboration Agreement in the United States and in global markets outside of the LG Chem Territory. In exchange for the licenses and other rights granted to LG Chem under the LG Chem Collaboration Agreement, LG Chem made a $5.0 million equity investment in common stock of the Company and a $5.0 million nonrefundable up-front cash payment. The Company is also eligible to receive up to an additional $400.0 million in research, development, regulatory and sales milestones. In addition, the LG Chem Collaboration Agreement also provides that LG Chem will pay the Company tiered single-digit percentage royalties on net sales of commercialized drug product candidates in the LG Chem Territory.

On May 16, 2019, LG Chem paid the Company a $2.5 million milestone payment for the U.S. Food and Drug Administration’s (“FDA”) acceptance of the investigational new drug application (“IND”) for the Company’s lead drug product candidate, CUE-101, pursuant to the LG Chem Collaboration Agreement. The $2.5 million milestone payment was recorded as a contract liability upon receipt of payment as it requires deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Of the $2.5 million milestone payment, approximately $412,500 was recognized as tax withholding, shown as income tax expense on the consolidated statement of operations and other comprehensive loss.

On December 7, 2020, the Company earned a $1.25 million milestone payment on the selection of a pre-clinical candidate pursuant to the LG Chem Collaboration Agreement. The $1.25 million milestone payment was recorded as a contract liability upon receipt. Revenue related to this milestone payment was recognized by the Company pursuant to the Company’s revenue recognition policy in relation to the performance of its obligations related to the development of this pre-clinical candidate. Of the $1.25 million milestone payment, approximately $206,250 was withheld as payment of foreign tax withholding and shown as income tax expense on the consolidated statement of operations and other comprehensive loss.

On November 23, 2021, the Company earned a $3 million milestone payment for the selection of a clinical product candidate in partnership with LG Chem. The $3 million milestone payment was recorded as a contract liability upon receipt. Revenue related to this milestone payment was recognized by the Company pursuant to the Company’s revenue recognition policy in relation to the performance of its obligations related to the development of this preclinical candidate. Of the $3 million milestone payment,

21


 

approximately $495,000 was withheld as payment of foreign tax withholding and shown as income tax expense on the consolidated statements of operations and comprehensive loss. Cash was collected in relation to this milestone payment in February 2022.

Aside from the $6.75 million in milestone payments earned to date, the Company does not believe that any variable consideration should be included in the transaction price as of September 30, 2023. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur. For the three months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $178,000 and approximately $68,000, respectively, related to the LG Chem Collaboration Agreement. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $243,000 and approximately $1,094,000, respectively, related to the LG Chem Collaboration Agreement. The Company did not record short- or long-term research and development liabilities on its balance sheet dated September 30, 2023 and December 31, 2022 as the performance obligation was met and completed. Research and development cost sharing provisions under the agreement expired on March 31, 2022.

Collaboration and Option Agreement with Ono

On February 22, 2023, the Company entered into a strategic collaboration agreement (the "Ono Collaboration and Option Agreement") with Ono Pharmaceutical Co., Ltd. ("Ono") to further develop CUE-401 and provide dedicated resources and capabilities to help advance CUE-401 toward the clinic. Under the terms of the Ono Collaboration and Option Agreement, Ono paid the Company an upfront payment and agreed to fully fund all research activities related to CUE-401 through a specified option period. During this option period, the Company will be responsible for the research and development of CUE-401. Upon Ono’s exercise of its option to license CUE-401, the Company will receive an option exercise payment and be eligible for development and commercial milestone payments up to an aggregate of approximately $220 million, as well as tiered royalties on sales. Upon any such exercise, Ono will receive worldwide rights to develop and commercialize CUE-401, with the Company retaining a 50% co-development and co-commercialization right in the United States.

Under the terms of the Ono Collaboration and Option Agreement, the Company will perform research activities related to CUE-401 through a specified option period of 24 months (the “Research Term”). During this Research Term, the Company will be responsible for the execution of scientific investigation, nonclinical, preclinical, and clinical drug research and development activities designed to progress CUE-401 toward a potential IND and regulatory approval (such activities, collectively referred to as “R&D”). Ono is responsible for the funding of R&D activities performed by the Company. Per the agreement, as consideration for the R&D activities performed by the Company, Ono (i) made a one-time, non-refundable, non-creditable upfront payment of $3.0 million to the Company and (ii) will reimburse the Company for all costs incurred in conducting research, including (a) pass through costs from third party contractors and (b) full time employee salaries capped at $2.1 million in the first 18 months of the Research Term. The term of the Ono Collaboration and Option Agreement extends until the expiration of the Research Term which cannot exceed a 24-month period. The Company has forecasted that it will be able to complete the R&D activities in 18 months based on the initial research and development plans it has established. The Company received the $3.0 million upfront payment in March 2023.

Aside from the $3.0 million upfront payment and funding related to pass through costs, the Company does not believe that any variable consideration should be included in the transaction price as of September 30, 2023. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur. For the three months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $1,922,000 and $0, respectively, related to the Ono Collaboration and Option Agreement. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $3,426,000 and $0, respectively, related to the Ono Collaboration and Option Agreement. The Company recorded short-term research and development liabilities on its balance sheet dated September 30, 2023, of approximately $2,238,000. The Company did not recognize short or long-term research and development liabilities on its balance sheet as of December 31, 2022, as the agreement was executed in February 2023.

Capitalization of Contract Costs

The Company considered the capitalization of contract costs under the guidance in ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers. As it related to the LG Chem Collaboration Agreement, the Company capitalized license expenses of approximately $908,000 as of September 30, 2023, paid to Einstein pursuant to the Einstein License Agreement which requires the Company to pay a percentage of sublicenses related to the Company’s patent rights for components of its core technology that is

22


 

licensed from Einstein. This amount is comprised of approximately $438,000 of capitalized license expenses related to the up-front payment received from LG Chem in December 2018, approximately $313,000 in capitalized license expenses related to the milestone payment received in June 2019, and approximately $157,000 in capitalized license expenses related to the milestone payment received in December 2020, net of accumulated amortization on all capitalized license expenses of approximately $908,000. As of September 30, 2023 and December 31, 2022, no capitalized license expenses net of accumulated amortization were included in prepaid expenses and other short-term assets related to the LG Chem Collaboration Agreement.

10. Commitments and Contingencies

Einstein License Agreement

In 2015, the Company entered into the Einstein License Agreement with Einstein for certain patent rights relating to the Company’s core technology platform for the engineering of biologics to control T cell activity, precision, immune-modulatory drug product candidates, and two supporting technologies that enable the discovery of costimulatory signaling molecules (ligands) and T cell targeting peptides. The Company entered into an amended and restated license agreement on July 31, 2017, as amended on October 2018, which modified certain obligations of the parties under the Einstein License Agreement. For each of the three months ended September 30, 2023 and 2022, the Company incurred $0 in fees and expenses to Einstein related to this license. For each of the nine months ended September 30, 2023 and 2022, the Company incurred $0 in fees and expenses to Einstein related to this license.

The Company’s remaining commitments with respect to the Einstein License Agreement are based on the attainment of future milestones. The aggregate amount of milestone payments made under the Einstein License Agreement may equal up to $1.85 million for each product, process or service that use the patents covered by the Einstein License Agreement, including certain technology received from Einstein related thereto (the "Licensed Product"), and up to $1.85 million for each new indication of a Licensed Product. Additionally, the aggregate amount of one-time milestone payments based on cumulative sales of all Licensed Products may equal up to $5.75 million. The Company is also party to a material transfer agreement with Einstein focusing on infectious disease and assessing the application of the Company's Neo-STAT asset for the treatment of infectious disease.

Collaboration Agreement with LG Chem

See discussion of the LG Chem Collaboration Agreement in Note 9.

Collaboration Agreement with Ono

See discussion of the Ono Collaboration and Option Agreement in Note 9.

Contingencies

The Company accrues contingent liabilities to the extent that the liability is probable and estimable. There are no accruals for contingent liabilities in the Company’s consolidated financial statements.

The Company may be subject to various legal proceedings from time to time as part of its business. As of September 30, 2023, the Company was not a party to any legal proceedings or threatened legal proceedings, the adverse outcome of which, individually or in the aggregate, would have a material adverse effect on its business, financial condition or results of operations.

11. Leases

 

On March 28, 2022, the Company entered into a License Agreement (the “License”) with MIL 40G, LLC (the “Licensor”), pursuant to which the Company leases approximately 13,000 square feet of office, research and development and laboratory space located at 40 Guest Street, Boston, Massachusetts 02135 (the “Premises”). The Company relocated its corporate headquarters to the Premises in April 2022. On March 28, 2022, the Company terminated its office and lab space lease in Cambridge Massachusetts (the “Laboratory and Office Lease”) effective April 30, 2022. The Company performed an analysis of the accounting implications of this termination based on ASC 360 Impairments and Abandonments guidance. At March 31, 2022, the Company recorded an adjustment to decrease the right-of-use asset and lease liability of approximately $8,124,000 and $8,382,000, respectively, and recorded a gain on right-of-use asset termination included in the consolidated statement of operations and other comprehensive loss of approximately $258,000.

23


 

The Company recognized a right of use asset of approximately $9,056,000 and an operating lease liability of approximately $9,056,000 which were recorded as of the Term Commencement Date (as defined below) related to the License.

The term of the License commenced on April 15, 2022 (the “Term Commencement Date”) and expires on April 14, 2026 (the “Term”). The License has a monthly rental rate of $200,700 for the first year of the Term, $208,728 for the second year of the Term, $217,077 for the third year of the Term and $225,760 for the remainder of the Term. Pursuant to the License, the Company prepaid two months of rent and a security deposit. The Licensor is obligated under the License to provide certain services to the Company, including providing certain gases, chemicals and equipment to the Premises’ laboratory space, IT support, security, office support and health and safety training. The Licensor has the right to terminate the License for Cause (as defined in the License).

On May 3, 2022, the Company entered into the First Amendment to the License ("First Amendment”) with the Licensor, pursuant to which the License was expanded to include an additional room effective July 15, 2022. In consideration of the First Amendment, the security deposit was increased from $225,760 to $235,884 effective July 15, 2022. Upon execution of the First Amendment, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. Effective July 15, 2022, the monthly rental rate under the First Amendment increased to $209,700 from $200,700. The Company recognized a right of use asset of approximately $369,000 and a short- and long-term operating lease liability of approximately $100,300 and $260,600, respectively, using the weighted average discount rate of 8%, which were recorded as of the Term Commencement Date related to the License.

On May 31, 2022, the Company entered into an operating lease for additional laboratory space at 40 Guest Street, Boston, Massachusetts for the period from December 1, 2022 through December 1, 2024 (the “40G Additional Laboratory Lease”). The 40G Additional Laboratory Lease contains escalating payments during the lease period. The monthly rental rate under the 40G Additional Laboratory Lease is $59,152 for the first 12 months and $61,519 for the remainder of the term. Under the terms of this lease agreement, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. The Company recognized a right of use asset of approximately $1,307,000 and a short- and long-term operating lease liability of approximately $712,000 and $535,000, respectively, using the weighted average discount rate of 10%, which were recorded as of the Term Commencement Date related to the 40G Additional Laboratory Lease.

On September 9, 2022, the Company terminated its lab space lease in Cambridge, Massachusetts with MIL 21E, LLC with an effective termination date of December 6, 2022. The Company performed an analysis of the accounting implications of this termination based on ASC 360 Impairments and Abandonment guidance. The Company recorded an entry to remove the remaining lease liability and right of use asset of $963,000 and $945,000, respectively. The difference between the carrying amounts of the right of use asset and lease liability of $19,000 was recorded at termination in September 2022, to gain on right of use asset and included in the consolidated statements of operations and other comprehensive loss.

For the three and nine months ended September 30, 2023, the Company recorded approximately $122,000 and $402,000, respectively, in non-cash interest expense to the lease liability. For the three and nine months ended September 30, 2022, the Company recorded approximately $146,000 and $309,000, respectively, in non-cash interest expense to the lease liability.

At September 30, 2023, the Company recorded approximately $7,060,000 to operating lease right-of-use asset, and approximately $3,399,000 and $3,855,000 to the short-term and long-term operating lease liability, respectively. At December 31, 2022, the Company recorded approximately $9,203,000 to operating lease right-of-use asset, and approximately $3,300,000 and $6,018,000 to short-term and long-term operating lease liability, respectively. As of September 30, 2023 and December 31, 2022, a security deposit of approximately $595,000 was included in deposits on the Company’s consolidated balance sheet related to the 40G Additional Laboratory Lease. Cash was collected in the amount of $0 and approximately $199,000 for the Company's former Cambridge 21 Erie Laboratory space during the three and nine months ended September 30, 2023, respectively.

Future minimum lease payments under the leases in effect at September 30, 2023 are as follows:

 

Year

 

(in thousands)

 

2023 (3 months remaining)

 

 

835

 

2024

 

 

3,368

 

2025

 

 

2,799

 

2026

 

 

818

 

Total lease payments

 

$

7,820

 

Less: present value discount

 

 

(566

)

Total

 

$

7,254

 

 

24


 

Total rent expense of approximately $853,000 and $860,000 was included in the consolidated statements of operations and other comprehensive loss for the three months ended September 30, 2023 and 2022, respectively. Total rent expense of approximately $2,566,000 and $3,309,000 was included in the consolidated statements of operations and other comprehensive loss for the nine months ended September 30, 2023 and 2022, respectively. Other information pertaining to the Company’s operating leases for the three and nine months ended September 30, 2023 is summarized in the table below.

 

Other information

 

Three Months Ended
September 30, 2023

 

Nine Months Ended
September 30, 2023

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

Operating cash flows from operating leases (in thousands)

 

$

(709

)

$

(2,064

)

Operating lease cost (in thousands)

 

$

853

 

$

2,566

 

Weighted average discount rate

 

5.75%

 

5.75%

 

Weighted average remaining lease term

 

2.39 years

 

2.39 years

 

 

25


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations of Cue Biopharma, Inc. and its subsidiary (“Cue Biopharma”, “we”, “us”, “our” or the “Company”) should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto for the fiscal year ended December 31, 2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 21, 2023, or the 2022 Annual Report.

Overview

 

We are a clinical-stage biopharmaceutical company developing a novel series of T cell engagers, termed Immuno-STAT™ (Selective Targeting and Alteration of T Cells), that are engineered to selectively engage and modulate disease-relevant T cells while avoiding the deleterious side effects of non-selective, systemic immune activation. This unique property of selectivity provides Immuno-STATs with the potential for providing superior clinical efficacy along with favorable tolerability. We believe that Immuno-STATs, as described below, build upon our core expertise in rational protein engineering to emulate nature's signals, or "cues", for selective T cell modulation. We believe our proprietary Immuno-STAT platform, as described below, will enable us to enhance the potential of the patient’s own immune system to restore health while avoiding the negative side effects of broad indiscriminate immune activation, in the case of cancer, and broad immune suppression in the case of autoimmune disease. Our selective immune modulation approach may be deployed for treating cancer, autoimmune diseases and chronic infections. In addition to the selective modulation of T cell activity, we believe core features of Immuno-STATs offer differentiated competitive advantages, including modularity, manufacturability, and convenient administration enabling the versatility to treat a broad range of disease. The unique property of Immuno-STATs to be T cell receptor, or TCR, -selective engagers provides core strategic advantages and differentiation from other classes of non-specific T cell engagers, as highlighted below.

The core framework of an Immuno-STAT molecule has a stabilized peptide human leukocyte antigen, or pHLA, component that selectively engages T cells harboring TCRs for binding to the tumor-specific peptide-HLA complex (representing Signal 1 in the orange box of the image below). In addition, Immuno-STATs contain activating signals (representing Signal 2 in the orange box of the image below), including modified interleukin 2, or IL-2, in the case of the CUE-100 series, the first series from our biologics platform, that can be selectively delivered to tumor-specific T cells. We believe Immuno-STATs provide an attractive solution for generation of a therapeutic index for immune activation signals, such as IL-2. The unique property of Immuno-STATs as TCR-selective engagers provides core strategic advantages and differentiation from other classes of non-specific T cell engagers, due to the targeting of specific TCRs via Signal 1, as highlighted below.

 

The Immuno-STAT Framework: CUE-100 Series

 

img77026815_0.jpg 

 

26


 

We believe the data generated from our ongoing clinical trials with CUE-101, our lead clinical drug product candidate from our IL-2 based CUE-100 series, has demonstrated the potential of the Immuno-STAT platform to improve cancer patient outcomes beyond that of the current standard of care. As described below, CUE-101 has demonstrated evidence of anti-tumor activity in our ongoing clinical trials through selective activation of the anti-cancer T-cells repertoires. Furthermore, CUE-101 has demonstrated a favorable tolerability profile in approximately 80 patients treated to date with doses of up to 8mg/kg. Importantly, the CUE-101 neoadjuvant trial that is currently being conducted by Washington University School of Medicine in patients with newly diagnosed, locally advanced oropharyngeal squamous-cell carcinoma will allow for the evaluation of the tumor tissue microenvironment, or TME, pre and post treatment to shed mechanistic insights into the anti-tumor cellular response. In addition to our encouraging CUE-101 clinical data generated to date, we also have emerging data from our ongoing Phase 1 dose escalation trial of CUE-102, which further enhances our confidence in the platform's versatility and potential for addressing a broad range of cancer types. Through these ongoing trials, we continue to develop datasets differentiating the CUE-100 series Immuno-STATs from competing approaches.

We have also recently observed promising preclinical data pertaining to the potential application of our platform for the treatment of a broad range of autoimmune diseases. In February 2023 we announced the establishment of a strategic collaboration with Ono Pharmaceuticals Co., Ltd., or Ono, focused on the development of CUE-401 for the potential treatment of autoimmune and inflammatory diseases through the induction and expansion of regulatory T cells, or Tregs.

Our drug product candidates are in various stages of clinical and preclinical development. The emerging preliminary clinical data for CUE-101 and CUE-102 bolsters our belief that we have developed a potential breakthrough approach for modulating cancer-specific T cells directly in the patient’s body. However, our activities are also subject to significant risks and uncertainties. We have not yet commenced any commercial revenue-generating operations, have limited cash flows from operations, and will need to access substantial additional capital to fund our growth and ongoing business operations.

Our Pipeline

The pipeline chart below details our current portfolio of oncology and autoimmune assets and their stages of development. In oncology, we have prioritized and strategically focused resources on our CUE-101 and CUE-102 programs in our IL-2 based CUE-100 series, and we are actively assessing strategic options for third party support through partnerships and collaborations, or alternative funding structures, to further develop CUE-103 and our Neo-STAT™ and RDI-STAT™ programs.

 

img77026815_1.jpg 

 

27


 

We continue to progress forward in our strategic collaboration with Ono to develop CUE-401, a preclinical IL-2/transforming growth factor beta (TGF-beta) based drug product candidate for autoimmune disease. Based on its unique mechanism of action, we believe CUE-401 has the potential to be a highly differentiated molecule for the induction and expansion of Tregs, and is distinct from the vast majority of other IL-2 muteins that are being pursued in this space. We are also assessing strategic alternatives for furthering the development of our CUE-300 series for the treatment of specific autoimmune diseases, such as type 1 diabetes and celiac disease.

 

CUE-101

CUE-101 is our most advanced clinical stage asset in oncology and is being investigated for the treatment of human papillomavirus positive, or HPV+, head and neck cancer. We completed enrollment of the patient expansion phase of our monotherapy Phase 1 clinical trial of CUE-101 at the 4 mg/kg recommended Phase 2 dose, or RP2D, for the treatment of third line, or 3L, and beyond recurrent/metastatic head and neck squamous cell cancer, or R/M HNSCC patients. These patients had received and failed several prior lines of systemic therapy, including chemotherapy and checkpoint inhibitors, or CPIs, such as KEYTRUDA®. Patients at this stage of disease progression have a high unmet medical need for alternative therapies that can extend life without the often severe side effects of traditional cancer therapies.

In this non-comparator monotherapy trial, CUE-101 has demonstrated evidence of anti-tumor clinical activity as a single agent, a favorable tolerability profile and an extension of median overall survival, or mOS. Of the 19 evaluable patients treated at the RP2D of 4 mg/kg, we observed a confirmed partial response, or PR, lasting for more than 36 weeks as well as six patients with durable stable disease, defined as stable disease on at least two consecutive post-treatment scans lasting at least 12 weeks. We have also observed promising preliminary data with respect to CUE-101’s pharmacokinetic, or PK, and pharmacodynamic, or PD, profile, as well as biomarker data with respect to HPV circulating free DNA, or cfDNA, as a potential proxy of anti-tumor response. Of note, one of the patients demonstrated stable disease for 24 months with no detectable evidence of HPV cfDNA in their blood after commencing treatment with CUE-101 and demonstrated an unconfirmed PR at the end of therapy. Importantly, a long overall survival has been observed in patients treated with CUE-101 as a monotherapy in 3L and beyond. For the patients treated at the RP2D in the monotherapy expansion cohort, the current Kaplan-Meier, or KM, estimate of mOS is 20.8 months, which compares favorably to the historical mOS of approximately eight months that was observed with pembrolizumab as a monotherapy in second line patients in Merck Sharp & Dohme Corp.'s, or Merck’s, KEYNOTE-040 trial and the historical mOS of approximately seven months that was observed with nivolumab as a monotherapy in the CHECKMATE 141 trial sponsored by Bristol-Myers Squibb. We continue to follow the patients treated in the monotherapy trial and anticipate this overall survival data to continue to mature through 2023.

 

CUE-101 Monotherapy in 3L+ R/M HNSCC: Kaplan-Meier mOS Estimate 20.8 Months

img77026815_2.jpg 

We have completed enrollment in our Phase 1 trial of CUE-101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), the current standard of care for first line, or 1L, R/M HNSCC. We completed the dose escalation portion of this trial without observing any dose-limiting-toxicity and enrolled patients in the patient expansion phase at the RP2D dose of 4 mg/kg of CUE-101 in combination with the approved dose of KEYTRUDA. The waterfall plot below was presented at the Society for Immunotherapy of Cancer, or SITC, meeting in November 2023. As shown below, as of the September 27, 2023 data cut-off date, the

28


 

overall response rate, or ORR, based on the best change from baseline, or CFB, in the sum of diameters of target lesions with best overall response as measured by RECIST 1.1 in the trial is 47% in the 17 evaluable patients treated with combination therapy at the RP2D of 4 mg/kg of CUE-101 and 200 mg of KEYTRUDA, including one patient with a confirmed complete response, or CR, and seven additional patients with confirmed PRs with a disease control rate, or DCR, of 65%, calculated by adding patient overall responses, partial responses and stable disease . The ORR of 47% in all patients with a combined positive score, or CPS, of ≥ 1, which reflects the levels of PD-L1 expression in the tumor, compares favorably to the historical ORR of 19% observed in all patients with CPS of ≥ 1 treated with pembrolizumab monotherapy in Merck's KEYNOTE-048 trial. Notably, five out of the eight objective responses in the CUE-101 Phase 1 combination trial with pembrolizumab were observed in patients with tumors with low PD-L1 expression, as evidenced by CPS of less than 20, i.e. an ORR of 56% versus 14% historical ORR observed in patients with CPS>1 and <20 treated with pembrolizumab monotherapy in Merck's KEYNOTE-048 trial.

 

CUE-101 in Combination with Pembrolizumab in 1L R/M HNSCC (data cut-off date September 27, 2023)

img77026815_3.jpg 

 

As shown below, patients with low CPS (1-19) treated with pembrolizumab alone in the KEYNOTE-48 trial had a lower ORR than all treated patients with CPS ≥1. Patients with low CPS (1-19), treated with CUE-101 and pembrolizumab in our ongoing Phase 1 combination trial demonstrated an ORR of 56%, compared to approximately 15% observed with pembrolizumab monotherapy in the KEYNOTE-048 trial. We believe that this supports the premise that CUE-101 and pembrolizumab given in combination could expand patient reach in HPV16+ R/M HNSCC patients with low PD-L1 expression. This is particularly important since patients with low CPS scores (CPS 1-19) represent approximately 50% of all patients that are CPS positive.

 

First-line (1L) R/M HNSCC Treated with CUE-101 4mg/kg in Combination with Pembrolizumab

vs. Pembrolizumab Monotherapy

29


 

img77026815_4.jpg 

 

We believe the evidence of combination activity of CUE-101 with KEYTRUDA is likely due to their complementary mechanisms of action, enabling anti-tumor T cells to effectively recognize and kill target tumor cells. We believe that CUE-101 has the potential to enhance the clinical activity of KEYTRUDA as well as other CPIs since the presence of expanded tumor-specific T cells is an obligatory pre-requisite for anti-PD-1 therapy. As such, we believe that CUE-101 has the potential to expand patient reach and enhance the therapeutic benefit of CPIs. On October 3, 2022, we received Fast Track Designation of CUE-101 for the treatment of R/M HPV+ HNSCC as a monotherapy and in combination with KEYTRUDA. As the data from the CUE-101 monotherapy trial and CUE-101 in combination with pembrolizumab trial matures, we are working to define potential registration paths for CUE-101, including a planned meeting with the FDA regarding CUE-101 as a monotherapy.

Importantly, it is our position that the CUE-101 clinical data generated to date has reduced the risk profile of the entire IL-2 based CUE-100 series due to the core framework of the CUE-100 series being conserved for each drug product candidate, with the only substantive modification being the targeting peptide epitope within the human leukocyte antigen, or HLA, pocket. Therefore, the core IL-2 scaffold is a shared molecular feature of all molecules generated within this series, including CUE-102 as described below which shares 99% sequence identity with CUE-101.

 

CUE-102

The second drug product candidate in our CUE-100 series, CUE-102, targets Wilms’ Tumor 1 protein, or WT1, an oncofetal antigen known to be over-expressed in more than 20 different cancers, including both solid tumors (such as colorectal, ovarian, pancreatic, gastric and lung tumors) and hematologic malignancies (such as acute myeloid leukemia, multiple myeloma and myelodysplastic syndromes). Based on the premise that CUE-102 shares the same core molecular framework as CUE-101, except for the T cell epitope pertaining to HPV-E7 versus WT1, its IND was supported by clinical and safety data from the ongoing CUE-101 monotherapy trial and did not require additional IND-enabling toxicology studies. This supports our premise that each CUE-100 series Immuno-STAT molecule provides further de-risking and acceleration of subsequent drug product candidates. With CUE-102 we believe there is a potential to reach an even larger patient population than for CUE-101 as WT1 can potentially treat a broad range of cancer types with significant unmet medical need. We are enrolling patients in a Phase 1 monotherapy dose-escalation trial with CUE-102 focused on WT1-positive recurrent/metastatic gastric, pancreatic, ovarian and colorectal cancers. As of October 1, 2023, 18 patients have received CUE-102 in doses ranging from 1 mg/kg to 8 mg/kg given every three weeks, 14 of the patients have at least one post dose scan and were evaluable for disease response and nine remain on treatment. CUE-102 has been well tolerated with no dose limiting toxicities observed.

As shown below, a DCR of 75-80% has been observed in patients treated with 2 mg/kg and 4 mg/kg of CUE-102. Monotherapy anti-tumor activity observed as of the data cut-off date of October 1, 2023 includes decreases in target tumor lesions, decreases in tumor biomarkers and durable stable disease in several patients.

 

CUE-102 Monotherapy Patient Status by Cohort (as of data cut-off date)

30


 

img77026815_5.jpg 

 

Two patients in dose escalation cohort 2 (treated with 2 mg/kg of CUE-102) demonstrated reductions in target tumor lesions as shown in the figures below. Both of these patients remain on treatment at the time of data cut-off. Both patients have advanced disease and were heavily pre-treated prior to enrollment in the CUE-102 monotherapy trial.

 

img77026815_6.jpg 

We anticipate opening the patient expansion cohort, or the Phase 1b portion of the trial, in patients with colorectal cancers as well as other indications in early 2024.

We believe that the modularity of our CUE-100 series platform enables the generation of new drug product candidates for tumor antigens that have already been clinically validated in adoptive cellular therapy approaches, resulting in further potential de-risking and accelerated development of future molecules to address a broad range of cancer types. For example, we have generated preclinical proof of concept data supporting the manufacturability and selective biologic activity of Immuno-STATs targeting mutated driver antigens (such as KRAS) and broadly expressed cancer antigens (such as MAGE-A4 and PRAME). These Immuno-STAT molecules contain peptide antigens presented on different HLA alleles, including HLA-A02, -A03, and -A11. Generating Immuno-STATs across these additional HLA alleles will enhance potential patient coverage and market reach globally. Based on the successful validation of the modularity of the core Immuno-STAT scaffold, multiple potential Immuno-STAT candidate molecules may be considered for nomination as subsequent clinical development programs. We are also exploring the application of our Immuno-STAT platform to CAR-T and TCR-T therapies to further expand and maintain T-cell levels in the patient's body to potentially increase efficacy of these therapies.

Furthermore, we have expanded the potential reach of the Immuno-STAT platform to address the heterogeneity and diversity present in many cancers by developing a derivative scaffold of the CUE-100 series containing stable “peptide-less” or “empty” HLA molecules, to which defined peptides of interest may be covalently attached. We refer to this derivative scaffold as Neo-STAT™. Neo-STAT is designed to provide greater flexibility for targeting multiple tumor epitopes, enhancing production efficiencies, and decreasing time and cost associated with manufacturing. We have also generated a derivative biologic designed to address a primary resistance mechanism found in a subset of solid tumors. This escape mechanism is based upon evading immune surveillance through down-regulation of HLA, thereby making the tumor “invisible” to T cells. This derivative of the CUE-100 series, referred to as RDI-STAT™, takes advantage of the clinical validation of the Immuno-STAT platform via the CUE-100 series by deploying an antibody-like targeting moiety binding to tumor specific antigens found on the surface of tumor cells. Through this approach, we believe we may be able to “paint” the tumor with a viral epitope placed within the HLA pocket of the CUE-100 series Immuno-STAT with the

31


 

objective of "redirecting" high frequency anti-viral T cells to attack the targeted tumor cells. As noted above, we are seeking partnerships to further develop our Neo-STAT and RDI-STAT assets.

In addition to these novel potential approaches to cancer immunotherapy, we have leveraged the modularity of the Immuno-STAT platform to develop additional biologic series outside of oncology. For example, CUE-300 and CUE-400 have been specifically designed through rational protein engineering to address distinct therapeutic approaches for treating autoimmune disease. The CUE-300 series incorporates the inhibitory PD-L1 co-modulator for selective inhibition of an autoreactive T cell repertoire. For example, CUE-301 has been engineered with an epitope known to be expressed in Type 1 diabetes. The CUE-400 series represents a novel class of bispecific molecules designed to selectively induce and expand Tregs. In February 2023, we announced a partnership with Ono supporting the development of CUE-401 for the potential treatment of autoimmune and inflammatory diseases.

Plan of Operation

Our technology is in the development phase. We believe that our platforms have the potential for creating a diverse pipeline of promising drug product candidates addressing multiple medical indications. We intend to maximize the value and probability of commercialization of our Immuno-STAT drug product candidates by focusing on researching, testing, optimizing, conducting pilot studies, performing early-stage clinical development and potentially partnering, where appropriate, for more extensive, later stages of clinical development, as well as seeking extensive patent protection and intellectual property development.

Since we are a development-stage company, the majority of our business activities to date have been, and our planned future activities will be, devoted to furthering research and development.

A fundamental part of our corporate development strategy is to establish strategic partnerships with leading pharmaceutical or biotechnology organizations that will allow us to more fully exploit the potential of our technology platform in the areas of oncology and autoimmune disease and accelerate and expand our CUE-100 series pipeline, such as our collaborations described below under the heading “Collaboration Agreement with LG Chem" and "Collaboration and Option Agreement with Ono”.

Critical Accounting Estimates and Significant Judgments

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, and the reported revenue and expenses during the reported periods. We evaluate these estimates and judgments, including those described below, on an ongoing basis. We base our estimates on historical experience, known trends and events, contractual milestones and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, we believe that the estimates, assumptions and judgments involved in the accounting policies described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in Item 7 of our 2022 Annual Report have the greatest potential impact on our financial statements, so we consider those estimates, assumptions and judgments to be our critical accounting policies and estimates. There were no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2023.

Recent Accounting Pronouncements and Adopted Standards

A discussion of recent accounting pronouncements is included in Note 2 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

Significant Contracts and Agreements Related to Research and Development Activities

Einstein License Agreement

On January 14, 2015, we entered into a license agreement, as amended and restated on July 31, 2017, and as amended on October 30, 2018, or the Einstein License, with Albert Einstein College of Medicine, or Einstein, for certain patent rights, or the Patents, relating to our core technology platform for the engineering of biologics to control T cell activity, precision, immune-modulatory drug product candidates, and two supporting technologies that enable the discovery of costimulatory signaling molecules (ligands) and T cell targeting peptides.

32


 

We hold an exclusive worldwide license, with the right to sublicense, import, make, have made, use, provide, offer to sell, and sell all products, processes and services that use the Patents, including certain technology received from Einstein related thereto, which we refer to as the Licensed Products. Under the Einstein License, we are required to:

Pay royalties and amounts based on a certain percentage of proceeds, as defined in the Einstein License, from sales of Licensed Products and sublicense agreements.
Pay escalating annual maintenance fees, which are non-refundable, but are creditable against the amount due to Einstein for royalties.
Make significant payments based upon the achievement of certain milestones, as defined in the Einstein License. As of September 30, 2023, two of these milestones had been achieved, as we had filed an IND in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021.
Incur minimum product development costs per year and meet certain diligence obligations until the first commercial sale of the first Licensed Product.

As of September 30, 2023, we were in compliance with our obligations under the Einstein License.

The Einstein License expires upon the expiration of the last obligation to make royalty payments to Einstein which may be due with respect to certain Licensed Products, unless terminated earlier under the provisions thereof. The Einstein License includes certain termination provisions that will be triggered if we fail to meet our obligations thereunder.

We account for the costs incurred in connection with the Einstein License in accordance with Accounting Standards Codification, or ASC, 730, Research and Development. For each of the three months ended September 30, 2023 and 2022, costs incurred with respect to the Einstein License were $0. For each of the nine months ended September 30, 2023 and 2022, costs incurred with respect to the Einstein License were $0. Such costs, if any, are included in research and development costs in our consolidated statements of operations and other comprehensive loss.

Pursuant to the Einstein License, we issued to Einstein 671,572 shares of our common stock in connection with the consummation of the initial public offering of our common stock on December 27, 2017.

Collaboration Agreement with LG Chem

Effective November 6, 2018, we entered into a Collaboration, License and Option Agreement, or the LG Chem Collaboration Agreement, with LG Chem Ltd., or LG Chem, related to the development of Immuno-STATs focused in the field of oncology.

Pursuant to the LG Chem Collaboration Agreement, we granted LG Chem an exclusive license to develop, manufacture and commercialize our lead product, CUE-101, as well as Immuno-STATs that target T cells against two additional cancer antigens, or the Drug Product Candidates, in Australia, Japan, Republic of Korea, Singapore, Malaysia, Vietnam, Thailand, Philippines, Indonesia, China (including Macau and Hong Kong) and Taiwan, which we refer to collectively as the LG Chem Territory. We retain rights to develop and commercialize all assets included in the LG Chem Collaboration Agreement in the United States and in global markets outside of the LG Chem Territory. Under the LG Chem Collaboration Agreement, we will engineer the selected Immuno-STATs for up to three alleles, which are expected to include the predominant alleles in the LG Chem Territory, thereby enhancing our market reach by providing for greater patient coverage of populations in global markets, while LG Chem will establish a chemistry, manufacturing and controls, or CMC, process for the development and commercialization of selected Drug Product Candidates. In addition, LG Chem has the option to select one additional Immuno-STAT for an oncology target, or an Additional Immuno-STAT, for an exclusive worldwide development and commercialization license. On December 18, 2019, we and LG Chem entered into a global license and collaboration agreement, which was amended on November 5, 2020. We refer to such agreement, as amended, as the Global License and Collaboration Agreement. The Global License and Collaboration Agreement supersedes the provisions of the LG Chem Collaboration Agreement related to LG Chem’s option for an Additional Immuno-STAT, which agreement provided for effectiveness if and when LG Chem exercised its option, other than certain select provisions including the length of the option period and representations, warranties and covenants of the parties. On April 30, 2021, LG Chem’s option pursuant to the Global License and Collaboration Agreement expired.

Under the terms of the LG Chem Collaboration Agreement, LG Chem paid us a $5.0 million non-refundable, non-creditable upfront payment and purchased approximately $5.0 million of shares of our common stock at a price per share equal to a 20% premium to the volume weighted-average closing price per share over the 30 trading day period immediately prior to the effective date of the LG Chem Collaboration Agreement. We are also eligible to receive additional aggregate payments of up to approximately $400.0 million if certain research, development, regulatory and commercial milestones are successfully achieved. On May 16, 2019, we earned a $2.5 million milestone payment for the FDA’s acceptance of the IND for our lead drug product candidate, CUE-101,

33


 

pursuant to the LG Chem Collaboration Agreement. On December 7, 2020, we earned a $1.25 million milestone payment on the selection of a preclinical candidate pursuant to the LG Chem Collaboration Agreement. On November 23, 2021, we earned a $3.0 million milestone payment for the selection of a Drug Product Candidate. In addition, the LG Chem Collaboration Agreement also provides that LG Chem will pay us tiered single-digit royalties on net sales of commercialized Drug Product Candidates, or Collaboration Products, in the LG Chem Territory on a product-by-product and country-by-country basis, until the later of expiration of patent rights in a country, the expiration of regulatory exclusivity in such country, or ten years after the first commercial sale of a Collaboration Product in such country, subject to certain royalty step-down provisions set forth in the LG Chem Collaboration Agreement.

Pursuant to the LG Chem Collaboration Agreement, the parties will share research costs related to Collaboration Products, and LG Chem will provide CMC process development for selected Drug Product Candidates and potentially additional downstream manufacturing capabilities, including clinical and commercial supply for Collaboration Products. In return for performing CMC process development, LG Chem is eligible to receive low-single digit percentage royalty payments on the sales of Collaboration Products sold in all countries outside the LG Chem Territory. For the three months ended September 30, 2023 and 2022, we recognized revenue of approximately $178,000 and approximately $68,000, respectively, related to the LG Chem Collaboration Agreement. For the nine months ended September 30, 2023 and 2022, we recognized revenue of approximately $243,000 and approximately $1,094,000, respectively, related to the LG Chem Collaboration Agreement. As of September 30, 2023, we had recorded approximately $19.8 million in collaboration revenue related to this agreement since the agreement was entered into. The majority of the research phase of the collaboration agreement was substantially complete on March 31, 2022.

The LG Chem Collaboration Agreement includes various representations, warranties, covenants, indemnities and other customary provisions. LG Chem may terminate the LG Chem Collaboration Agreement for convenience or change of control of us on a program-by-program, product-by-product or country-by-country basis, or in its entirety, at any time following the notice period set forth in the LG Chem Collaboration Agreement. Either party may terminate the LG Chem Collaboration Agreement, in its entirety or on a program-by-program, product-by-product or country-by-country basis, in the event of an uncured material breach. The LG Chem Collaboration Agreement is also terminable by either party (i) upon the bankruptcy, insolvency or liquidation of the other party or (ii) for certain activities involving the challenge of certain patents controlled by the other party. Unless earlier terminated, the LG Chem Collaboration Agreement will expire on a product-by-product and country-by-country basis upon the expiration of the applicable royalty term.

To date, LG Chem has selected one additional cancer antigen, WT1, which is the focus of the CUE-102 research program. We are currently developing two Collaboration Products with LG Chem pursuant to this agreement.

Collaboration and Option Agreement with Ono

On February 22, 2023, we entered into a strategic collaboration agreement, or the Ono Collaboration and Option Agreement, with Ono Pharmaceutical Co., Ltd., or Ono, to further develop CUE-401 and provide dedicated resources and capabilities to help advance CUE-401 toward the clinic. Under the terms of the Ono Collaboration and Option Agreement, Ono paid us an upfront payment and agreed to fully fund all research activities related to CUE-401 through a specified option period. During this option period, we will be responsible for the research and development of CUE-401. Upon Ono’s exercise of its option to license CUE-401, we will receive an option exercise payment and be eligible for development and commercial milestone payments up to an aggregate of approximately $220 million, as well as tiered royalties on sales. Upon any such exercise, Ono will receive worldwide rights to develop and commercialize CUE-401, with us retaining a 50% co-development and co-commercialization right in the United States.

Under the terms of the Ono Collaboration and Option Agreement, we will perform research activities related to CUE-401 through a specified option period of 24 months, or the Research Term. During this Research Term, we will be responsible for the execution of scientific investigation, nonclinical, preclinical, and clinical drug research and development activities designed to progress CUE-401 toward a potential IND and regulatory approval, collectively referred to as R&D. Ono is responsible for the funding of R&D activities performed by us. Per the Ono Collaboration and Option Agreement, as consideration for the R&D activities performed by us, Ono (i) made a one-time, non-refundable, non-creditable upfront payment of $3.0 million to us and (ii) will reimburse us for all costs incurred in conducting research, including (a) pass through costs from third party contractors and (b) full time employee salaries capped at $2.1 million in the first 18 months of the Research Term. The term of the Ono Collaboration and Option Agreement extends until the expiration of the Research Term which cannot exceed a 24-month period. We have forecasted that we will be able to complete the R&D activities in 18 months based on the initial research and development plans we have established. We received the $3.0 million upfront payment in March 2023.

Aside from the $3.0 million upfront payment and funding related to pass through costs, we do not believe that any variable consideration should be included in the transaction price as of September 30, 2023. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent we have had a

34


 

high degree of confidence that revenue would not be reversed in a subsequent reporting period. We will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur. For the three months ended September 30, 2023 and 2022, we recognized revenue of approximately $1,922,000 and $0, respectively, related to the Ono Collaboration and Option Agreement. For the nine months ended September 30, 2023 and 2022, we recognized revenue of approximately $3,426,000 and $0, respectively, related to the Ono Collaboration and Option Agreement. We recorded short-term research and development liabilities on our balance sheet dated September 30, 2023, of approximately $2,238,000. We did not recognize short- or long-term research and development liabilities on our balance sheet as of December 31, 2022, as the agreement was executed in February 2023.

Results of Operations

 

Collaboration Revenue

We have not generated commercial revenue from product sales. To date, we have generated collaboration revenue from our former collaboration agreement with Merck, the LG Chem Collaboration Agreement and the Ono Collaboration and Option Agreement. Collaboration revenue may vary from period to period depending on the progress of our work in connection with either or both of our collaboration agreements.

Operating Expenses

We generally recognize operating expenses as they are incurred in two general categories, general and administrative expenses and research and development expenses. Our operating expenses also include non-cash components related to depreciation and amortization of property and equipment and stock-based compensation, which are allocated, as appropriate, to general and administrative expenses and research and development expenses.

General and administrative expenses consist of salaries and related expenses for executive, legal, finance, human resources, information technology and administrative personnel, as well as professional fees, insurance costs, and other general corporate expenses. We expect general and administrative expenses to increase in future periods as we incur additional expenses related to our operation as a public company which requires our compliance with certain regulatory and legal procedures. We expect activities supporting our operations including legal, accounting, insurance, employee compensation and other expenses to increase.

Research and development expenses consist primarily of compensation expenses, fees paid to consultants, outside service providers and organizations (including research institutes at universities), facility expenses, and development and clinical trial expenses with respect to our drug product candidates. We charge research and development expenses to operations as they are incurred. We expect research and development expenses to increase in the future as we continue to advance the clinical development of CUE-101 and CUE-102, including our ongoing and planned clinical trials, and develop potential future drug product candidates based on our technology and research. We also believe that rising inflation, supply chain disruptions and labor shortages may also contribute to increased research and development costs.

35


 

Three and Nine Months Ended September 30, 2023 and 2022

Our consolidated statements of operations and other comprehensive loss for the three and nine months ended September 30, 2023 and 2022, as discussed herein, are presented below.

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

(in thousands)

 

 

(in thousands)

 

Collaboration revenue

 

$

2,100

 

 

$

68

 

 

$

3,669

 

 

$

1,094

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

3,645

 

 

 

3,528

 

 

 

12,071

 

 

 

12,465

 

Research and development

 

 

9,874

 

 

 

7,571

 

 

 

29,915

 

 

 

27,246

 

Gain on right-of-use asset termination

 

 

 

 

 

 

 

 

 

 

 

(258

)

Total operating expenses

 

 

13,519

 

 

 

11,099

 

 

 

41,986

 

 

 

39,453

 

Loss from operations

 

 

(11,419

)

 

 

(11,031

)

 

 

(38,317

)

 

 

(38,359

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

700

 

 

 

200

 

 

 

1,756

 

 

 

296

 

Interest expense, net

 

 

(286

)

 

 

(124

)

 

 

(738

)

 

 

(355

)

Total other (expense) income

 

 

414

 

 

 

76

 

 

 

1,018

 

 

 

(59

)

Net loss

 

$

(11,005

)

 

$

(10,955

)

 

$

(37,299

)

 

$

(38,418

)

Unrealized gain (loss) from available-for-sale securities

 

 

5

 

 

 

(92

)

 

 

96

 

 

 

(92

)

Comprehensive loss

 

$

(11,000

)

 

$

(11,047

)

 

$

(37,203

)

 

$

(38,510

)

Net loss per common share – basic and diluted

 

$

(0.24

)

 

$

(0.31

)

 

$

(0.82

)

 

$

(1.11

)

Weighted average common shares outstanding –basic and diluted

 

 

46,358,555

 

 

 

35,383,430

 

 

 

45,274,124

 

 

 

34,471,499

 

 

Collaboration Revenue

Collaboration revenue was approximately $2,100,000 and $68,000 for the three months ended September 30, 2023 and 2022, respectively. We recognized collaboration revenue of $3,669,000 and $1,094,000 for the nine months ended September 30, 2023 and 2022, respectively. The increase of approximately $2,032,000 and $2,575,000 during the three and nine months ended September 30, 2023 compared to the three and nine months ended September 30, 2022, respectively, was due to the Ono Collaboration and Option Agreement executed in February 2023. All collaboration revenue recognized in the three and nine months ended September 30, 2023 was related to the performance of services under our collaboration agreements with Ono and LG Chem, including a $3.0 million upfront payment received pursuant to the Ono Collaboration and Option Agreement and pass through costs related to research activities. All collaboration revenue recognized in the three and nine months ended September 30, 2022 was related to the performance of services under our collaboration agreement with LG Chem.

General and Administrative

General and administrative expenses totaled approximately $3,645,000 and $3,528,000 for the three months ended September 30, 2023 and 2022, respectively. This increase of approximately $117,000 during the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was due primarily to higher professional and consulting fees, offset by a decrease in rent expense.

General and administrative expenses for the three months ended September 30, 2023 consisted of expenses related to employee and board compensation of $1,209,000, professional and consulting fees of $1,071,000, stock-based compensation of $858,000, rent of $173,000, insurance expense of $71,000 and other expenses of $263,000. General and administrative expenses for the three months ended September 30, 2022 consisted of expenses related to employee and board compensation of $1,140,000, stock-based compensation of $1,003,000, professional and consulting fees of $906,000, rent of $182,000, insurance expense of $95,000 and other expenses of $202,000.

General and administrative expenses totaled approximately $12,071,000 and $12,465,000 for the nine months ended September 30, 2023 and 2022, respectively. This decrease of approximately $394,000 during the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 was due primarily to lower stock-based compensation related to executive management.

General and administrative expenses for the nine months ended September 30, 2023 consisted of expenses related to employee and board compensation of $4,100,000, professional and consulting fees of $3,833,000, stock-based compensation of $2,708,000, rent

36


 

of $544,000, insurance expense of $227,000, and other expenses of $659,000. General and administrative expenses for the nine months ended September 30, 2022 consisted of expenses related to employee and board compensation of $3,682,000, stock-based compensation of $3,650,000, professional and consulting fees of $3,555,000, rent of $716,000, insurance expense of $267,000, and other expenses of $595,000.

Research and Development

Research and development expenses totaled approximately $9,874,000 and $7,571,000 for the three months ended September 30, 2023 and 2022, respectively. This increase of approximately $2,303,000 during the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was due primarily to higher clinical expenses, stock-based compensation and research and laboratory expenses.

 

Research and development expenses for the three months ended September 30, 2023 included expenses related to clinical expenses of $3,429,000, employee and board compensation of $2,272,000, research and laboratory expenses of $1,560,000, stock-based compensation expense of $1,215,000, rent expense of $679,000, insurance expense of $203,000, depreciation and amortization of $126,000, and other expenses of $390,000. Research and development expenses for the three months ended September 30, 2022 included expenses related to employee compensation of $2,368,000, clinical expenses of $1,495,000, research and laboratory expenses of $1,286,000, stock-based compensation expense of $1,061,000, rent of $677,000, insurance expense of $252,000, depreciation and amortization of $196,000, and other expenses of $236,000.

 

Research and development expenses totaled approximately $29,915,000 and $27,246,000 for the nine months ended September 30, 2023 and 2022, respectively. This increase of approximately $2,669,000 was due primarily to clinical expenses related to the CUE-101 clinical trial and expenses related to the initiation of the Phase 1 monotherapy clinical trial of CUE-102. Rising inflation, supply chain disruptions, and labor shortages may also contribute to future increases in research and development expense.

 

Research and development expenses for the nine months ended September 30, 2023 included expenses related to research and laboratory expenses of $7,736,000, employee and board compensation of $7,404,000, clinical expenses of $7,029,000, stock-based compensation of $3,399,000, rent expense of $2,022,000, insurance expense of $615,000, other professional fees of $539,000, depreciation and amortization of $426,000, and other expenses of $745,000. Research and development expenses for the nine months ended September 30, 2022, included expenses related to employee compensation of $7,920,000, research and laboratory expenses of $5,619,000, clinical expenses of $4,570,000, stock-based compensation of $3,734,000, rent of $2,592,000, insurance expense of $756,000, depreciation and amortization of $687,000, and other expenses of $1,368,000.

Gain on Right-of-use Asset Termination

Gain on right-of-use asset termination was $0 and $258,000 for the three and nine months ended September 30, 2023 and 2022, respectively. This decrease of $258,000 was due to the gain on right-of-use asset related to the termination of our operating lease agreement for our laboratory and office space in Cambridge, Massachusetts at 21 Erie Street, effective on April 30, 2022.

Interest Income

Interest income was approximately $700,000 for the three months ended September 30, 2023 as compared to approximately $200,000 for the three months ended September 30, 2022. Interest income for the three months ended September 30, 2023 included approximately $576,000 in income resulting from amortization of discounts received on certain of our marketable securities and approximately $124,000 of interest income from our operating sweep account, compared to approximately $200,000 of interest income for the three months ended September 30, 2022.

Interest income was approximately $1,756,000 for the nine months ended September 30, 2023 as compared to approximately $296,000 for the nine months ended September 30, 2022. Interest income for the nine months ended September 30, 2023 included approximately $1,490,000 in income resulting from amortization of discounts received on certain of our marketable securities and approximately $266,000 of interest income from our operating sweep account, compared to approximately $296,000 of interest income for the nine months ended September 30, 2022.

Interest Expense

Interest expense was approximately $286,000 and $124,000 for the three months ended September 30, 2023 and 2022, respectively. This increase of $162,000 was primarily due to cash paid for interest expense related to the proceeds from borrowings under our Loan and Security Agreement, as amended, or the Loan Agreement, with Silicon Valley Bridge Bank, N.A., or SVBB, of

37


 

$288,000, and amortization of deferred issuance costs of $9,000, offset by approximately $11,000 from amortization/accretion on investments.

Interest expense was approximately $738,000 and $355,000 for the nine months ended September 30, 2023 and 2022, respectively. This increase of $383,000 was primarily due to cash paid for interest expense related to the proceeds from borrowings under the Loan Agreement with SVBB of $946,000, and amortization of deferred issuance costs of $28,000, offset by cash received on the sale of property and equipment of $2,000 and approximately $234,000 from amortization/accretion on investments.

Liquidity and Capital Resources

We have financed our working capital requirements primarily through private and public offerings of equity securities, cash received from Merck, LG Chem, and Ono under the respective collaboration agreements and borrowings under the Loan Agreement. At September 30, 2023, we had cash and cash equivalents totaling $54,691,000 available to fund our ongoing business activities. Additional information concerning our financial condition and results of operations is provided in the financial statements included in this Quarterly Report on Form 10-Q.

The amounts that we actually spend for any specific purpose may vary significantly and will depend on a number of factors, including, but not limited to, our research and development activities and programs, clinical testing, regulatory approval, market conditions, and changes in or revisions to our business strategy and technology development plans.

On May 9, 2023, we filed a registration statement on Form S-3, which was declared effective on May 26, 2023 (File No. 333-271786), to register for sale from time to time up to $300.0 million of our common stock, preferred stock, debt securities, warrants, subscription rights and/or units in one or more offerings.

In October 2021, we entered into an open market sale agreement, or the October 2021 ATM Agreement, with Jefferies LLC, or Jefferies, to sell shares of our common stock for aggregate gross proceeds of up to $80.0 million, from time to time, through an "at-the-market" equity offering program under which Jefferies acts as sales agent. The October 2021 ATM Agreement will terminate upon the earliest of (a) the sale of $80.0 million of shares of our common stock pursuant to the October 2021 ATM Agreement or (b) the termination of the October 2021 ATM Agreement by us or Jefferies. During the three months ended September 30, 2023,we sold 1,378,867 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $5,589,000 net of commission paid, but excluding transaction expenses. During the nine months ended September 30, 2023, we sold 1,915,131 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $7,605,000, net of commission paid, but excluding transaction expenses. As of September 30, 2023, we had sold an aggregate of 5,508,538 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $31.2 million, net of commission paid, but excluding transaction expenses, since its inception.

On February 15, 2022, we entered into the Loan Agreement, pursuant to which we have borrowed $10.0 million. The Loan Agreement was amended in April 2023. The term loans under the Loan Agreement, or the Term Loans, bear interest at a floating rate per annum equal to the greater of (A) the prime rate (as published in the money rates section of The Wall Street Journal) plus 2.25% and (B) 5.50%. On the first calendar day of each month, we will be required to make monthly interest payments and commencing on June 30, 2023, we are required to repay the Term Loans in (i) 30 consecutive installments of principal plus monthly payments of accrued interest if the additional term loans are not advanced and (ii) 24 months if the additional term loans are advanced. All outstanding principal and accrued and unpaid interest under the Term Loans and all other outstanding obligations with respect to the Term Loans are due and payable in full on December 1, 2025.

The Loan Agreement permits voluntary prepayment of all, but not less than all, of the Term Loans, subject to a prepayment premium except if the facility is refinanced with another SVBB facility. Such prepayment premium would be 2.00% of the principal amount of the Term Loans if prepaid on or after the first anniversary of the date on which we entered the Loan Agreement but prior to the second anniversary of the date on which we entered the Loan Agreement, and 1.00% of the principal amount of the Term Loans if prepaid on or after the second anniversary of the date on which we entered the Loan Agreement. Upon prepayment or repayment in full of the Term Loans, we will be required to pay a one-time final payment fee equal to 5.00% of the original principal amount of any funded Term Loans being repaid. The Loan Agreement also requires us to maintain in our accounts at the Lender unrestricted and unencumbered cash equal to the lesser of all of our cash or $20,000,000.

On March 10, 2023, Silicon Valley Bank, or SVB, was closed and the Federal Deposit Insurance Company, or FDIC, was appointed receiver for the bank. The FDIC created a successor bridge bank, SVBB, and all deposits of SVB were transferred to SVBB under a systemic risk exception approved by the U.S. Department of the Treasury, the Federal Reserve and the FDIC. SVBB continues to hold our Term Loans under the same existing terms and covenants which were in place with SVB. The vast majority of our cash and cash equivalents reside in custodial accounts at US Bank for which SVB Asset Management is the advisor.

38


 

On November 14, 2022, we entered into securities purchase agreements with accredited investors pursuant to which, on November 16, 2022, we issued and sold to such investors in a private placement an aggregate of 7,656,966 shares of common stock and, in lieu of shares of common stock to certain investors, pre-funded warrants, or Pre-Funded Warrants, to purchase an aggregate of 1,531,440 shares of common stock, and, in each case, accompanying warrants, or Warrants, to purchase an aggregate of up to 9,188,406 additional shares of common stock (or Pre-Funded Warrants in lieu thereof) at a price of $3.265 per share and accompanying Warrant (or $3.2649 per Pre-Funded Warrant and accompanying Warrant), or the PIPE Financing. The exercise price of the Warrants is $3.93 per share, or if exercised for a Pre-Funded Warrant in lieu thereof, $3.9299 per Pre-Funded Warrant. The Warrants are exercisable at any time after they are issued and ending on the fifth anniversary of the closing. The Pre-Funded Warrants are exercisable at any time after they are issued and will not expire. We received aggregate gross proceeds from the PIPE Financing of approximately $30 million, before deducting placement agent fees and offering expenses of $2.6 million. Piper Sandler & Co. acted as lead placement agent and Public Ventures LLC acted as co-placement agent for the PIPE Financing.

 

If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of our common stock. If we issue debt securities, we may be required to grant security interests in our assets, could have substantial debt service obligations, and lenders may have a senior position (compared to stockholders) in any potential future bankruptcy or liquidation. Additionally, corporate collaboration and licensing arrangements may require us to incur non-recurring and other charges, give up certain rights relating to our intellectual property and research and development activities, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, issue debt which may require liens on our assets and which will increase our monthly expense obligations, or disrupt our management and business.

Cash Flows

The following table summarizes our changes in cash, cash equivalents, and restricted cash for the nine months ended September 30, 2023 and 2022:

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2023

 

 

2022

 

 

 

(in thousands)

 

Net cash provided by (used in):

 

 

 

 

 

 

Operating activities

 

$

(29,003

)

 

$

(31,292

)

Investing activities

 

 

25,002

 

 

 

(29,609

)

Financing activities

 

 

7,078

 

 

 

26,256

 

Net increase in cash, cash equivalents, and restricted cash

 

$

3,077

 

 

$

(34,645

)

 

Operating Activities

During the nine months ended September 30, 2023 and 2022, we used cash of $29,003,000 and $31,292,000, respectively, to fund our operating activities. Cash used in operating activities during the nine months ended September 30, 2023 consisted primarily of our net loss of $37,299,000 and decreases of $2,064,000 in operating lease liability, $1,603,000 in accounts receivable, $324,000 in prepaid expenses and other current assets, $251,000 in accounts payable, $234,000 in amortization of discount on purchased securities and $2,000 in gain on sale of property and equipment. Cash used in operating activities was offset by increases of $6,108,000 in stock-based compensation, $2,238,000 in research and development contract liability, $2,142,000 in amortization of operating lease right-of-use asset, $1,573,000 in accrued expenses, $443,000 in depreciation and amortization, $139,000 in deposits, $98,000 in accretion on final payment of Term Loans, $28,000 in amortization of debt issuance costs and $5,000 in accrued interest.

Cash used in operating activities during the nine months ended September 30, 2022 consisted primarily of our net loss of $38,418,000 and decreases of $741,000 in accrued expenses, $645,000 in research and development contract liability, $258,000 in gain on right-of-use asset termination, $546,000 in accounts payable, $395,000 in deposits, $397,000 in operating lease liability, $101,000 in amortization of discount on purchased securities, $3,000 in accrued interest on purchased securities, and $846,000 in prepaid expenses and other current assets. Cash used in operating activities was partially offset by increases of $7,384,000 in stock-based compensation, $507,000 in amortization of operating lease right-of-use asset, $21,000 in amortization of debt issuance costs, $76,000 in accretion on final payment of Term Loans, $719,000 in depreciation and amortization, $2,347,000 in accounts receivable, and $4,000 in loss on disposal of fixed assets.

39


 

Investing Activities

During the nine months ended September 30, 2023, our investing activities provided $25,002,000 in cash, compared to cash used in investing activities of $29,609,000 during the nine months ended September 30, 2022. Cash provided in investing activities during the nine months ended September 30, 2023 consisted of the net redemption of short-term investments in marketable securities of $25,000,000 and the cash received from the sale of property and equipment of $2,000. Cash used in investing activities during the nine months ended September 30, 2022 consisted of the purchase of property and equipment of $170,000, and the purchase of short-term investments in marketable securities of $29,500,000, offset by cash received from the sale of fixed assets of $6,000.

Financing Activities

During the nine months ended September 30, 2023 and 2022, we generated cash from financing activities of $7,078,000 and $26,256,000, respectively, a decrease of $19,178,000. Cash from financing activities during the nine months ended September 30, 2023 consisted of cash proceeds from the sale of common stock pursuant to the October 2021 ATM Agreement of $7,605,000 net of sales agent commissions and fees, and cash proceeds from the exercise of stock options of $473,000. Cash from financing activities during the nine months ended September 30, 2022 consisted of cash proceeds from the sale of common stock pursuant to the October 2021 ATM Agreement of $16,598,000 net of sales agent commissions and fees, and proceeds from borrowings under the Loan Agreement of $10,000,000, partially offset by cash used for restricted stock buy-back at vesting of $200,000 and payment of debt issuance costs of $142,000.

Funding Requirements

We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of our Immuno-STAT platform, continue ongoing and initiate new clinical trials of and seek marketing approval for our drug product candidates. In addition, we expect to incur additional costs associated with operating as a public company. Our expenses will also increase if, and as, we:

continue the clinical development of our CUE-100 series, including CUE-101 and CUE-102;
leverage our programs to advance our other drug product candidates into preclinical and clinical development;
seek regulatory approvals for any drug product candidates for which we successfully complete clinical trials;
seek to discover and develop additional drug product candidates in the CUE-100 series, including Neo-STATs;
establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any drug product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly;
hire additional clinical, quality control and scientific personnel;
expand our manufacturing, quality, operational, financial and management systems;
increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;
maintain, expand and protect our intellectual property portfolio;
acquire or in-license other drug product candidates and technologies; and
incur additional legal, accounting and other expenses in operating as a public company.

 

In the first quarter of 2022, we prioritized our strategic focus on our CUE-101 and CUE-102 oncology programs in our CUE-100 series. The data generated from our ongoing clinical trials provides a sound basis for establishing strategic partnerships to enhance our capacity by subsidizing development of these highly promising programs. We are actively seeking third party support through partnerships and collaborations, or alternative funding structures, to more fully exploit the potential of our technology platform in the areas of oncology and autoimmune disease, accelerate and expand our CUE-100 series pipeline including the further development of CUE-103 and our Neo-STAT and RDI-STAT programs as well as our CUE-300 and CUE-400 series. In 2022, we also took proactive steps to decrease our office and lab footprint and to restructure our research and development functions in support of prioritized corporate objectives and strategies. These steps have realized cost savings to date that have been allocated to our key programs.

We believe that our existing cash and cash equivalents as of September 30, 2023 will enable us to fund our operating requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

40


 

We will need to raise additional capital or incur additional indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, many of which are outside of our control, and we may be unable to raise financing when needed, or on terms favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market drug product candidates that we would otherwise prefer to develop and market ourselves, which could adversely affect our business prospects, and we may be unable to continue our operations. Because of numerous risks and uncertainties associated with the research, development and commercialization of our drug product candidates, we are unable to estimate the exact amount of our working capital requirements. Factors that may affect our planned future capital requirements and accelerate our need for additional working capital include the following:

the progress, timing, scope and costs of our clinical trials, including the ability to timely enroll patients in our ongoing, planned and potential future clinical trials;
the outcome, timing and cost of regulatory approvals by the FDA and other comparable regulatory authorities, including the potential that the FDA or other comparable regulatory authorities may require that we perform more studies than those that we currently expect;
the number and characteristics of drug product candidates that we may in-license and develop;
our ability to successfully commercialize our drug product candidates, if approved;
the amount of sales and other revenues from drug product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party reimbursement;
selling and marketing costs associated with our potential products, including the cost and timing of expanding our marketing and sales capabilities;
the terms and timing of any potential future collaborations, licensing or other arrangements that we may establish;
cash requirements of any future acquisitions and/or the development of other drug product candidates;
the costs of operating as a public company;
the cost and timing of completion of commercial-scale, outsourced manufacturing activities;
the time and cost necessary to respond to technological and market developments;
any disputes which may occur between us and Einstein, employees, collaborators or other prospective business partners; and
the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these or other variables with respect to the development of any of our drug product candidates could significantly change the costs and timing associated with the development of that drug product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties and grants from organizations and foundations. If we raise additional funds by selling shares of our common stock or other equity-linked securities, the ownership interest of our current stockholders will be diluted. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or drug product candidates or to grant licenses on terms that may not be acceptable to us. If we raise additional funds through debt financing, we may have to grant a security interest on our assets to the future lenders, our debt service costs may be substantial, and the lenders may have a preferential position in connection with any future bankruptcy or liquidation.

If we are unable to raise additional capital when needed, we may be required to curtail the development of our technology or materially curtail or reduce our operations. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds on commercially reasonable terms could have a material adverse effect on our business, results of operation and financial condition, including the possibility that a lack of funds could cause our business to fail, dissolve and liquidate with little or no return to investors.

41


 

Principal Commitments

During the three and nine months ended September 30, 2023, there were no material changes to our contractual obligations and commitments as of December 31, 2022 described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2022 Annual Report.

 

42


 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this Item 3.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Based on our management’s evaluation (with the participation of our principal executive officer and our principal financial officer) of our disclosure controls and procedures as required by Rule 13a-15 under the Exchange Act, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective as of September 30, 2023, the end of the period covered by this report.

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer and our principal financial officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of control effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

43


 

PART II. OTHER INFORMATION

We are not currently a party to any material legal proceedings.

ITEM 1A. RISK FACTORS

We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In evaluating us and our business, you should carefully consider the information included in this Quarterly Report on Form 10-Q and in other documents we file with the SEC and the risk factors previously disclosed in “Part I, Item 1A. Risk Factors” of our 2022 Annual Report.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

44


 

ITEM 6. EXHIBITS

 

Incorporated by Reference

Exhibit

Number

Exhibit Description

Filed

Herewith

Form

Exhibit

Filing Date

Registration/File No.

10.1

Amendment No. 1 to Consulting Agreement between Cue Biopharma, Inc. and Peter A. Kiener, dated September 1, 2023

X

 

 

 

 

31.1

Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934

X

 

 

 

31.2

Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934

X

 

32.1

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

X

 

 

101.INS

Inline eXtensible Business Reporting Language (XBRL) Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

X

 

 

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema Document

X

 

 

 

 

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

X

 

 

 

 

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

X

 

 

 

 

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

X

 

 

 

 

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

X

 

 

 

 

104

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, has been formatted in Inline XBRL.

X

 

 

 

 

 

 

45


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Cue Biopharma, Inc.

 

 

 

 

 

 

 

 

 

 

Dated:  November 3, 2023

 

By:

 

/s/ Daniel R. Passeri

 

 

 

 

 

 

 

 

 

Daniel R. Passeri

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

Dated:  November 3, 2023

 

By:

 

/s/ Kerri-Ann Millar

 

 

 

 

 

 

 

 

 

Kerri-Ann Millar

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

46


EX-10.1 2 cue-ex10_1.htm EX-10.1 EX-10.1

 

 

 

 

EXHIBIT 10.1

 

AMENDMENT NO. 1 TO CONSULTING AGREEMENT

 

THIS AMENDMENT NO. 1 TO CONSULTING AGREEMENT (this “Amendment No. 1”)

effective September 1, 2023 is entered into between Cue Biopharma, Inc., a Delaware corporation having an address of 40 Guest Street, Boston MA 02135 (the “Company”), and Peter Kiener D.Phil, (“Consultant”) whose address is [**}. Company and Consultant may be referred to herein individually as “Party” or jointly as “Parties.”

 

Whereas the Parties executed a Consulting Agreement having an effective date of June 7, 2023, and now wish to revise Exhibit A of the Consulting Agreement to amend the monthly retainer to be provided to the Consultant, the Parties hereby agree as follows:

 

1.
Exhibit A is amended as follows:

 

Consultant will provide agreed upon services for at least 20 hours per month for a monthly retainer of $9,166.67

 

2.
Except as amended herein, all of the terms, provisions and conditions set forth in the original Consulting Agreement are hereby confirmed and shall remain in full force and effect. The original Consulting Agreement and this Amendment No. 1 shall be read and construed together as a single agreement and the term “Agreement” as used shall henceforth be deemed a reference to the original Consulting Agreement as amended by this Amendment No. 1.

 

3.
Counterparts. This Amendment No. 1 may be signed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

 

 

 


 

 

THE COMPANY

 

Cue Biopharma, Inc.



 


 

CONSULTANT

 

Peter A Kiener, D.Phil

 

 


 

 

 

 

/s/ Daniel R. Passeri

/s/ Peter Kiener

Name: Daniel R. Passeri

Name: Peter A Kiener, D. Phil

Title: Chief Executive Officer

Title: Consultant

(Principal Executive Officer)

 

 

 


EX-31.1 3 cue-ex31_1.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Daniel R. Passeri, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Cue Biopharma, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 3, 2023

/s/ Daniel R. Passeri

Name: Daniel R. Passeri

Title: Chief Executive Officer

(Principal Executive Officer)

 


EX-31.2 4 cue-ex31_2.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kerri-Ann Millar, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Cue Biopharma, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 3, 2023

/s/ Kerri-Ann Millar

Name: Kerri-Ann Millar

Title: Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 


EX-32.1 5 cue-ex32_1.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Cue Biopharma, Inc. (the “Company”) for the three months ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Daniel R. Passeri, Chief Executive Officer of the Company, and Kerri-Ann Millar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to our knowledge that:

1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Daniel R. Passeri

/s/ Kerri-Ann Millar

Name: Daniel R. Passeri

Name: Kerri-Ann Millar

Title: Chief Executive Officer

Title: Chief Financial Officer

(Principal Executive Officer)

(Principal Financial Officer and Principal Accounting Officer)

Date: November 3, 2023

Date: November 3, 2023


GRAPHIC 6 img77026815_0.jpg GRAPHIC begin 644 img77026815_0.jpg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img77026815_1.jpg GRAPHIC begin 644 img77026815_1.jpg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end GRAPHIC 8 img77026815_2.jpg GRAPHIC begin 644 img77026815_2.jpg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img77026815_3.jpg GRAPHIC begin 644 img77026815_3.jpg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end GRAPHIC 10 img77026815_4.jpg GRAPHIC begin 644 img77026815_4.jpg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img77026815_5.jpg GRAPHIC begin 644 img77026815_5.jpg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end GRAPHIC 12 img77026815_6.jpg GRAPHIC begin 644 img77026815_6.jpg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end EX-101.SCH 13 cue-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Loan with Silicon Valley Bank - Summary of Future Principal Debt Payments on Term Loan Agreement (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Loan with Silicon Valley Bank link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Collaboration Revenue link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Loan with Silicon Valley Bank (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Warrants (Table) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Fair Value - Schedule of Fair Value Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Fair Value - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Marketable Securities - Schedule of Fair Value of Available-for-Sale Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Loan with Silicon Valley Bank (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Loan with Silicon Valley Bank - Summary of Future Principal Debt Payments on Term Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Stock Based Compensation - Schedule of Estimated Fair Value of Each Stock Option Award (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Stock Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Stock Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Stock Based Compensation - Schedule of Stock-Based Compensation Included in Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Warrants - Summary of Common Stock Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Collaboration Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Collaboration Revenue - Additional Information (Details1) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Collaboration Revenue - Additional Information (Details1) [Default] link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Leases - Schedule of Future Minimum Lease Payments on Operating Leases (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Leases - Schedule of Future Minimum Lease Payments on Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Leases - Schedule of Other Information of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Subsequent Events (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 14 cue-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 15 cue-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 2023 (3 months remaining) Lessee, Operating Lease, Liability, to be Paid, Year One Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Transition Report Document Transition Report Stock based payment options outstanding weighted average remaining term Weighted Average Remaining Contractual Life (in Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Transaction price recorded in liabilities Revenue, Remaining Performance Obligation, Amount Trademark Trademark Policy [Text Block] Trademark. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Unrealized losses from available-for-sale securities Geographical Geographical [Axis] Unrealized gain on investments Unrealized Gain (Loss) on Investments Debt Instruments [Abstract] Recognized Revenue Cost of Revenue Cost of Revenue, Total Debt Securities, Available-for-Sale, Total Debt Securities, Available-for-Sale Marketable securities Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Restricted Stock Units Restricted Stock Units (RSUs) [Member] Issuance of Pre-funded Warrants, shares Issuance of PreFunded Warrants Issuance Of PreFunded Warrants Level 1 Fair Value, Inputs, Level 1 [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Other Long-Term Debt, Total Other Long-Term Debt Long-term debt issuance costs Fair Value Fair Value Disclosures [Text Block] Estimated useful lives Property, Plant and Equipment, Useful Life Revenue from Contract with Customer, Excluding Assessed Tax, Total Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Tranche 2 [Member] Tranche 2 [Member] Tranche 2 Prepayment premium rate Prepayment premium rate Prepayment premium rate Aggregate amount of additional milestone payments Aggregate Amount Of Additional Milestone Payments Maximum Aggregate amount of a one-time additional milestone payments based on cumulative sales of all licensed products, maximum. February 2020 Awarded And Granted February2020 Awarded And Granted [Member] February 2020 awarded and granted. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Unrecognized stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount License monthly rental rate License monthly rental rate License monthly rental rate Warrant Issued December Twenty Seven Two Thousand Seventeen [Member] Warrant Issued December Twenty Seven Two Thousand Seventeen Member Pre-Funded Warrants [Member] Pre-Funded Warrants [Member] Interest expense, net Interest Income (Expense), Net Interest Income (Expense), Net, Total Term Loan Agreement Member Term Loan Agreement [Member] Term Loan Agreement Deposits Increase Decrease In Deposit Liabilities Increase decrease in deposit liabilities. Schedule of Stock-Based Compensation Included in Statement of Operations Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Proceeds from sale of common stock Proceeds From Sale Of Common Stock Net Commission Paid1 ProceedsFromSaleOfCommonStockNetCommissionPaid. Subsequent Events Subsequent Events [Text Block] Schedule of Fair Value Assets Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Debt Securities Available For Sale [Table] Debt Securities, Available-for-Sale [Table] Operating Lease Agreement For Additional Laboratory Space Operating Lease Agreement For Additional Laboratory Space [Member] Operating lease agreement for additional laboratory space. Adjustment related to right of use asset Adjustment Related To Right Of Use Asset Adjustment related to right of use asset Balance Sheet Location Balance Sheet Location [Axis] Total current assets Assets, Current Current assets Vesting [Domain] Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents [Axis] Total liabilities and stockholders' equity Liabilities and Equity Entity Address State or Province Entity Address, State or Province Lease agreement effective date Lease Agreement Effective Date Lease agreement effective date. 2024 2025 Operating Leases, Future Minimum Payments, Due in Two Years Boston, Massachusetts Boston [Member] Boston [Member] Issuance of common stock from ATM offering, net ofsales agent commission and fees Stock Issued During Period, Value, New Issues Full time employe salary payable in first research term Full time employe salary payable in first research term Number of Shares, Outstanding Beginning Balance Number of Shares, Outstanding Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Comprehensive loss Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Trading Symbol Trading Symbol Common Stock, Shares, Issued, Total Common stock, shares issued Common Stock, Shares, Issued Common stock shares issued Schedule Of Available For Sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Long-Term Debt, Maturity, Year Two 2024 Prepaid expenses and other short-term assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Lease expiration date Lease Expiration Date Balance, Shares Balance, Shares Shares, Outstanding 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. AOCI Attributable to Parent AOCI Attributable to Parent [Member] Long-Term Debt, Current Maturities, Total Long-Term Debt, Current Maturities Total current portion of long-term debt Entity Address, City or Town Entity Address, City or Town Laboratory Equipment Laboratory Equipment [Member] Laboratory equipment. Long-Term Debt, Maturity, Remainder of Fiscal Year 2022 Operating lease, weighted average discount rate Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Shares remaining to be issued as of September 30, 2023 Shares remaining to be issued as of December 31, 2022 Common stock warrants outstanding Class of Warrant or Right, Outstanding Debt Disclosure [Text Block] Loan with Silicon Valley Bank Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Expired Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Subsequent Event [Member] Subsequent Event Subsequent Event Type [Axis] Share-Based Payment Arrangement, Tranche Two [Member] Tranche B Long-Term Debt, Maturity Date Closing date Lease modification date Lease Modification Date Lease modification date. Additional Paid-in Capital Additional Paid-in Capital [Member] Current liabilities: Liabilities, Current [Abstract] One Time Up Front Payment Payable As Consideration RD Activities OneTimeUpFrontPaymentPayableAsConsiderationRDActivities OneTimeUpFrontPaymentPayableAsConsiderationRDActivities Current assets: Assets, Current [Abstract] February Fifteen Two Thousand Twenty Four [Member] February Fifteen Two Thousand Twenty Four [Member] February 15, 2024 Counterparty Name Counterparty Name [Axis] Sales Agreement November 2019 Agreement2 [Member] Agreement 2 member. Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Transaction Expense Transaction Expense [Member] Transaction expense. Statement of Stockholders' Equity [Abstract] Operating lease liability, current portion Operating Lease, Liability, Current Marketable Securities Marketable Securities, Policy [Policy Text Block] Lender Name [Axis] Long-Term Debt Long-term debt, net of current portion, unamortized debt issuance costs Current portion of long-term debt, net Total long-term debt Derivative Contract Derivative Contract [Domain] Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Net property and equipment Property and equipment, net Property, Plant and Equipment, Net First Amendment First Amendment [Member] First Amendment Scenario [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Lessee Operating Lease Monthly Rental Payments For First Twelve Months Lessee operating lease monthly rental payments for first twelve months. Lessee operating lease monthly rental payments for second year Entity Central Index Key Entity Central Index Key Plan Name Plan Name [Domain] COVID 19 Pandemic Covid19 Pandemic Policy [Text Block] Disclosure of accounting policy for Covid 19 pandemic. Proceeds from sale of common stock Proceeds From Sale Of Common Stock Proceeds From Sale Of Common Stock Net Commission Paid Proceeds from sale of common stock net commission paid. Restricted cash Restricted Cash, Noncurrent Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Loss (gain) on sale of property and equipment Total Cash equivalents and marketable securities Assets, Fair Value Disclosure Increase (Decrease) in Other Operating Assets, Total Other assets Increase (Decrease) in Other Operating Assets Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Tranche 3 Warrant Tranche Three Member Warrant Tranche Three Member Revenue expected to be recognized Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Total current liabilities Liabilities, Current Entity Tax Identification Number Entity Tax Identification Number Schedule of Future Minimum Lease Payments for Operating Lease Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Line of Credit Facility, Description Term Loan Agreement Payments of Debt Issuance Costs Payment of debt issuance cost Payment of debt issuance cost Deposits Deposits Assets, Noncurrent Financial Instruments Financial Instruments [Domain] Award Date Award Date [Domain] Line of Credit Facility [Table] Debt Securities, Trading and Available-for-Sale, Total Debt Securities, Trading and Available-for-Sale Fair Value Award Type Award Type [Axis] Gain on right-of-use asset termination Gain on right-of-use asset modification Operating Lease, Lease Income Operating Lease, Lease Income, Total Leases Lessee, Operating Leases [Text Block] Class Of Warrant Or Right [Line Items] Class of Warrant or Right [Line Items] Plan Name Plan Name [Axis] Intrinsic value of exercisable fair value per share Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share Share based compensation arrangement by share based payment award fair value of options exercisable intrinsic fair value per share. Issuance of common stock upon exercise of warrants, net Issuance Of Common Stock Upon Net Exercise Of Warrants Value Issuance of common stock upon net exercise of warrants value. Derivative Instrument Derivative Instrument [Axis] Geographical Geographical [Domain] Lease term Lessee, Operating Lease, Term of Contract Total assets Assets Tranche 2 Warrant Tranche 2 Warrant Tranche Two [Member] Warrant tranche two. Security deposit Security Deposit Liability Operating lease right-of-use Operating Lease, Right-of-Use Asset License monthly rental rate second year License monthly rental rate second year License monthly rental rate second year Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Current Liabilities Current Liabilities [Member] Current liabilities. Entity Registrant Name Entity Registrant Name Debt Issuance Costs, Net, Total Debt Issuance Costs, Net Debt issuance costs Interest Expense relating accretion of the final payment Interest Expense, Other Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Related Party, Type [Domain] Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Supplemental Cash Flow Information [Abstract] Accumulated Deficit Retained Earnings [Member] Number of Shares, Nonvested balance at March 31, 2023 Number of Shares, Nonvested balance as of December 31, 2022 Number of shares, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Minimum Minimum [Member] Minimum [Member] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Estimated Useful Lives of Assets Estimated Useful Lives Of Assets Table [Text Block] Estimated useful lives of assets. Operating Lease, Liability, Total Operating Lease, Liability Total Total Forecast [Member] Share-Based Payment Arrangement, Tranche One [Member] Tranche A Revenue Recognition Revenue [Policy Text Block] Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Equity Component Equity Component [Domain] Adjustment related to right of use asset lease liability Adjustment Related To Right Of Use Asset And Lease Liability Adjustment related to right of use asset and lease liability. LG Chem Life Sciences L G Chem Life Sciences [Member] LG Chem Life Sciences. Securities Financing Transaction Securities Financing Transaction [Axis] Amended Additional Laboratory Lease Amended Additional Laboratory Lease [Member] Amended additional laboratory lease. Adjustments to reconcile net loss to cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Less: unamortized debt issuance costs Measurement Frequency Measurement Frequency [Axis] Silicon Valley Bank [Member] Silicon Valley Bank [Member] Silicon Valley Bank Debt Disclosure [Abstract] Debt Instrument, Basis Spread on Variable Rate Variable interest rate (percentage) Entity Current Reporting Status Entity Current Reporting Status Common stock, shares authorized Common Stock, Shares Authorized Research and Development Expense, Total Research and development Research and Development Expense Assets Assets [Abstract] Milestone payments received Milestone Payments Received Milestone payments received. Amortization of Intangible Assets, Total Amortization of intangible assets Amortization of Intangible Assets Non-Cash Interest Expense Non-Cash Interest Expense Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Common stock, $0.001 par value; 100,000,000 shares authorized; 45,123,281 and 43,042,548 shares issued and outstanding, at September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Placement Fees Placement Fees Shareholders' Equity and Share-Based Payments [Text Block] Stock-based compensation Loss on right-of-use asset Loss on right-of-use asset loss on right-of-use asset Cash received from the sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment, Total Milestone payment associated with contract liability Contract with Customer, Liability, Revenue Recognized Furniture and Fixtures Furniture and Fixtures [Member] Accrued Liabilities, Current, Total Accrued expenses Accrued Liabilities, Current Lab Space Lease Member Lab Space Lease [Member] Lab Space Lease Member Additional Laboratory Lease Third Amendment Additional Laboratory Lease Third Amendment [Member] Additional laboratory lease third amendment member. Current Fiscal Year End Date Current Fiscal Year End Date Einstein Einstein [Member] Einstein. Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Loss from operations Loss from operations Operating Income (Loss) Entity Ex Transition Period Entity Ex Transition Period Lessee operating lease monthly rental payments for remaining term Lessee Operating Lease Monthly Rental Payments For Remaining Term Lessee operating lease monthly rental payments for remaining term. Percentage of right to development and commercialized Percentage of right to development and commercialized Percentage of right to development and commercialized Income Tax Expense (Benefit), Total Income tax expense Income Tax Expense (Benefit) Research and Development Research and Development Expense [Member] Jefferies LLC Jefferies LLC [Member] Leases Lessee, Leases [Policy Text Block] Warrants Warrants [Text Block] Warrants. Restricted stock awards withheld at vesting to cover taxes, Shares Restricted stock awards withheld at vesting to cover taxes, Shares Restricted stock awards withheld at vesting to cover taxes, Shares Restricted stock awards withheld at vesting to cover taxes, Shares Stock-based compensation Share-Based Payment Arrangement, Expense Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Indefinite-lived Intangible Assets Indefinite-Lived Intangible Assets [Axis] Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Lessee operating lease monthly rental payments Lessee Operating Lease Monthly Rental Payments Amount of cash outflow of lessee operating lease monthly rental payments. Laboratory Equipment Equipment [Member] Eligible to earn achievement of certain research and development milestones Eligible To Earn Achievement Of Certain Research And Development Milestones Eligible to earn achievement of certain research and development milestones. Number of supporting technologies Number Of Supporting Technologies Under License Agreement Number of supporting technologies under license agreement. ASU 2016-02 Accounting Standards Update 2016-02 [Member] Income Taxes Paid Collaboration Revenue Revenue from Contract with Customer [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Stock options granted purchase shares Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Restricted stock awards released, shares Stock Issued During Period, Shares, Restricted Stock Award, Gross Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Earnings (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] 2025 Operating Leases, Future Minimum Payments, Due in Three Years Milestone payment upon the renewal Milestone Payment Upon the Renewal Milestone payment upon the renewal Sale of Stock, Price Per Share Sale of stock price per share Proceeds From Discount On Securities Purchase Proceeds From Discount On Securities Purchase Discount on securities purchased Lease monthly rental payments Lease Monthly Rental Payments Lease monthly rental payments. 2023 Operating Leases, Future Minimum Payments Due, Next 12 Months Issuance of common stock upon exercise of warrants, net, Shares Issuance Of Common Stock Upon Net Exercise Of Warrants Shares Issuance of common stock upon net exercise of warrants shares. Operating lease modification Operating lease modification Operating Lease Modification Operating expenses (income): Operating Expenses [Abstract] Property, Plant and Equipment [Abstract] Long-Term Debt, Type [Domain] Achievement of certain commercial milestones Achievement Of Ccertain Commercial Milestones Achievement of certain commercial milestones. Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Subsequent Events [Abstract] Schedule of Fair Value of Available-for-Sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Other Assets, Noncurrent, Total Other long-term assets Other long-term assets Other Assets, Noncurrent Number of Shares, Granted Number of shares, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Depreciation, Total Depreciation expense Depreciation Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Investor [Member] Investor [Member] Public Offerings Public Offering Policy [Text Block] Disclosure of accounting policy for public offering. Securities Financing Transaction Securities Financing Transaction [Domain] Long-term research and development contract liability Research and development contract liability, net of current portion Research And Development Contract Liability Noncurrent Research and development contract liability, noncurrent. Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Debt Interest Only Payment Date Debt Interest Only Payment Date Interest-only payment date Stockholders' equity: Equity, Attributable to Parent [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Other Information of Operating Leases Lease, Cost [Table Text Block] Gain (Loss) on Disposition of Property Plant Equipment, Total Gain (Loss) on disposal of property and equipment Gain (Loss) on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Debt Issuance Costs, Gross, Current Less: unamortized debt issuance costs Less: unamortized debt issuance costs Additional Laboratory Lease Fourth Amendment [Member] Additional Laboratory Lease Fourth Amendment [Member] Additional Laboratory Lease Fourth Amendment Cost of Goods and Services Sold, Total Patent expenses Cost of Goods and Services Sold Lease Contractual Term Lease Contractual Term [Domain] Cash obligation percentage Cash obligation percentage Cash obligation percentage Unrealized gain (loss) from available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Schedule of Future Minimum Lease Payments for Operating Lease Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Indefinite-lived Intangible Assets, Major Class Name Indefinite-Lived Intangible Assets, Major Class Name [Domain] Cash Concentrations Cash Concentration Policy [Text Block] Cash Concentration Policy [Policy Text Block] Accounting Policies [Abstract] Lessee Lease Description [Table] Lessee, Lease, Description [Table] Scenario [Axis] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock Option Equity Option [Member] Nonvested Restricted Stock Units Nonvested Restricted Stock Units [Member] Nonvested restricted stock units. Net loss per common share, basic Earnings Per Share, Basic, Total Earnings Per Share, Basic Commitments and Contingencies Commitments and contingencies (Note 10) Up Front Non Refundable Payment Up front non refundable payment. Intrinsic value of common stock warrants Common Stock Warrants Exercisable Intrinsic Value Common stock warrants exercisable intrinsic value. Income Statement [Abstract] Debt Securities, Available-for-sale, Current, Total Marketable securities Debt Securities, Available-for-Sale, Current Proceeds from sale of common stock Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Related Party, Type [Axis] Additional Paid In Capital Warrant Issued Adjustments to Additional Paid in Capital, Warrant Issued Operating lease cost (in thousands) Operating Lease, Cost Milestone payments for each new indication of licensed product Aggregate Amount Of Milestone Payments For Each New Indication Of Licensed Product Maximum Aggregate amount of milestone payments for each new indication of licensed product, maximum. 2016 Omnibus Incentive Plan Two Thousand Sixteen Omnibus Incentive Plan [Member] Two thousand sixteen omnibus incentive plan. Statistical Measurement Statistical Measurement [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Equity investment for research collaboration agreement Equity Investment For Research Collaboration Agreement Equity investment for research collaboration agreement. Proceeds from Issuance of Debt Proceeds from borrowings under term loan Award Type All Award Types Document Period End Date Document Period End Date Statistical Measurement Statistical Measurement [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Operating cash flows from operating leases (in thousands) Operating cash flows from operating leases Operating Lease, Payments Merck Merck [Member] Merck. Net loss per common share, diluted Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Increase in security deposit Increase in security deposit Increase in security deposit Revenue from Contract with Customer [Abstract] Number of tranches Number Of Tranches Number of tranches. Operating Lease Agreement Operating Lease Agreement [Member] Operating lease agreement. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Debt Number Of Installments Of Principal Debt Number Of Installments Of Principal Number of installments of principal Number of Shares, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Research and development contract liability, net of current portion Research and development contract liability, net of current portion Research and development contract liability, net of current portion Related Party Transaction Related Party Transaction [Domain] Tranche B loan [Member] Tranche B loan [Member] Tranche B loan Fair Value Measurements, Recurring Basis Fair Value, Recurring [Member] Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid in capital Additional Paid in Capital, Common Stock Schedule of Maturities of Long-Term Debt [Table Text Block] Summary of Future Principal Debt Payments on Term Loan Agreement March 2020 Awarded And Granted March2020 Awarded And Granted [Member] March 2020 awarded and granted. US Treasury Securities [Member] U.S. Treasury securities Restricted stock awards withheld at vesting to cover taxes Payments for Repurchase of Common Stock Rent expense Operating Leases Rent Expense Operating Leases Rent Expense Licensing Fees and Costs Licensing Fees And Costs Policy [Text Block] Licensing fees and costs. Number of Shares, Exercised Exercise of stock options, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Consolidation Consolidation, Policy [Policy Text Block] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Twenty one erie laboratory and office lease. Twenty One Erie Laboratory and Office Lease [Member] 21 Erie Laboratory and Office Lease Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Private Placement [Member] Private Placement [Member] Einstein License License Agreement For Patent Rights [Member] License agreement for patent rights. Restricted Stock Award, Forfeitures, Total Restricted Stock Award, Forfeitures Repurchase of restricted stock awards Warrants and Rights Note Disclosure [Abstract] February Fifteen Two Thousand Twenty Three [Member] February Fifteen Two Thousand Twenty Three [Member] February 15, 2023 Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Less: present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Weighted Average Exercise Price, Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Depreciation Amortization Of Trademark Amortization of trademark. Equity Components Equity Components [Axis] Account receivable Increase (Decrease) in Accounts Receivable Tranche A loan [Member] Tranche A loan [Member] Tranche A loan Investments, Debt and Equity Securities [Abstract] Weighted Average Grant Date Fair Value Per Share, Vested/Released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Local Phone Number Local Phone Number Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Sale of Stock [Axis] Weighed Average Exercise Price, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Statement of Cash Flows [Abstract] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Additional amount receivable research development regulatory and sales milestones Additional Amount Receivable Research Development Regulatory And Sales Milestones Additional amount receivable research development regulatory and sales milestones. Summary of Common Stock Warrant Activity Schedule Of Common Stock Warrants Activity Table [Text Block] Schedule Of Common Stock Warrants Activity Table Text Block. Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Common stock, par value Common Stock, Par or Stated Value Per Share Line of Credit Facility, Maximum Amount Outstanding During Period Loan available to draw Interest income Interest Income (Expense), Nonoperating, Net Debt Instrument, Interest Rate, Stated Percentage Interest rate Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Maximum Maximum [Member] Contract Liabilities Contract Liabilities [Member] Contract liabilities. Proceeds from Issuance of Private Placement Private investment in Public Equity (PIPE) Related Party Transaction Related Party Transaction [Axis] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in measurement of lease liabilities. Long-Term Debt, Term Amortization months Level 3 Fair Value, Inputs, Level 3 [Member] APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2026 Operating Leases, Future Minimum Payments, Due in Five Years Equity investment nonrefundable upfront cash payment Equity Investment Nonrefundable Upfront Cash Payment Equity investment nonrefundable upfront cash payment. General and Administrative Expense General and Administrative Expense [Member] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. Number of Shares, Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Achievement of certain research and development milestones Achievement Of Certain Research And Development Milestones Achievement of certain research and development milestones. Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Repurchase of restricted stock awards, Shares Other Long-Term Debt, Current Current portion of long-term debt, net Current portion of long-term debt, net Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] City Area Code City Area Code Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Research and development contract liability Increase Decrease In Research And Development Contract Liability Increase (decrease) in research and development contract liability. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment General and Administrative Expense, Total General and administrative General and Administrative Expense Fair value assets transfers between Level 2 and Level 3 Fair Value Assets Among Level2 And Level3 Transfers Amount Fair value assets among level 2 and level 3 transfers amount. Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value weighted average grant date fair value Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Laboratory And Office Lease Laboratory And Office Lease [Member] Laboratory and office Lease. Schedule of Nonvested Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Short-term research and development contract liability Research And Development Contract Liability Current Research and development contract liability, current. Research and development contract liability, current portion Statement [Table] Statement [Table] Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Lease agreement description Description of Lessee Leasing Arrangements, Operating Leases Schedule of Estimated Fair Value of Each Stock Option Award Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Total lease payment Lessee, Operating Lease, Liability, to be Paid Withheld as payment to cover issued shares Class Of Warrant Or Right Number Of Securities Withheld Class Of Warrant Or Right Number Of Securities Withheld. Ono Collaboration and Option Agreement [Member] Ono Collaboration and Option Agreement [Member] Ono Collaboration and Option Agreement [Member] Debt Instrument, Convertible, Conversion Date Closing Date 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Statement [Line Items] Statement [Line Items] Leases beginning date Operations Commenced Date Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock Warrants Warrant Warrant [Member] Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Common Stock Common Stock [Member] Amortization of capitalized license expense Amortization Of Capitalized License Expense Amortization of capitalized license expense. Common stock warrants expiration date Warrants and Rights Outstanding, Maturity Date Warrant Issued June Fifteen Two Thousand Fifteen [Member] Warrant Issued June Fifteen Two Thousand Fifteen Member Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Intrinsic value of exercisable stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Cover [Abstract] Operating lease liability Increase Decrease In Operating Lease Liabilities Increase decrease in operating lease liabilities. Vesting [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Patent Expenses Intangible Assets, Finite-Lived, Policy [Policy Text Block] Sale of Stock [Domain] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Weighted average grant date fair value per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Change In Operating Lease Right Of Use Asset Change in operating lease right-of-use asset. Decrease in the carrying amount of right-of-use-assets Payment of term loan Payment of term loan Payment of term loan Security Exchange Name Security Exchange Name First Research Term Processed Milestone Payment Under Agreement First Research Term Processed Milestone Payment Under Agreement First Research Term Processed Milestone Payment Under Agreement Operating Leases, Rent Expense, Net, Total Rent expense Operating Leases, Rent Expense, Net Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Preferred Stock, Shares Issued, Total Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares authorized Preferred Stock, Shares Authorized Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property, plant and equipment, gross Property, Plant and Equipment, Gross Accretion of final payment on term loan Accretion of final payment on term loan Right-of-use asset and lease liability (new lease) Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted Average Exercise Price, Cancelled Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Financial Instrument Financial Instrument [Axis] Common stock warrants life Warrants and Rights Outstanding, Term Class Of Warrant Or Right [Table] Class of Warrant or Right [Table] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Restricted stock awards released Stock Issued During Period, Value, Restricted Stock Award, Gross Common Stock Options Common Stock Options [Member] Common stock options. Redemption of short-term investments Payments For Redemption Of Short Term Investments Payments for redemption of short term investments. Disposal of property and equipment, gross Property Plant And Equipment Disposal Gross Property plant and equipment disposal gross. Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accounting Standards Update Accounting Standards Update [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Albert Einstein College Of Medicine Albert Einstein College Of Medicine [Member] Albert Einstein College of Medicine. Proceeds from Lines of Credit, Total Proceeds from Lines of Credit Proceeds from issuance of loan payable Leases [Abstract] Variable Rate [Domain] Entity File Number Securities Act File Number Collaboration Agreement with Merck Collaboration Agreement With Merck [Member] Collaboration agreement with merck. Issued via cashless exercises Class Of Warrants Or Rights Cashless Issue Exercises Class of warrants or rights cashless issue exercises. Lease extended date Lease Extended Date Lease extended date. Long-Term Debt, Excluding Current Maturities Long-term debt, net Less: Unamortized debt issuance costs Long-term debt, net Lease Cash Collected Lease Cash Collected Cash collected Share-Based Payment Arrangement [Abstract] 2026 Operating Leases, Future Minimum Payments, Due in Four Years Development and commercial milestone payment payable cuo biopharma Development and commercial milestone payment payable cuo biopharma Development and commercial milestone payment payable cuo biopharma Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Debt Instrument, Interest Rate, Basis for Effective Rate Interest rate Weighted Average Grant Date Fair Value Per Share, Nonvested balance at March 31, 2023 Weighted Average Grant Date Fair Value Per Share, Nonvested balance as of December 31, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Adjustment related to lease liability Adjustment Related To Lease Liability Adjustment related to lease liability Total operating expenses Operating Expenses Milestone payments for each product, process or service Aggregate Amount Of Milestone Payments For Each Product Process Or Service Maximum The maximum aggregate amount of milestone payments for each product, process or service. Long-Term Debt, Maturity, Year One 2023 Expected life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022 Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company License monthly rental rate third year License monthly rental rate third year License monthly rental rate third year Sale of common stock, number of shares Sale of Stock, Number of Shares Issued in Transaction Reduction to right-of-use asset Increase Decrease In Right Of Use Assets Increase decrease in right of use assets. Exercise price of common stock warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right Class of Warrant or Right [Domain] Certificate of Deposit Certificates of Deposit [Member] Computer and office equipment [Member] Computer Equipment [Member] February Two Thousand Twenty Five [Member] February Two Thousand Twenty Five [Member] February, 2025 Entity Address, Address Line One Entity Address, Address Line One Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Antidilutive Securities Antidilutive Securities [Axis] Proceeds from sale of common stock. Proceeds From Sale of Common Stock Unsettled cash receivable from the sale of common stock Subsequent Event Type [Domain] Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Income Statement Location Income Statement Location [Axis] Long-Term Debt, Maturity, Year Three 2025 Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Amortization of premium/discount on purchased securities Amortization of Debt Discount (Premium) Debt Instrument Final Fee Debt Instrument Final Fee Final fee (percentage) Type of Cost, Good or Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Long-Term Debt, Type [Axis] Net Loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Pre Funded Warrants Pre Funded Warrants Line of Credit Facility, Lender [Domain] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies Level 2 Fair Value, Inputs, Level 2 [Member] Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Long-Term Debt, Gross Total principal payments Total maturities Title of 12(b) Security Title of 12(b) Security Restricted stock awards withheld at vesting to cover taxes, Amount Restricted stock awards withheld at vesting to cover taxes, Amount Restricted stock awards withheld at vesting to cover taxes, Amount Purchase of additional shares of common stock. Purchase of Additional Shares Of Common Stock Purchase of additional shares of common stock Lease Contractual Term Lease Contractual Term [Axis] Prime Rate [Member] WSJ Prime Rate plus Marketable securities, Maturity period Debt Securities, Held-to-Maturity, Threshold Period Past Due Accounting Standards Update Accounting Standards Update [Axis] Einstein License And Service Agreement Einstein License And Service Agreement [Member] Einstein license and service agreement. Trademarks Trademarks [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Collected from sale of fixed assets Property, Plant and Equipment, Disposals Amortization of Debt Issuance Costs Amortization of debt issuance costs Long-term Line of Credit, Total Long-Term Line of Credit Loan Other Income Other Income [Member] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Subsequent Event [Table] Subsequent Event [Table] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Office space for lease Land Subject to Ground Leases Warrants purchase shares of common stock Warrants purchase shares of common stock Weighted Average Remaining Contractual Life (in Years), Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Common Stock, Shares, Outstanding Proceeds from ATM offering, net of sales agent commission and fees Proceeds From At Time Market Offering Net Of Commission And Fees Proceeds from At the time market offering net of commission and fees. Short-term Debt, Total Short-Term Debt Term loan Short-term debt, net Cash obligation Cash Obligation Cash obligation Present value of lease payments, discounting rate Lessee, Operating Lease, Discount Rate Income Statement Location Income Statement Location [Domain] Weighted Average Exercise Price, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price License Agreement License Agreement Terms [Member] Restricted Cash and Cash Equivalents, Current, Total Restricted cash used to collateralize a credit card Restricted Cash and Cash Equivalents, Current Document Type Document Type Collaboration Agreement with LG Chem Life Sciences Collaboration Agreement With L G Chem Life Sciences [Member] Collaboration agreement with LG Chem Life Sciences. Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Document Quarterly Report Document Quarterly Report License monthly rental rate remainder of the term License monthly rental rate remainder of the term License monthly rental rate remainder of the term Cash and cash equivalents, and marketable securities Marketable Securities, Total Marketable Securities Counterparty Name Counterparty Name [Domain] Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Interest rate, floating Weighted average fair value, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Entity Filer Category Entity Filer Category Lessee Operating Lease Monthly Rental Payments For First Eighteen Months Lessee operating lease monthly rental payments for first eighteen months. Lessee operating lease monthly rental rate for third year Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosures of non-cash investing and financing activities: Balance Sheet Location Balance Sheet Location [Domain] Increase (Decrease) in Accrued Interest Receivable, Net Accrued interest Accrued interest License monthly rental rate first year License monthly rental rate first year License monthly rental rate first year Increase (Decrease) in Accrued Liabilities, Total Accrued expenses Increase (Decrease) in Accrued Liabilities Variable Rate [Axis] Stifel Nicolaus and Company Inc. Stifel Nicolaus And Company Incorporated [Member] Total other (expense) income Total other income Nonoperating Income (Expense) Total liabilities Liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Cambridge, Massachusetts MASSACHUSETTS Payments to Acquire Short-Term Investments Purchase of short term investments Purchase of short-term investments Total stockholders' equity Balance Balance Equity, Attributable to Parent Useful life of trademark Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Warrant Issued November Sixteen Two Thousand Twenty Two [Member] Warrant Issued November Sixteen Two Thousand Twenty Two Member Net loss Net loss Net loss Net Income (Loss) Other (expense) income: Nonoperating Income (Expense) [Abstract] Interest Expense, Total Interest Expense Interest expense, net Interest expense Interest expense, net Organization and Basis of Presentation Business Description and Basis of Presentation [Text Block] Proceeds from Issuance Initial Public Offering Proceeds from Issuance Initial Public Offering Gain on right-of-use asset termination Gain On Right Of Use Asset Termination Gain on right-of-use asset termination Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Award Date Award Date [Axis] Statement of Financial Position [Abstract] Weighted average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Forty G office and additional laboratory. Forty G Office and Additional Laboratory [Member] 40G Office and Additional Laboratory Marketable securities of investments Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Amended Lease Agreement Amended Lease Agreement [Member] Amended lease agreement. Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Unsettled cash receivable from the sale of common stock Unsettled cash receivable from the sale of common stock Use of Estimates Use of Estimates, Policy [Policy Text Block] Accretion of final payment Accretion of final payment Computer and Office Equipment Computer And Office Equipment [Member] Computer and office equipment. Shares Granted Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture, Total Weighted Average Exercise Price, Outstanding Beginning Balance Weighted Average Exercise Price, Outstanding Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Leasehold Improvements Leasehold Improvements [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Monthly installments Monthly installments Monthly installments Fair Value Disclosures [Abstract] Level 2 Fair Value Hierarchy and NAV [Axis] Public Utilities, Requested Debt Capital Structure, Percentage Additional final payment rate Measurement Frequency Measurement Frequency [Domain] Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Non-cash interest expense to the lease liability Finance Lease, Interest Expense Number of Shares, Vested/Released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Stock Issued During Period, Shares, New Issues Issuance of common stock from ATM offering, net of sales agent commission and fees, Shares Stock Issued During Period, Shares, New Issues Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Class of Warrant or Right Class of Warrant or Right [Axis] Decrease in Lease Liability Increase Decrease In Lease Liability Increase decrease in lease liability. Fair value of common stock Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Of Common Stock Share based compensation arrangement by share based payment award fair value of common stock. Tranche 1 Warrant Tranche One [Member] Warrant tranche one. Loss on right-of-use asset Gain Loss On Right Of Use Asset Gain and loss on right of use asset. EX-101.PRE 16 cue-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.CAL 17 cue-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT XML 18 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2023
Nov. 01, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Trading Symbol CUE  
Entity Registrant Name Cue Biopharma, Inc.  
Entity Central Index Key 0001645460  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Interactive Data Current Yes  
Document Transition Report false  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Security Exchange Name NASDAQ  
Entity Incorporation, State or Country Code DE  
Document Quarterly Report true  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   45,123,281
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity File Number 001-38327  
Entity Tax Identification Number 47-3324577  
Entity Address, Address Line One 40 Guest Street  
Entity Address, City or Town Boston  
Entity Address State or Province MA  
Entity Address, Postal Zip Code 02135  
City Area Code 617  
Local Phone Number 949-2680  
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 54,691,000 $ 51,614,000
Marketable securities 0 24,675,000
Accounts receivable 1,661,000 57,000
Prepaid expenses and other current assets 1,165,000 841,000
Total current assets 57,517,000 77,187,000
Property and equipment, net 1,064,000 1,499,000
Operating lease right-of-use 7,060,000 9,203,000
Deposits 2,977,000 3,116,000
Restricted cash 150,000 150,000
Other long-term assets 120,000 128,000
Total assets 68,888,000 91,283,000
Current liabilities:    
Accounts payable 2,480,000 2,731,000
Accrued expenses 5,127,000 3,554,000
Research and development contract liability, current portion 2,238,000 0
Operating lease liability, current portion 3,399,000 3,300,000
Current portion of long-term debt, net 3,963,000 1,963,000
Total current liabilities 17,207,000 11,548,000
Operating lease liability, net of current portion 3,855,000 6,017,000
Long-term debt, net 5,160,000 8,035,000
Total liabilities 26,222,000 25,600,000
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022 0 0
Common stock, $0.001 par value; 100,000,000 shares authorized; 45,123,281 and 43,042,548 shares issued and outstanding, at September 30, 2023 and December 31, 2022, respectively 45,000 43,000
Additional paid in capital 330,376,000 316,192,000
Accumulated other comprehensive loss (0) (96,000)
Accumulated deficit (287,755,000) (250,456,000)
Total stockholders' equity 42,666,000 65,683,000
Total liabilities and stockholders' equity $ 68,888,000 $ 91,283,000
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 45,123,281 43,042,548
Common stock, shares outstanding 45,123,281 43,042,548
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Collaboration revenue $ 2,100 $ 68 $ 3,669 $ 1,094
Operating expenses (income):        
General and administrative 3,645 3,528 12,071 12,465
Research and development 9,874 7,571 29,915 27,246
Gain on right-of-use asset termination 0 0 0 (258)
Total operating expenses 13,519 11,099 41,986 39,453
Loss from operations (11,419) (11,031) (38,317) (38,359)
Other (expense) income:        
Interest income 700 200 1,756 296
Interest expense, net (286) (124) (738) (355)
Total other (expense) income 414 76 1,018 (59)
Net loss (11,005) (10,955) (37,299) (38,418)
Unrealized gain (loss) from available-for-sale securities 5 (92) 96 (92)
Comprehensive loss $ (11,000) $ (11,047) $ (37,203) $ (38,510)
Net loss per common share, basic $ (0.24) $ (0.31) $ (0.82) $ (1.11)
Net loss per common share, diluted $ (0.24) $ (0.31) $ (0.82) $ (1.11)
Weighted average common shares outstanding, basic 46,358,555 35,383,430 45,274,124 34,471,499
Weighted average common shares outstanding, diluted 46,358,555 35,383,430 45,274,124 34,471,499
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
AOCI Attributable to Parent
Accumulated Deficit
Balance at Dec. 31, 2021 $ 65,492 $ 32 $ 262,906   $ (197,446)
Balance, Shares at Dec. 31, 2021   32,202,496      
Issuance of common stock from ATM offering, net ofsales agent commission and fees 16,598 $ 3 16,595    
Issuance of common stock from ATM offering, net of sales agent commission and fees, Shares   3,117,220      
Stock-based compensation 7,384   7,384    
Issuance of common stock upon exercise of warrants, net, Shares   9,549      
Restricted stock awards released, shares   98,335      
Restricted stock awards withheld at vesting to cover taxes, Shares   (42,018)      
Restricted stock awards withheld at vesting to cover taxes, Amount (200)   (200)    
Unrealized losses from available-for-sale securities (92)     $ (92)  
Net loss (38,418)       (38,418)
Balance at Sep. 30, 2022 50,764 $ 35 286,685 (92) (235,864)
Balance, Shares at Sep. 30, 2022   35,385,582      
Balance at Jun. 30, 2022 59,756 $ 35 284,630   (224,909)
Balance, Shares at Jun. 30, 2022   35,381,743      
Stock-based compensation 2,064   2,064    
Restricted stock awards released, shares   6,667      
Restricted stock awards withheld at vesting to cover taxes, Shares   (2,828)      
Restricted stock awards withheld at vesting to cover taxes, Amount (9)   (9)    
Unrealized losses from available-for-sale securities (92)     (92)  
Net loss (10,955)       (10,955)
Balance at Sep. 30, 2022 50,764 $ 35 286,685 (92) (235,864)
Balance, Shares at Sep. 30, 2022   35,385,582      
Balance at Dec. 31, 2022 65,683 $ 43 316,192 (96) (250,456)
Balance, Shares at Dec. 31, 2022   43,042,548      
Issuance of common stock from ATM offering, net ofsales agent commission and fees 7,605 $ 2 7,603    
Issuance of common stock from ATM offering, net of sales agent commission and fees, Shares   1,915,131      
Stock-based compensation 6,108   6,108    
Exercise of stock options $ 473   473    
Exercise of stock options, Shares 165,602 165,602      
Unrealized losses from available-for-sale securities $ 96     96  
Net loss (37,299)       (37,299)
Balance at Sep. 30, 2023 42,666 $ 45 330,376 (0) (287,755)
Balance, Shares at Sep. 30, 2023   45,123,281      
Balance at Jun. 30, 2023 46,004 $ 44 322,715 (5) (276,750)
Balance, Shares at Jun. 30, 2023   43,744,414      
Issuance of common stock from ATM offering, net ofsales agent commission and fees 5,589 $ 1 5,588    
Issuance of common stock from ATM offering, net of sales agent commission and fees, Shares   1,378,867      
Stock-based compensation 2,073   2,073    
Unrealized losses from available-for-sale securities 5     5  
Net loss (11,005)       (11,005)
Balance at Sep. 30, 2023 $ 42,666 $ 45 $ 330,376 $ (0) $ (287,755)
Balance, Shares at Sep. 30, 2023   45,123,281      
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities    
Net Loss $ (37,299,000) $ (38,418,000)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 443,000 719,000
Stock-based compensation 6,108,000 7,384,000
Decrease in the carrying amount of right-of-use-assets 2,142,000 507,000
Gain on right-of-use asset termination 0 (258,000)
Loss (gain) on sale of property and equipment (2,000) 4,000
Amortization of premium/discount on purchased securities (234,000) (101,000)
Amortization of debt issuance costs 28,000 21,000
Accretion of final payment on term loan 98,000 76,000
Changes in operating assets and liabilities:    
Account receivable (1,603,000) 2,347,000
Prepaid expenses and other current assets (324,000) (846,000)
Deposits 139,000 (395,000)
Accounts payable (251,000) (546,000)
Accrued expenses 1,573,000 (741,000)
Research and development contract liability 2,238,000 (645,000)
Operating lease liability (2,064,000) (397,000)
Accrued interest 0 (3,000)
Net cash used in operating activities (29,003,000) (31,292,000)
Cash flows from investing activities    
Purchases of property and equipment 0 (170,000)
Cash received from the sale of property and equipment 2,000 6,000
Redemption of short-term investments 25,000,000 0
Purchase of short-term investments 0 (29,445,000)
Net cash provided by (used in) investing activities 25,002,000 (29,609,000)
Cash flows from financing activities    
Proceeds from ATM offering, net of sales agent commission and fees 7,605,000 16,598,000
Proceeds from borrowings under term loan 0 10,000,000
Payment of term loan (1,000,000) 0
Proceeds from exercise of stock options 473,000 0
Payment of debt issuance cost 0 (142,000)
Restricted stock awards withheld at vesting to cover taxes 0 (200,000)
Net cash provided by financing activities 7,078,000 26,256,000
Net increase (decrease) in cash, cash equivalents, and restricted cash 3,077,000 (34,645,000)
Cash, cash equivalents, and restricted cash at beginning of period 51,764,000 64,521,000
Cash, cash equivalents, and restricted cash at end of period 54,841,000 29,876,000
Supplemental disclosures of non-cash investing and financing activities:    
Cash paid for interest 768,000 354,000
Right-of-use asset and lease liability (new lease) 0 9,057,000
Operating lease modification $ 0 $ 7,119,000
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Basis of Presentation
9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation
1.
Organization and Basis of Presentation

Cue Biopharma, Inc. (the "Company") is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s corporate office and research facilities are located in Boston, Massachusetts.

The Company is in the development stage and has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2023, the Company had cash and cash equivalents of approximately $54,691,000. Management believes that current cash and cash equivalents on hand at September 30, 2023 are sufficient to fund operations for at least the next twelve months from the date of issuance of these financial statements; however, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations and to fund research and development costs in order to seek approval for commercialization of its drug product candidates. The Company’s failure to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategies as this capital is necessary for the Company to perform the research and development activities required to develop and commercialize the Company’s drug product candidates in order to generate future revenue streams.

XML 25 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2.
Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements as of September 30, 2023, and for the three and nine months ended September 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for financial information, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp., which was incorporated in the Commonwealth of Massachusetts in December 2018. In the opinion of management, these financial statements reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2023.

Interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future periods.

 

Public Offerings

In October 2021, the Company entered into an open market sale agreement (the “October 2021 ATM Agreement”) with Jefferies LLC ("Jefferies"), as agent, to sell shares of the Company’s common stock for aggregate gross proceeds of up to $80 million, from time to time, through an at-the-market equity offering program. The October 2021 ATM Agreement will terminate upon the earliest of (a) the sale of $80 million of shares of the Company’s common stock pursuant to the October 2021 ATM Agreement or (b) the termination of the October 2021 ATM Agreement by the Company or Jefferies. During the three months ended September 30, 2023, the Company sold 1,378,867 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $5,589,000 net of commission paid, but excluding transaction expenses. During the nine months ended September 30, 2023, the Company sold 1,915,131 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $7,605,000 net of commission paid, but excluding transaction expenses. As of September 30, 2023, the Company had sold an aggregate of 5,508,538 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $31.2 million, net of commission paid, but excluding transaction expenses, since its inception.

Consolidation

The accompanying consolidated financial statements include the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp. The Company has eliminated all intercompany transactions.

 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.

Cash Concentrations

The Company maintains its cash balances with financial institutions in federally insured accounts and may periodically have cash balances in excess of insurance limits. The Company maintains its accounts with financial institutions with a high credit rating. The Company has not experienced any losses to date from our deposits with these financial institutions and believes that it is not exposed to any significant credit risk on cash.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company currently invests available cash in money market funds.

Marketable Securities

Marketable securities consist of investments with original maturities greater than ninety days and less than one year from the balance sheet date. The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are recognized and determined on a specific identification basis and are included in other comprehensive loss. Realized gains and losses are determined on a specific identification basis and are included in other income on the consolidated statement of operations and other comprehensive loss. Amortization and accretion of discounts and premiums is recorded in interest income. The Company has invested available cash in U.S. Treasury obligations.

Restricted Cash

The Company had $150,000 in restricted cash deposited with separate commercial banks to collateralize a credit card as of September 30, 2023 and December 31, 2022.

Property and Equipment

Property and equipment is recorded at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from dispositions of property and equipment are included in income and expense when realized. Amortization of leasehold improvements is provided using the straight-line method over the shorter of the lease term or the useful life of the underlying assets. Depreciation of property and equipment is provided using the straight-line method over the following estimated useful lives:

 

Laboratory equipment

 

5 years

Computer and office equipment

 

3 years

Furniture and fixtures

 

3-8 years

 

The Company recognizes depreciation and amortization expense in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on how each category of property and equipment is utilized in the Company’s business activities.

Trademark

Trademark consists of the Company’s right, title and interest to the CUE BIOLOGICS Mark, and any derivative mark incorporating CUE, throughout the world, together with all associated goodwill and common law rights appurtenant thereto, including, but not limited to, any right, title and interest in any corporate name, company name, business, name, trade name, dba, domain name, or other source identifier incorporating CUE.

The Company has classified the trademark as a component of other long-term assets, having a useful life of 15 years. The Company evaluates the status of this intangible asset for amortization and impairment at each quarter end and year end reporting date. For each of the three and nine months ended September 30, 2023 and 2022, the Company recorded approximately $3,000 and $9,000, respectively, in amortization expense on a straight-line basis.

 

Debt Issuance Costs

Debt issuance costs are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and other comprehensive loss.

Revenue Recognition

The Company recognizes collaboration revenue under certain of the Company’s license and collaboration agreements that are within the scope of Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the expected value method.

Research and Development Expenses

Research and development expenses consist primarily of compensation costs, fees paid to consultants, outside service providers and organizations (including research institutes at universities), facility costs, and development and clinical trial costs with respect to the Company’s drug product candidates.

Research and development expenses incurred under contracts are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different pattern of performance is more appropriate. Other research and development expenses are charged to operations as incurred.

Nonrefundable advance payments are recognized as an expense as the related services are performed. The Company evaluates whether it expects the services to be rendered at each quarter end and year end reporting date. If the Company does not expect the services to be rendered, the advance payment is charged to expense. Nonrefundable advance payments for research and development services are included in prepaid and other current assets on the balance sheet. To the extent that a nonrefundable advance payment is for contracted services to be performed within 12 months from the reporting date, such advance is included in current assets; otherwise, such advance is included in non-current assets.

The Company evaluates the status of its research and development agreements and contracts, and the carrying amount of the related assets and liabilities, at each quarter end and year end reporting date, and adjusts the carrying amounts and their classification on the balance sheet as appropriate.

 

Patent Expenses

The Company is the exclusive worldwide licensee of, and has patent applications pending for, numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development of one or more commercially viable drug product candidates based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal fees, filing fees and other costs are charged to general and administrative expense as incurred. For the three and nine months ended September 30, 2023, patent expenses were approximately $503,000 and $1,649,000, respectively. For the three and nine months ended September 30, 2022, patent expenses were $395,000 and $1,625,000, respectively.

Licensing Fees and Costs

Licensing fees and costs consist primarily of costs relating to the acquisition of the Company’s license agreement (the “Einstein License Agreement”) with the Albert Einstein College of Medicine (“Einstein”), including related royalties, maintenance fees, milestone payments and product development costs. Licensing fees and costs are charged to research and development expense as incurred.

Long-Lived Assets

The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs.

Leases

 

The Company accounts for leases under ASC 842, Leases, which requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases are required.

Stock-Based Compensation

The Company periodically issues stock-based awards to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values. Stock option grants, which are generally time-vested, are measured at the grant date fair value and charged to operations on a straight-line basis over the service period, which generally approximates the vesting term. The Company also grants performance-based awards periodically to officers of the Company. The Company recognizes compensation costs related to performance awards over the requisite service period if and when the Company concludes that it is probable that the performance condition will be achieved.

The fair value of stock options and restricted stock units is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading history for its common stock that approximates the expected term of the options, estimated volatility is based on the average historical volatility of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends and has no plans to do so for the foreseeable future. As permitted by Staff Accounting Bulletin No. 107, due to the Company’s limited trading history and option activity, management

utilizes the simplified method to estimate the expected term of options at the date of grant. The exercise price is determined based on the fair value of our common stock at the date of grant. The Company accounts for forfeitures as they occur.

The Company recognizes the fair value of stock-based compensation in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on the type of services provided by the recipient of the equity award.

Comprehensive Income (Loss)

Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive income (loss) includes net income (loss) as well as changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. The Company’s only element of other comprehensive income (loss) in periods presented was unrealized gain or loss on available-for-sale securities.

Earnings (Loss) Per Share

The Company’s computation of earnings (loss) per share (“EPS”) for the respective periods includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares that would result from the exercise of outstanding stock options and warrants as if they had been exercised at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Basic and diluted loss per common share is the same for all periods presented because all outstanding stock options and warrants are anti-dilutive.

Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included 1,531,440 pre-funded warrants in the denominator of basic EPS at September 30, 2023.

At September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

 

 

 

September 30,

 

 

 

2023

 

2022

 

Common stock warrants

 

 

10,719,846

 

 

789,358

 

Common stock options

 

 

7,500,480

 

 

6,268,729

 

Total

 

 

18,220,326

 

 

7,058,087

 

 

Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active exchange-traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

The Company had approximately $54,691,000 in cash equivalents as of September 30, 2023. The Company had approximately $45,423,000 in cash equivalents and approximately $24,675,000 in short-term marketable securities that were measured and recorded at fair value on the Company’s balance sheet at December 31, 2022.

The carrying value of financial instruments (consisting of cash, a certificate of deposit, accounts payable, accrued compensation and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) (CECL). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The new standard is effective for annual reporting periods beginning after December 15, 2022, including interim reporting periods within each annual reporting period for smaller reporting companies. The Company adopted ASU No. 2016-13 but there was no financial impact to the Company’s consolidated financial statements for the year ended December 31, 2022 or for the nine months ended September 30, 2023.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

XML 26 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value
3.
Fair Value

The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022, and indicate the level of the fair value hierarchy utilized to determine such fair value:

 

 

 

Fair Value Measurements as of September 30, 2023

 

 

 

(in thousands)

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Fair Value

 

Cash equivalents

 

$

54,691

 

 

$

 

 

$

 

 

$

54,691

 

Marketable securities

 

 

 

 

$

 

 

 

 

 

 

 

Total

 

$

54,691

 

 

$

 

 

$

 

 

$

54,691

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements as of December 31, 2022

 

 

 

(in thousands)

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Fair Value

 

Cash equivalents

 

$

45,423

 

 

$

 

 

$

 

 

$

45,423

 

Marketable securities

 

 

 

 

 

24,675

 

 

 

 

 

 

24,675

 

Total

 

$

45,423

 

 

$

24,675

 

 

$

 

 

$

70,098

 

 

As of September 30, 2023, the Company reported approximately $54,691,000 in cash equivalents. The Company measures the cash equivalents that are invested in money market funds using Level 1 inputs for identical securities. The Company measures the fair value of marketable securities that are invested in U.S. Treasury securities using Level 2 inputs and primarily relies on quoted prices in active markets for similar marketable securities. As of December 31, 2022, the Company reported approximately $45,423,000 and $24,675,000 in cash equivalents and marketable securities, respectively. During the three and nine months ended September 30, 2023, and the year ended December 31, 2022, there were no transfers between Level 2 and Level 3.

XML 27 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities
9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities
4.
Marketable Securities

As of September 30, 2023, the Company had no marketable securities. The Company had marketable securities that consisted of $24,675,000 at December 31, 2022. The following table presents the Company's marketable securities at December 31, 2022:

 

 

 

December 31, 2022

 

(In thousands)

 

Amortized Cost

 

 

Gross Unrealized
Gains

 

 

Gross Unrealized
Losses

 

 

Fair Value

 

U.S. Treasury Securities

 

$

24,771

 

 

$

 

 

$

(96

)

 

$

24,675

 

 

$

24,771

 

 

$

 

 

$

(96

)

 

$

24,675

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2022, the Company's marketable securities consisted of $24,771,000 of investments that mature within 12 months and the Company recorded an unrealized loss on investments of $96,000 for the year ended December 31, 2022.

XML 28 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment
5.
Property and Equipment

Property and equipment as of September 30, 2023 and December 31, 2022 consisted of the following:

 

 

 

September 30,
2023

 

 

December 31,
2022

 

 

 

(in thousands)

 

Laboratory equipment

 

$

5,205

 

 

$

5,246

 

Furniture and fixtures

 

 

81

 

 

 

81

 

Computer and office equipment

 

 

296

 

 

 

296

 

Leasehold improvements

 

 

118

 

 

 

118

 

 

 

5,699

 

 

 

5,741

 

Less accumulated depreciation

 

 

(4,635

)

 

 

(4,242

)

Net property and equipment

 

$

1,064

 

 

$

1,499

 

 

Depreciation expense for the three months ended September 30, 2023 and 2022 was approximately $128,000 and $198,000, respectively. Depreciation expense for the nine months ended September 30, 2023 and 2022 was approximately $434,000 and $630,000, respectively. Depreciation expense for the nine months ended September 30, 2023 excludes trademark amortization expense of approximately $9,000. Depreciation expense for the nine months ended September 30, 2022 excludes trademark amortization expense of approximately $9,000, and amortization of capitalized license expenses of approximately $80,000. During the nine months ended September 30, 2023, the Company sold fully depreciated lab equipment with an acquisition cost of $41,450 and collected cash of $2,000. The Company recorded a gain on the sale of fixed assets of $2,000, which is presented in other income on the consolidated statements of operations and other comprehensive loss. During the nine months ended September 30, 2022, the Company sold furniture and fixtures with an acquisition cost of $30,000 and collected cash of $5,800. The Company recorded a loss on the sale of fixed assets of $4,300, which is presented in other income on the consolidated statements of operations and other comprehensive loss.

XML 29 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Loan with Silicon Valley Bank
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Loan with Silicon Valley Bank
6.
Loan with Silicon Valley Bank

On February 15, 2022 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”), with Silicon Valley Bank, as lender (“SVB”). The Company drew $10,000,000 in term loans under the Loan Agreement (the "Term Loans") on the Closing Date. The Loan Agreement was amended in April 2023.

The Term Loans bear interest at a floating rate per annum equal to the greater of (A) the prime rate (as published in the money rates section of The Wall Street Journal) plus 2.25% and (B) 5.50%. The Term Loans were interest only from the Closing Date through June 30, 2023, after which the Company is required to pay 30 equal monthly installments of principal. At September 30, 2023, the interest rate was 10.75% based on the prime rate plus 2.25%.

The Term Loans may be prepaid in full prior to February 15, 2024 with payment of a 2.00% prepayment premium, on or after which they may be prepaid in full with payment of a 1.00% prepayment premium. Upon prepayment or repayment in full of the Term Loans, the Company will be required to pay a one-time final payment fee equal to 5.00% of the original principal amount of any funded Term Loans being repaid. This one-time final payment fee is recorded to interest expense using the effective interest method over the period of the Term Loans in the consolidated statements of operation and other comprehensive loss.

The Term Loans and related obligations under the Loan Agreement are secured by substantially all of the Company’s properties, rights and assets, except for its intellectual property which is subject to a negative pledge under the Loan Agreement.

The Loan Agreement contains customary representations, warranties, events of default and covenants, including a requirement that the Company maintain in accounts of the Company at SVB unrestricted and unencumbered cash equal to the lesser of all of the Company’s cash or $20,000,000. On March 10, 2023, SVB was closed by state regulators and the Federal Deposit Insurance Company ("FDIC") was appointed receiver for the bank. The FDIC created a successor bridge bank, Silicon Valley Bridge Bank, N.A. (“SVBB”) and all deposits of SVB were transferred to SVBB under a systemic risk exception approved by the U.S. Department of the Treasury, the Federal Reserve and the FDIC. SVBB continues to hold the Company’s Term Loans under the same existing terms and covenants which were in place with SVB.

During the three and nine months ended September 30, 2023, the Company recognized interest expense related to the Term Loans of $254,000 and $848,000, respectively, and $33,000 and $98,000, respectively, in interest expense related to accretion of the final payment. During the three and nine months ended September 30, 2022, the Company recognized interest expense related to the Term Loans of $183,000 and $354,000, respectively, and $33,000 and $76,000 in interest expense related to accretion of the final payment for the three months and nine months ended September 30, 2022, respectively.

The following tables present the aggregate maturities of long-term and current portion of debt as of September 30, 2023 (in thousands):

 

 

 

 

 

 

 

Year

Aggregate Minimum Payments

 

 

 

2023

$

 

1,000

 

 

 

2024

 

 

4,000

 

 

 

2025

 

 

4,000

 

 

 

Total maturities

$

 

9,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total long-term debt

 

 

 

$

5,000

 

Accretion of final payment

 

 

207

 

Less: unamortized debt issuance costs

 

 

 

 

(46

)

Long-term debt, net

 

$

5,160

 

 

 

 

 

 

 

Total current portion of long-term debt

 

 

 

$

4,000

 

Less: unamortized debt issuance costs

 

 

 

 

(37

)

Current portion of long-term debt, net

 

$

3,963

 

 

 

Debt Issuance Costs

Debt issuance costs are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and comprehensive loss. The Company incurred approximately $141,748 in debt issuance costs related to the Loan Agreement. For the three and nine months ended September 30, 2023, the Company recorded approximately $9,000 and $28,000, respectively, in amortization of debt issuance costs to interest expense in the consolidated statements of operations and comprehensive loss. For the three and nine months ended September 30, 2022, the Company recorded approximately $9,000 and $21,000, respectively, in amortization of debt issuance costs to interest expense in the consolidated statements of operations and comprehensive loss.

XML 30 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based compensation

7. Stock-Based Compensation

Stock Option Valuation

For stock options requiring an assessment of value during the nine months ended September 30, 2023 and 2022, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:

 

 

 

September 30, 2023

Risk-free interest rate

 

3.4% - 4.16%

Expected dividend yield

 

0%

Expected volatility

 

97.03% - 110.4%

Expected life

 

5.50 to 6.25 years

 

 

 

 

 

September 30, 2022

Risk-free interest rate

 

1.53% - 2.92%

Expected dividend yield

 

0%

Expected volatility

 

92.1% - 95.7%

Expected life

 

5.50 to 6.25 years

 

A summary of stock option activity for the nine months ended September 30, 2023 is as follows:

 

 

 

Number of
Shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Life
(in Years)

 

Stock options outstanding at December 31, 2022

 

 

6,173,867

 

 

$

9.60

 

 

 

5.05

 

Granted

 

 

2,576,900

 

 

 

3.65

 

 

 

 

Exercised

 

 

(165,602

)

 

 

2.86

 

 

 

 

Cancelled

 

 

(1,084,685

)

 

 

4.78

 

 

 

 

Stock options outstanding at September 30, 2023

 

 

7,500,480

 

 

 

8.40

 

 

 

6.35

 

Stock options exercisable at September 30, 2023

 

 

4,365,960

 

 

$

10.38

 

 

 

4.54

 

 

The Company recognized approximately $2,073,000 and $6,108,000 in stock-based compensation expense during the three and nine months ended September 30, 2023, respectively, related to stock options activity. As of September 30, 2023, total unrecognized stock-based compensation expense was approximately $12,141,000, which is expected to be recognized as an operating expense in the Company’s consolidated statement of operations and other comprehensive loss over the weighted average remaining period of 2.16 years. During the three months ended September 30, 2023, the Company granted stock options to purchase 1,115,000 shares of common stock with a weighted average grant date fair value of $4.17 per share. During the nine months ended September 30, 2023, the Company granted stock options to purchase 2,576,900 shares of common stock with a weighted average grant date fair value of $3.65 per share.

 

The Company recognized approximately $2,045,000 and $6,537,000 in stock-based compensation expense during the three and nine months ended September 30, 2022, respectively, related to stock options activity. As of September 30, 2022, total unrecognized stock-based compensation expense was approximately $13,856,000, which is expected to be recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss over the weighted average remaining period of 2.13 years. During the three months ended September 30, 2022, the Company granted stock options to purchase 12,500 shares of common stock with a weighted average grant date fair value of $2.45 per share. During the nine months ended September 30, 2022, the Company granted stock options to purchase 828,500 shares of common stock with a weighted average grant date fair value of $6.99 per share.

The intrinsic value of exercisable but unexercised in-the-money stock options at September 30, 2023 was approximately $0, based on a weighted average grant date fair value of $10.38 per share on September 30, 2023.

 

Restricted Stock Units

 

On October 3, 2019, the Company granted 100,000 restricted stock units (“RSUs”) with time-based vesting conditions to an executive officer having an average grant date fair value of $7.53 per share. The RSUs vested in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter. Compensation expense is recognized on a straight-line basis.

 

On February 5, 2020, the Company granted 150,000 RSUs with time-based vesting conditions to an executive officer. One-half of the RSUs vested on September 30, 2021, and the balance vested on March 31, 2022. On March 31, 2020, the Company granted 50,000 RSUs with time-based vesting conditions to an executive officer. The RSUs vested in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter. Compensation expense is recognized on a straight-line basis.

On August 21, 2020, the Company granted 20,000 RSUs with time-based vesting conditions to an executive officer. The RSUs vest in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter, subject to the recipient’s continued service on each applicable vesting date. Compensation expense is recognized on a straight-line basis.

 

The Company recognized $0 in stock-based compensation during the three and nine months ended September 30, 2023 related to RSU activity. As of September 30, 2023, total unrecognized stock-based compensation was fully recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss. The Company recognized approximately $19,000 and $847,000 in stock-based compensation during the three and nine months ended September 30, 2022, respectively, related to RSU activity. As of September 30, 2022, total unrecognized stock-based compensation was fully recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss.


 

Stock-based Compensation

 

Stock-based compensation expense for the three and nine months ended September 30, 2023 and 2022 was included in the Company’s consolidated statements of operations and other comprehensive loss as follows:

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended September 30,

 

(in thousands)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

General and administrative

 

$

858

 

 

$

1,003

 

 

$

2,708

 

 

$

3,650

 

Research and development

 

 

1,215

 

 

 

1,061

 

 

 

3,399

 

 

 

3,734

 

Total

 

$

2,073

 

 

$

2,064

 

 

$

6,108

 

 

$

7,384

 

XML 31 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Warrants
9 Months Ended
Sep. 30, 2023
Warrants and Rights Note Disclosure [Abstract]  
Warrants

8. Warrants

The Company has one tranche of common stock warrants outstanding at September 30, 2023. The Company issued warrants exercisable for 1,500 shares of common stock on June 15, 2015 with an exercise price of $2.70 per share, which warrants expired at the end of their 7-year term on June 15, 2022. The Company issued another tranche of warrants exercisable for an aggregate of 882,071 shares of common stock with an exercise price of $9.38 per share when issued on December 27, 2017, which warrants expired at the end of their 5-year term on December 26, 2022. On November 16, 2022, the Company issued in a private placement 9,188,406 warrants with an exercise price of $3.93 and 1,531,440 pre-funded warrants.

Each tranche of warrants was evaluated under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and the Company determined that equity classification was appropriate. The Company determined equity classification for both warrants and pre-funded warrants as they do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Per ASC 815-40-25, the Company accounts for the warrants and pre-funded warrants as equity, as the Company does not provide the holder a fixed or guaranteed return.

The Company recorded cash received from 1,531,440 pre-funded warrants to additional paid in capital in the amount of $4,999,999. The Company recorded placement fees and expenses related to the sale of pre-funded warrants in the amount of $299,999 as a charge to additional paid in capital in the consolidated balance sheet at December 31, 2022.

Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included 1,531,440 pre-funded warrants in the denominator of basic EPS at September 30, 2023.

 

The following table shows common stock warrants outstanding as of September 30, 2023:

 

 

 

Warrant Issued
November 16, 2022

 

 

Total

 

Balance at December 31, 2022

 

 

10,719,846

 

 

 

10,719,846

 

Issued via cashless exercises

 

 

 

 

 

 

Withheld as payment to cover issued shares

 

 

 

 

 

 

Expired

 

 

 

 

 

 

Issued

 

 

 

 

 

 

Balance at September 30, 2023

 

 

10,719,846

 

 

 

10,719,846

 

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Revenue
9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Collaboration Revenue

9. Collaboration Revenue

The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and if, over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company’s contracts may include options to acquire additional goods and/or services.

The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front payment, and pass through costs related to research activities, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of pass through costs and milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any development, regulatory or commercial milestones or royalty revenue resulting from any of its collaboration arrangements. Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis, when applicable. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.

Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. The Company measures progress toward satisfaction of the performance obligation over time as effort is expended.

Collaboration Agreement with LG Chem

On November 6, 2018, the Company entered into a collaboration agreement (the “LG Chem Collaboration Agreement”) with LG Chem Ltd. (“LG Chem”) related to the development of the Company’s Immuno-STATs focused in the field of oncology. Pursuant to the LG Chem Collaboration Agreement, the Company granted LG Chem an exclusive license to develop, manufacture and commercialize the Company’s lead product, CUE-101, as well as Immuno-STATs that target T cells against two additional cancer antigens, in certain Asian countries (collectively, the “LG Chem Territory”). On April 30, 2021, LG Chem’s option pursuant to the Global License and Collaboration Agreement entered into between the Company and LG Chem on December 18, 2019 and as amended on November 5, 2020 (the "Global License and Collaboration Agreement"), expired, and accordingly the Company no longer has any material obligations under the Global License and Collaboration Agreement. In June 2021, after ongoing discussions regarding the selection of the second of the two additional cancer antigens, LG Chem and the Company agreed to let the selection period expire without a second antigen being selected. The Company retains rights to develop and commercialize all assets included in the LG Chem Collaboration Agreement in the United States and in global markets outside of the LG Chem Territory. In exchange for the licenses and other rights granted to LG Chem under the LG Chem Collaboration Agreement, LG Chem made a $5.0 million equity investment in common stock of the Company and a $5.0 million nonrefundable up-front cash payment. The Company is also eligible to receive up to an additional $400.0 million in research, development, regulatory and sales milestones. In addition, the LG Chem Collaboration Agreement also provides that LG Chem will pay the Company tiered single-digit percentage royalties on net sales of commercialized drug product candidates in the LG Chem Territory.

On May 16, 2019, LG Chem paid the Company a $2.5 million milestone payment for the U.S. Food and Drug Administration’s (“FDA”) acceptance of the investigational new drug application (“IND”) for the Company’s lead drug product candidate, CUE-101, pursuant to the LG Chem Collaboration Agreement. The $2.5 million milestone payment was recorded as a contract liability upon receipt of payment as it requires deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Of the $2.5 million milestone payment, approximately $412,500 was recognized as tax withholding, shown as income tax expense on the consolidated statement of operations and other comprehensive loss.

On December 7, 2020, the Company earned a $1.25 million milestone payment on the selection of a pre-clinical candidate pursuant to the LG Chem Collaboration Agreement. The $1.25 million milestone payment was recorded as a contract liability upon receipt. Revenue related to this milestone payment was recognized by the Company pursuant to the Company’s revenue recognition policy in relation to the performance of its obligations related to the development of this pre-clinical candidate. Of the $1.25 million milestone payment, approximately $206,250 was withheld as payment of foreign tax withholding and shown as income tax expense on the consolidated statement of operations and other comprehensive loss.

On November 23, 2021, the Company earned a $3 million milestone payment for the selection of a clinical product candidate in partnership with LG Chem. The $3 million milestone payment was recorded as a contract liability upon receipt. Revenue related to this milestone payment was recognized by the Company pursuant to the Company’s revenue recognition policy in relation to the performance of its obligations related to the development of this preclinical candidate. Of the $3 million milestone payment,

approximately $495,000 was withheld as payment of foreign tax withholding and shown as income tax expense on the consolidated statements of operations and comprehensive loss. Cash was collected in relation to this milestone payment in February 2022.

Aside from the $6.75 million in milestone payments earned to date, the Company does not believe that any variable consideration should be included in the transaction price as of September 30, 2023. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur. For the three months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $178,000 and approximately $68,000, respectively, related to the LG Chem Collaboration Agreement. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $243,000 and approximately $1,094,000, respectively, related to the LG Chem Collaboration Agreement. The Company did not record short- or long-term research and development liabilities on its balance sheet dated September 30, 2023 and December 31, 2022 as the performance obligation was met and completed. Research and development cost sharing provisions under the agreement expired on March 31, 2022.

Collaboration and Option Agreement with Ono

On February 22, 2023, the Company entered into a strategic collaboration agreement (the "Ono Collaboration and Option Agreement") with Ono Pharmaceutical Co., Ltd. ("Ono") to further develop CUE-401 and provide dedicated resources and capabilities to help advance CUE-401 toward the clinic. Under the terms of the Ono Collaboration and Option Agreement, Ono paid the Company an upfront payment and agreed to fully fund all research activities related to CUE-401 through a specified option period. During this option period, the Company will be responsible for the research and development of CUE-401. Upon Ono’s exercise of its option to license CUE-401, the Company will receive an option exercise payment and be eligible for development and commercial milestone payments up to an aggregate of approximately $220 million, as well as tiered royalties on sales. Upon any such exercise, Ono will receive worldwide rights to develop and commercialize CUE-401, with the Company retaining a 50% co-development and co-commercialization right in the United States.

Under the terms of the Ono Collaboration and Option Agreement, the Company will perform research activities related to CUE-401 through a specified option period of 24 months (the “Research Term”). During this Research Term, the Company will be responsible for the execution of scientific investigation, nonclinical, preclinical, and clinical drug research and development activities designed to progress CUE-401 toward a potential IND and regulatory approval (such activities, collectively referred to as “R&D”). Ono is responsible for the funding of R&D activities performed by the Company. Per the agreement, as consideration for the R&D activities performed by the Company, Ono (i) made a one-time, non-refundable, non-creditable upfront payment of $3.0 million to the Company and (ii) will reimburse the Company for all costs incurred in conducting research, including (a) pass through costs from third party contractors and (b) full time employee salaries capped at $2.1 million in the first 18 months of the Research Term. The term of the Ono Collaboration and Option Agreement extends until the expiration of the Research Term which cannot exceed a 24-month period. The Company has forecasted that it will be able to complete the R&D activities in 18 months based on the initial research and development plans it has established. The Company received the $3.0 million upfront payment in March 2023.

Aside from the $3.0 million upfront payment and funding related to pass through costs, the Company does not believe that any variable consideration should be included in the transaction price as of September 30, 2023. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur. For the three months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $1,922,000 and $0, respectively, related to the Ono Collaboration and Option Agreement. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $3,426,000 and $0, respectively, related to the Ono Collaboration and Option Agreement. The Company recorded short-term research and development liabilities on its balance sheet dated September 30, 2023, of approximately $2,238,000. The Company did not recognize short or long-term research and development liabilities on its balance sheet as of December 31, 2022, as the agreement was executed in February 2023.

Capitalization of Contract Costs

The Company considered the capitalization of contract costs under the guidance in ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers. As it related to the LG Chem Collaboration Agreement, the Company capitalized license expenses of approximately $908,000 as of September 30, 2023, paid to Einstein pursuant to the Einstein License Agreement which requires the Company to pay a percentage of sublicenses related to the Company’s patent rights for components of its core technology that is

licensed from Einstein. This amount is comprised of approximately $438,000 of capitalized license expenses related to the up-front payment received from LG Chem in December 2018, approximately $313,000 in capitalized license expenses related to the milestone payment received in June 2019, and approximately $157,000 in capitalized license expenses related to the milestone payment received in December 2020, net of accumulated amortization on all capitalized license expenses of approximately $908,000. As of September 30, 2023 and December 31, 2022, no capitalized license expenses net of accumulated amortization were included in prepaid expenses and other short-term assets related to the LG Chem Collaboration Agreement.

XML 33 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

10. Commitments and Contingencies

Einstein License Agreement

In 2015, the Company entered into the Einstein License Agreement with Einstein for certain patent rights relating to the Company’s core technology platform for the engineering of biologics to control T cell activity, precision, immune-modulatory drug product candidates, and two supporting technologies that enable the discovery of costimulatory signaling molecules (ligands) and T cell targeting peptides. The Company entered into an amended and restated license agreement on July 31, 2017, as amended on October 2018, which modified certain obligations of the parties under the Einstein License Agreement. For each of the three months ended September 30, 2023 and 2022, the Company incurred $0 in fees and expenses to Einstein related to this license. For each of the nine months ended September 30, 2023 and 2022, the Company incurred $0 in fees and expenses to Einstein related to this license.

The Company’s remaining commitments with respect to the Einstein License Agreement are based on the attainment of future milestones. The aggregate amount of milestone payments made under the Einstein License Agreement may equal up to $1.85 million for each product, process or service that use the patents covered by the Einstein License Agreement, including certain technology received from Einstein related thereto (the "Licensed Product"), and up to $1.85 million for each new indication of a Licensed Product. Additionally, the aggregate amount of one-time milestone payments based on cumulative sales of all Licensed Products may equal up to $5.75 million. The Company is also party to a material transfer agreement with Einstein focusing on infectious disease and assessing the application of the Company's Neo-STAT asset for the treatment of infectious disease.

Collaboration Agreement with LG Chem

See discussion of the LG Chem Collaboration Agreement in Note 9.

Collaboration Agreement with Ono

See discussion of the Ono Collaboration and Option Agreement in Note 9.

Contingencies

The Company accrues contingent liabilities to the extent that the liability is probable and estimable. There are no accruals for contingent liabilities in the Company’s consolidated financial statements.

The Company may be subject to various legal proceedings from time to time as part of its business. As of September 30, 2023, the Company was not a party to any legal proceedings or threatened legal proceedings, the adverse outcome of which, individually or in the aggregate, would have a material adverse effect on its business, financial condition or results of operations.

XML 34 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Leases

11. Leases

 

On March 28, 2022, the Company entered into a License Agreement (the “License”) with MIL 40G, LLC (the “Licensor”), pursuant to which the Company leases approximately 13,000 square feet of office, research and development and laboratory space located at 40 Guest Street, Boston, Massachusetts 02135 (the “Premises”). The Company relocated its corporate headquarters to the Premises in April 2022. On March 28, 2022, the Company terminated its office and lab space lease in Cambridge Massachusetts (the “Laboratory and Office Lease”) effective April 30, 2022. The Company performed an analysis of the accounting implications of this termination based on ASC 360 Impairments and Abandonments guidance. At March 31, 2022, the Company recorded an adjustment to decrease the right-of-use asset and lease liability of approximately $8,124,000 and $8,382,000, respectively, and recorded a gain on right-of-use asset termination included in the consolidated statement of operations and other comprehensive loss of approximately $258,000.

The Company recognized a right of use asset of approximately $9,056,000 and an operating lease liability of approximately $9,056,000 which were recorded as of the Term Commencement Date (as defined below) related to the License.

The term of the License commenced on April 15, 2022 (the “Term Commencement Date”) and expires on April 14, 2026 (the “Term”). The License has a monthly rental rate of $200,700 for the first year of the Term, $208,728 for the second year of the Term, $217,077 for the third year of the Term and $225,760 for the remainder of the Term. Pursuant to the License, the Company prepaid two months of rent and a security deposit. The Licensor is obligated under the License to provide certain services to the Company, including providing certain gases, chemicals and equipment to the Premises’ laboratory space, IT support, security, office support and health and safety training. The Licensor has the right to terminate the License for Cause (as defined in the License).

On May 3, 2022, the Company entered into the First Amendment to the License ("First Amendment”) with the Licensor, pursuant to which the License was expanded to include an additional room effective July 15, 2022. In consideration of the First Amendment, the security deposit was increased from $225,760 to $235,884 effective July 15, 2022. Upon execution of the First Amendment, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. Effective July 15, 2022, the monthly rental rate under the First Amendment increased to $209,700 from $200,700. The Company recognized a right of use asset of approximately $369,000 and a short- and long-term operating lease liability of approximately $100,300 and $260,600, respectively, using the weighted average discount rate of 8%, which were recorded as of the Term Commencement Date related to the License.

On May 31, 2022, the Company entered into an operating lease for additional laboratory space at 40 Guest Street, Boston, Massachusetts for the period from December 1, 2022 through December 1, 2024 (the “40G Additional Laboratory Lease”). The 40G Additional Laboratory Lease contains escalating payments during the lease period. The monthly rental rate under the 40G Additional Laboratory Lease is $59,152 for the first 12 months and $61,519 for the remainder of the term. Under the terms of this lease agreement, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. The Company recognized a right of use asset of approximately $1,307,000 and a short- and long-term operating lease liability of approximately $712,000 and $535,000, respectively, using the weighted average discount rate of 10%, which were recorded as of the Term Commencement Date related to the 40G Additional Laboratory Lease.

On September 9, 2022, the Company terminated its lab space lease in Cambridge, Massachusetts with MIL 21E, LLC with an effective termination date of December 6, 2022. The Company performed an analysis of the accounting implications of this termination based on ASC 360 Impairments and Abandonment guidance. The Company recorded an entry to remove the remaining lease liability and right of use asset of $963,000 and $945,000, respectively. The difference between the carrying amounts of the right of use asset and lease liability of $19,000 was recorded at termination in September 2022, to gain on right of use asset and included in the consolidated statements of operations and other comprehensive loss.

For the three and nine months ended September 30, 2023, the Company recorded approximately $122,000 and $402,000, respectively, in non-cash interest expense to the lease liability. For the three and nine months ended September 30, 2022, the Company recorded approximately $146,000 and $309,000, respectively, in non-cash interest expense to the lease liability.

At September 30, 2023, the Company recorded approximately $7,060,000 to operating lease right-of-use asset, and approximately $3,399,000 and $3,855,000 to the short-term and long-term operating lease liability, respectively. At December 31, 2022, the Company recorded approximately $9,203,000 to operating lease right-of-use asset, and approximately $3,300,000 and $6,018,000 to short-term and long-term operating lease liability, respectively. As of September 30, 2023 and December 31, 2022, a security deposit of approximately $595,000 was included in deposits on the Company’s consolidated balance sheet related to the 40G Additional Laboratory Lease. Cash was collected in the amount of $0 and approximately $199,000 for the Company's former Cambridge 21 Erie Laboratory space during the three and nine months ended September 30, 2023, respectively.

Future minimum lease payments under the leases in effect at September 30, 2023 are as follows:

 

Year

 

(in thousands)

 

2023 (3 months remaining)

 

 

835

 

2024

 

 

3,368

 

2025

 

 

2,799

 

2026

 

 

818

 

Total lease payments

 

$

7,820

 

Less: present value discount

 

 

(566

)

Total

 

$

7,254

 

 

Total rent expense of approximately $853,000 and $860,000 was included in the consolidated statements of operations and other comprehensive loss for the three months ended September 30, 2023 and 2022, respectively. Total rent expense of approximately $2,566,000 and $3,309,000 was included in the consolidated statements of operations and other comprehensive loss for the nine months ended September 30, 2023 and 2022, respectively. Other information pertaining to the Company’s operating leases for the three and nine months ended September 30, 2023 is summarized in the table below.

 

Other information

 

Three Months Ended
September 30, 2023

 

Nine Months Ended
September 30, 2023

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

Operating cash flows from operating leases (in thousands)

 

$

(709

)

$

(2,064

)

Operating lease cost (in thousands)

 

$

853

 

$

2,566

 

Weighted average discount rate

 

5.75%

 

5.75%

 

Weighted average remaining lease term

 

2.39 years

 

2.39 years

 

XML 35 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying unaudited consolidated financial statements as of September 30, 2023, and for the three and nine months ended September 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for financial information, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp., which was incorporated in the Commonwealth of Massachusetts in December 2018. In the opinion of management, these financial statements reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2023.

Interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future periods.

Public Offerings

Public Offerings

In October 2021, the Company entered into an open market sale agreement (the “October 2021 ATM Agreement”) with Jefferies LLC ("Jefferies"), as agent, to sell shares of the Company’s common stock for aggregate gross proceeds of up to $80 million, from time to time, through an at-the-market equity offering program. The October 2021 ATM Agreement will terminate upon the earliest of (a) the sale of $80 million of shares of the Company’s common stock pursuant to the October 2021 ATM Agreement or (b) the termination of the October 2021 ATM Agreement by the Company or Jefferies. During the three months ended September 30, 2023, the Company sold 1,378,867 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $5,589,000 net of commission paid, but excluding transaction expenses. During the nine months ended September 30, 2023, the Company sold 1,915,131 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $7,605,000 net of commission paid, but excluding transaction expenses. As of September 30, 2023, the Company had sold an aggregate of 5,508,538 shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $31.2 million, net of commission paid, but excluding transaction expenses, since its inception.

Consolidation

Consolidation

The accompanying consolidated financial statements include the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp. The Company has eliminated all intercompany transactions.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.

Cash Concentrations

Cash Concentrations

The Company maintains its cash balances with financial institutions in federally insured accounts and may periodically have cash balances in excess of insurance limits. The Company maintains its accounts with financial institutions with a high credit rating. The Company has not experienced any losses to date from our deposits with these financial institutions and believes that it is not exposed to any significant credit risk on cash.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company currently invests available cash in money market funds.

Marketable Securities

Marketable Securities

Marketable securities consist of investments with original maturities greater than ninety days and less than one year from the balance sheet date. The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are recognized and determined on a specific identification basis and are included in other comprehensive loss. Realized gains and losses are determined on a specific identification basis and are included in other income on the consolidated statement of operations and other comprehensive loss. Amortization and accretion of discounts and premiums is recorded in interest income. The Company has invested available cash in U.S. Treasury obligations.

Restricted Cash

Restricted Cash

The Company had $150,000 in restricted cash deposited with separate commercial banks to collateralize a credit card as of September 30, 2023 and December 31, 2022.

Property and Equipment

Property and Equipment

Property and equipment is recorded at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from dispositions of property and equipment are included in income and expense when realized. Amortization of leasehold improvements is provided using the straight-line method over the shorter of the lease term or the useful life of the underlying assets. Depreciation of property and equipment is provided using the straight-line method over the following estimated useful lives:

 

Laboratory equipment

 

5 years

Computer and office equipment

 

3 years

Furniture and fixtures

 

3-8 years

 

The Company recognizes depreciation and amortization expense in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on how each category of property and equipment is utilized in the Company’s business activities.

Trademark

Trademark

Trademark consists of the Company’s right, title and interest to the CUE BIOLOGICS Mark, and any derivative mark incorporating CUE, throughout the world, together with all associated goodwill and common law rights appurtenant thereto, including, but not limited to, any right, title and interest in any corporate name, company name, business, name, trade name, dba, domain name, or other source identifier incorporating CUE.

The Company has classified the trademark as a component of other long-term assets, having a useful life of 15 years. The Company evaluates the status of this intangible asset for amortization and impairment at each quarter end and year end reporting date. For each of the three and nine months ended September 30, 2023 and 2022, the Company recorded approximately $3,000 and $9,000, respectively, in amortization expense on a straight-line basis.

 

Debt Issuance Costs

Debt issuance costs are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and other comprehensive loss.

Revenue Recognition

Revenue Recognition

The Company recognizes collaboration revenue under certain of the Company’s license and collaboration agreements that are within the scope of Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the expected value method.

Research and Development Expenses

Research and Development Expenses

Research and development expenses consist primarily of compensation costs, fees paid to consultants, outside service providers and organizations (including research institutes at universities), facility costs, and development and clinical trial costs with respect to the Company’s drug product candidates.

Research and development expenses incurred under contracts are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different pattern of performance is more appropriate. Other research and development expenses are charged to operations as incurred.

Nonrefundable advance payments are recognized as an expense as the related services are performed. The Company evaluates whether it expects the services to be rendered at each quarter end and year end reporting date. If the Company does not expect the services to be rendered, the advance payment is charged to expense. Nonrefundable advance payments for research and development services are included in prepaid and other current assets on the balance sheet. To the extent that a nonrefundable advance payment is for contracted services to be performed within 12 months from the reporting date, such advance is included in current assets; otherwise, such advance is included in non-current assets.

The Company evaluates the status of its research and development agreements and contracts, and the carrying amount of the related assets and liabilities, at each quarter end and year end reporting date, and adjusts the carrying amounts and their classification on the balance sheet as appropriate.

Patent Expenses

Patent Expenses

The Company is the exclusive worldwide licensee of, and has patent applications pending for, numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development of one or more commercially viable drug product candidates based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal fees, filing fees and other costs are charged to general and administrative expense as incurred. For the three and nine months ended September 30, 2023, patent expenses were approximately $503,000 and $1,649,000, respectively. For the three and nine months ended September 30, 2022, patent expenses were $395,000 and $1,625,000, respectively.

Licensing Fees and Costs

Licensing Fees and Costs

Licensing fees and costs consist primarily of costs relating to the acquisition of the Company’s license agreement (the “Einstein License Agreement”) with the Albert Einstein College of Medicine (“Einstein”), including related royalties, maintenance fees, milestone payments and product development costs. Licensing fees and costs are charged to research and development expense as incurred.

Long-Lived Assets

Long-Lived Assets

The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs.
Leases

Leases

 

The Company accounts for leases under ASC 842, Leases, which requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases are required.

Stock-Based Compensation

Stock-Based Compensation

The Company periodically issues stock-based awards to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values. Stock option grants, which are generally time-vested, are measured at the grant date fair value and charged to operations on a straight-line basis over the service period, which generally approximates the vesting term. The Company also grants performance-based awards periodically to officers of the Company. The Company recognizes compensation costs related to performance awards over the requisite service period if and when the Company concludes that it is probable that the performance condition will be achieved.

The fair value of stock options and restricted stock units is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading history for its common stock that approximates the expected term of the options, estimated volatility is based on the average historical volatility of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends and has no plans to do so for the foreseeable future. As permitted by Staff Accounting Bulletin No. 107, due to the Company’s limited trading history and option activity, management

utilizes the simplified method to estimate the expected term of options at the date of grant. The exercise price is determined based on the fair value of our common stock at the date of grant. The Company accounts for forfeitures as they occur.

The Company recognizes the fair value of stock-based compensation in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on the type of services provided by the recipient of the equity award.

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive income (loss) includes net income (loss) as well as changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. The Company’s only element of other comprehensive income (loss) in periods presented was unrealized gain or loss on available-for-sale securities.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

The Company’s computation of earnings (loss) per share (“EPS”) for the respective periods includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares that would result from the exercise of outstanding stock options and warrants as if they had been exercised at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Basic and diluted loss per common share is the same for all periods presented because all outstanding stock options and warrants are anti-dilutive.

Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included 1,531,440 pre-funded warrants in the denominator of basic EPS at September 30, 2023.

At September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

 

 

 

September 30,

 

 

 

2023

 

2022

 

Common stock warrants

 

 

10,719,846

 

 

789,358

 

Common stock options

 

 

7,500,480

 

 

6,268,729

 

Total

 

 

18,220,326

 

 

7,058,087

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active exchange-traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

The Company had approximately $54,691,000 in cash equivalents as of September 30, 2023. The Company had approximately $45,423,000 in cash equivalents and approximately $24,675,000 in short-term marketable securities that were measured and recorded at fair value on the Company’s balance sheet at December 31, 2022.

The carrying value of financial instruments (consisting of cash, a certificate of deposit, accounts payable, accrued compensation and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) (CECL). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The new standard is effective for annual reporting periods beginning after December 15, 2022, including interim reporting periods within each annual reporting period for smaller reporting companies. The Company adopted ASU No. 2016-13 but there was no financial impact to the Company’s consolidated financial statements for the year ended December 31, 2022 or for the nine months ended September 30, 2023.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

XML 36 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Estimated Useful Lives of Assets Depreciation of property and equipment is provided using the straight-line method over the following estimated useful lives:

 

Laboratory equipment

 

5 years

Computer and office equipment

 

3 years

Furniture and fixtures

 

3-8 years

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

At September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

 

 

 

September 30,

 

 

 

2023

 

2022

 

Common stock warrants

 

 

10,719,846

 

 

789,358

 

Common stock options

 

 

7,500,480

 

 

6,268,729

 

Total

 

 

18,220,326

 

 

7,058,087

 

XML 37 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value (Tables)
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Assets Measured on Recurring Basis

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022, and indicate the level of the fair value hierarchy utilized to determine such fair value:

 

 

 

Fair Value Measurements as of September 30, 2023

 

 

 

(in thousands)

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Fair Value

 

Cash equivalents

 

$

54,691

 

 

$

 

 

$

 

 

$

54,691

 

Marketable securities

 

 

 

 

$

 

 

 

 

 

 

 

Total

 

$

54,691

 

 

$

 

 

$

 

 

$

54,691

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements as of December 31, 2022

 

 

 

(in thousands)

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Fair Value

 

Cash equivalents

 

$

45,423

 

 

$

 

 

$

 

 

$

45,423

 

Marketable securities

 

 

 

 

 

24,675

 

 

 

 

 

 

24,675

 

Total

 

$

45,423

 

 

$

24,675

 

 

$

 

 

$

70,098

 

XML 38 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities (Tables)
9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Fair Value of Available-for-Sale Marketable Securities The following table presents the Company's marketable securities at December 31, 2022:

 

 

 

December 31, 2022

 

(In thousands)

 

Amortized Cost

 

 

Gross Unrealized
Gains

 

 

Gross Unrealized
Losses

 

 

Fair Value

 

U.S. Treasury Securities

 

$

24,771

 

 

$

 

 

$

(96

)

 

$

24,675

 

 

$

24,771

 

 

$

 

 

$

(96

)

 

$

24,675

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2022, the Company's marketable securities consisted of $24,771,000 of investments that mature within 12 months and the Company recorded an unrealized loss on investments of $96,000 for the year ended December 31, 2022.

XML 39 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment

Property and equipment as of September 30, 2023 and December 31, 2022 consisted of the following:

 

 

 

September 30,
2023

 

 

December 31,
2022

 

 

 

(in thousands)

 

Laboratory equipment

 

$

5,205

 

 

$

5,246

 

Furniture and fixtures

 

 

81

 

 

 

81

 

Computer and office equipment

 

 

296

 

 

 

296

 

Leasehold improvements

 

 

118

 

 

 

118

 

 

 

5,699

 

 

 

5,741

 

Less accumulated depreciation

 

 

(4,635

)

 

 

(4,242

)

Net property and equipment

 

$

1,064

 

 

$

1,499

 

XML 40 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Loan with Silicon Valley Bank (Tables)
9 Months Ended
Sep. 30, 2023
Summary of Future Principal Debt Payments on Term Loan Agreement

The following tables present the aggregate maturities of long-term and current portion of debt as of September 30, 2023 (in thousands):

 

 

 

 

 

 

 

Year

Aggregate Minimum Payments

 

 

 

2023

$

 

1,000

 

 

 

2024

 

 

4,000

 

 

 

2025

 

 

4,000

 

 

 

Total maturities

$

 

9,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total long-term debt

 

 

 

$

5,000

 

Accretion of final payment

 

 

207

 

Less: unamortized debt issuance costs

 

 

 

 

(46

)

Long-term debt, net

 

$

5,160

 

 

 

 

 

 

 

Total current portion of long-term debt

 

 

 

$

4,000

 

Less: unamortized debt issuance costs

 

 

 

 

(37

)

Current portion of long-term debt, net

 

$

3,963

 

 

 

XML 41 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2023
Schedule of Estimated Fair Value of Each Stock Option Award

For stock options requiring an assessment of value during the nine months ended September 30, 2023 and 2022, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:

 

 

 

September 30, 2023

Risk-free interest rate

 

3.4% - 4.16%

Expected dividend yield

 

0%

Expected volatility

 

97.03% - 110.4%

Expected life

 

5.50 to 6.25 years

 

 

 

 

 

September 30, 2022

Risk-free interest rate

 

1.53% - 2.92%

Expected dividend yield

 

0%

Expected volatility

 

92.1% - 95.7%

Expected life

 

5.50 to 6.25 years

Summary of Stock Option Activity

A summary of stock option activity for the nine months ended September 30, 2023 is as follows:

 

 

 

Number of
Shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Life
(in Years)

 

Stock options outstanding at December 31, 2022

 

 

6,173,867

 

 

$

9.60

 

 

 

5.05

 

Granted

 

 

2,576,900

 

 

 

3.65

 

 

 

 

Exercised

 

 

(165,602

)

 

 

2.86

 

 

 

 

Cancelled

 

 

(1,084,685

)

 

 

4.78

 

 

 

 

Stock options outstanding at September 30, 2023

 

 

7,500,480

 

 

 

8.40

 

 

 

6.35

 

Stock options exercisable at September 30, 2023

 

 

4,365,960

 

 

$

10.38

 

 

 

4.54

 

Schedule of Stock-Based Compensation Included in Statement of Operations

Stock-based compensation expense for the three and nine months ended September 30, 2023 and 2022 was included in the Company’s consolidated statements of operations and other comprehensive loss as follows:

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended September 30,

 

(in thousands)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

General and administrative

 

$

858

 

 

$

1,003

 

 

$

2,708

 

 

$

3,650

 

Research and development

 

 

1,215

 

 

 

1,061

 

 

 

3,399

 

 

 

3,734

 

Total

 

$

2,073

 

 

$

2,064

 

 

$

6,108

 

 

$

7,384

 

XML 42 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Warrants (Table)
9 Months Ended
Sep. 30, 2023
Warrants and Rights Note Disclosure [Abstract]  
Summary of Common Stock Warrant Activity

The following table shows common stock warrants outstanding as of September 30, 2023:

 

 

 

Warrant Issued
November 16, 2022

 

 

Total

 

Balance at December 31, 2022

 

 

10,719,846

 

 

 

10,719,846

 

Issued via cashless exercises

 

 

 

 

 

 

Withheld as payment to cover issued shares

 

 

 

 

 

 

Expired

 

 

 

 

 

 

Issued

 

 

 

 

 

 

Balance at September 30, 2023

 

 

10,719,846

 

 

 

10,719,846

 

XML 43 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Schedule of Future Minimum Lease Payments for Operating Lease

Future minimum lease payments under the leases in effect at September 30, 2023 are as follows:

 

Year

 

(in thousands)

 

2023 (3 months remaining)

 

 

835

 

2024

 

 

3,368

 

2025

 

 

2,799

 

2026

 

 

818

 

Total lease payments

 

$

7,820

 

Less: present value discount

 

 

(566

)

Total

 

$

7,254

 

Schedule of Other Information of Operating Leases Other information pertaining to the Company’s operating leases for the three and nine months ended September 30, 2023 is summarized in the table below.

 

Other information

 

Three Months Ended
September 30, 2023

 

Nine Months Ended
September 30, 2023

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

Operating cash flows from operating leases (in thousands)

 

$

(709

)

$

(2,064

)

Operating lease cost (in thousands)

 

$

853

 

$

2,566

 

Weighted average discount rate

 

5.75%

 

5.75%

 

Weighted average remaining lease term

 

2.39 years

 

2.39 years

 

XML 44 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Basis of Presentation - Additional Information (Details)
Sep. 30, 2023
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash and cash equivalents, and marketable securities $ 54,691,000
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended 24 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items]            
Proceeds from ATM offering, net of sales agent commission and fees     $ 7,605,000 $ 16,598,000    
Useful life of trademark     15 years      
Type of Cost, Good or Service [Extensible List] us-gaap:LicenseMember   us-gaap:LicenseMember      
Cash equivalents $ 54,691,000   $ 54,691,000   $ 54,691,000 $ 45,423,000
Marketable securities           24,675,000
Pre Funded Warrants     1,531,440      
General and Administrative Expense [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Patent expenses 503,000 $ 395,000 $ 1,649,000 1,625,000    
Trademarks            
Summary Of Significant Accounting Policies [Line Items]            
Amortization of intangible assets 3,000 $ 9,000 3,000 $ 9,000    
Certificate of Deposit            
Summary Of Significant Accounting Policies [Line Items]            
Restricted cash used to collateralize a credit card 150,000   $ 150,000   150,000 $ 150,000
Transaction Expense            
Summary Of Significant Accounting Policies [Line Items]            
Sale of common stock, number of shares     1,915,131      
Transaction Expense | Agreement2 [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Sale of common stock, number of shares     5,508,538      
Proceeds from sale of common stock $ 5,589,000,000   $ 7,605,000,000   31,200,000  
Jefferies LLC [Member] | Maximum            
Summary Of Significant Accounting Policies [Line Items]            
Proceeds from Issuance Initial Public Offering     80,000,000      
Jefferies LLC [Member] | Transaction Expense            
Summary Of Significant Accounting Policies [Line Items]            
Stock Issued During Period, Shares, New Issues 1,378,867          
Proceeds from sale of common stock $ 80,000,000   $ 80,000,000   $ 80,000,000  
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Details)
Sep. 30, 2023
Laboratory Equipment  
Property Plant And Equipment [Line Items]  
Estimated useful lives 5 years
Computer and Office Equipment  
Property Plant And Equipment [Line Items]  
Estimated useful lives 3 years
Furniture and Fixtures | Minimum [Member]  
Property Plant And Equipment [Line Items]  
Estimated useful lives 3 years
Furniture and Fixtures | Maximum  
Property Plant And Equipment [Line Items]  
Estimated useful lives 8 years
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 18,220,326 7,058,087
Common Stock Warrants    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 10,719,846 789,358
Common Stock Options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share 7,500,480 6,268,729
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value - Schedule of Fair Value Assets Measured on Recurring Basis (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents $ 54,691,000 $ 45,423,000
Marketable securities 0 24,675,000
Total 54,691,000 45,423,000
Fair Value Measurements, Recurring Basis    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 54,691,000 45,423,000
Marketable securities 0 24,675,000
Total 54,691,000 70,098,000
Fair Value Measurements, Recurring Basis | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 54,691,000 45,423,000
Marketable securities 0 0
Total 54,691,000 45,423,000
Fair Value Measurements, Recurring Basis | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Marketable securities 0 24,675,000
Total 0 24,675,000
Fair Value Measurements, Recurring Basis | Level 3    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Marketable securities 0 0
Total $ 0 $ 0
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value - Additional Information (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Fair Value Disclosures [Abstract]    
Cash equivalents and marketable securities $ 54,691,000 $ 45,423,000
Marketable securities 0 24,675,000
Fair value assets transfers between Level 2 and Level 3 $ 0 $ 0
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities - Schedule of Fair Value of Available-for-Sale Marketable Securities (Details)
Dec. 31, 2022
USD ($)
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost $ 24,771,000
Gross Unrealized Gains 0
Gross Unrealized Losses (96,000)
Fair Value 24,675,000
U.S. Treasury securities  
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost 24,771,000
Gross Unrealized Gains 0
Gross Unrealized Losses (96,000)
Fair Value $ 24,675,000
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]    
Marketable securities $ 24,675,000 $ 0
Unrealized gain on investments $ 96,000  
Marketable securities, Maturity period 12 months  
Amortized Cost $ 24,771,000  
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 5,699 $ 5,741
Less accumulated depreciation (4,635) (4,242)
Net property and equipment 1,064 1,499
Laboratory Equipment    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross 5,205 5,246
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross 81 81
Computer and office equipment [Member]    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross 296 296
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 118 $ 118
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Property Plant And Equipment [Line Items]        
Depreciation expense $ 128,000 $ 198,000 $ 434,000 $ 630,000
Depreciation     9,000 9,000
Amortization of capitalized license expense       80,000
Laboratory Equipment        
Property Plant And Equipment [Line Items]        
Disposal of property and equipment, gross $ 41,450,000 $ 30,000 41,450,000 30,000
Cash Collected from sale of fixed assets     2,000 5,800
Laboratory Equipment | Other Income        
Property Plant And Equipment [Line Items]        
Gain (Loss) on disposal of property and equipment     $ 2,000 $ 4,300
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Loan with Silicon Valley Bank (Additional Information) (Details) - USD ($)
3 Months Ended 9 Months Ended
Feb. 15, 2025
Feb. 15, 2024
Feb. 15, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Line of Credit Facility [Line Items]              
Interest expense, net       $ (254,000) $ (33,000) $ (848,000) $ (98,000)
Interest Expense relating accretion of the final payment       183,000 33,000 354,000 76,000
Debt issuance costs       141,748   141,748  
Amortization of debt issuance costs       9,000 $ 9,000 28,000 $ 21,000
Cash obligation       $ 20,000,000   $ 20,000,000  
Silicon Valley Bank              
Line of Credit Facility [Line Items]              
Final fee (percentage)     5.00%        
Prepayment premium rate 1.00% 2.00%          
Silicon Valley Bank | Term Loan Agreement              
Line of Credit Facility [Line Items]              
Short-Term Debt     $ 10,000,000        
Interest rate           10.75  
Closing Date       Jun. 30, 2023   Jun. 30, 2023  
Variable interest rate (percentage)           2.25%  
Silicon Valley Bank | Term Loan Agreement | Maximum              
Line of Credit Facility [Line Items]              
Interest rate, floating       5.50%   5.50%  
Silicon Valley Bank | Term Loan Agreement | Minimum              
Line of Credit Facility [Line Items]              
Variable interest rate (percentage)           2.25%  
Silicon Valley Bank | Tranche A loan              
Line of Credit Facility [Line Items]              
Monthly installments           30 months  
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Loan with Silicon Valley Bank - Summary of Future Principal Debt Payments on Term Loan Agreement (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Instruments [Abstract]    
2023 $ 1,000  
2024 4,000  
2025 4,000  
Total maturities 9,000  
Total long-term debt 5,000  
Accretion of final payment 207  
Less: unamortized debt issuance costs (46)  
Long-term debt, net 5,160 $ 8,035
Total current portion of long-term debt 4,000  
Less: unamortized debt issuance costs (37)  
Current portion of long-term debt, net $ 3,963 $ 1,963
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Stock Based Compensation - Schedule of Estimated Fair Value of Each Stock Option Award (Details)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Risk-free interest rate, minimum 3.40% 1.53%
Risk-free interest rate, maximum 4.16% 2.92%
Expected dividend yield 0.00% 0.00%
Expected volatility, minimum 97.03% 92.10%
Expected volatility, maximum 110.40% 95.70%
Maximum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected life 6 years 3 months 6 years 3 months
Minimum [Member]    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected life 5 years 6 months 5 years 6 months
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Stock Based Compensation - Summary of Stock Option Activity (Details) - $ / shares
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]    
Number of Shares, Outstanding Beginning Balance 6,173,867  
Number of Shares, Granted 2,576,900  
Number of Shares, Exercised (165,602)  
Number of Shares, Cancelled (1,084,685)  
Number of Shares, Outstanding Ending Balance 7,500,480 6,173,867
Number of Shares, Exercisable 4,365,960  
Weighted Average Exercise Price, Outstanding Beginning Balance $ 9.6  
Weighted Average Exercise Price, Granted 3.65  
Weighted Average Exercise Price, Exercised 2.86  
Weighted Average Exercise Price, Cancelled 4.78  
Weighted Average Exercise Price, Outstanding Ending Balance 8.4 $ 9.6
Weighed Average Exercise Price, Exercisable $ 10.38  
Weighted Average Remaining Contractual Life (in Years) 6 years 4 months 6 days 5 years 18 days
Weighted Average Remaining Contractual Life (in Years), Exercisable 4 years 6 months 14 days  
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Stock Based Compensation - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 05, 2020
Oct. 03, 2019
Mar. 31, 2020
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Aug. 21, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation       $ 2,073,000 $ 2,064,000 $ 6,108,000 $ 7,384,000    
Stock based payment options outstanding weighted average remaining term           6 years 4 months 6 days   5 years 18 days  
Number of Shares, Granted           2,576,900      
Weighted Average Exercise Price, Granted           $ 3.65      
Unrecognized stock-based compensation       12,141,000 $ 13,856,000 $ 12,141,000 13,856,000    
Intrinsic value of exercisable stock options       $ 0   $ 0      
Intrinsic value of exercisable fair value per share       $ 10.38   $ 10.38      
Number of shares, granted           2,576,900      
Stock-based compensation           $ 6,108,000 7,384,000    
Common Stock [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock options granted purchase shares       1,115,000 12,500        
weighted average grant date fair value       $ 4.17 $ 2.45        
Restricted Stock Units                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation       $ 0   0      
Number of shares, granted   100,000             20,000
Weighted average grant date fair value per share   $ 7.53              
Stock-based compensation         $ 19,000   847,000    
Restricted Stock Units | February 2020 Awarded And Granted                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of Shares, Granted 150,000                
Number of shares, granted 150,000                
Restricted Stock Units | March 2020 Awarded And Granted                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of Shares, Granted     50,000            
Number of shares, granted     50,000            
Stock Option                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation       $ 2,073,000 $ 2,045,000 $ 6,108,000 $ 6,537,000    
Stock based payment options outstanding weighted average remaining term           2 years 1 month 28 days 2 years 1 month 17 days    
Number of Shares, Granted           2,576,900 828,500    
weighted average grant date fair value           $ 3.65 $ 6.99    
Number of shares, granted           2,576,900 828,500    
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Stock Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) - Restricted Stock Units
Aug. 21, 2020
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of Shares, Nonvested balance as of December 31, 2022 100,000
Number of Shares, Nonvested balance at March 31, 2023 20,000
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Stock Based Compensation - Schedule of Stock-Based Compensation Included in Statement of Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation $ 2,073 $ 2,064 $ 6,108 $ 7,384
General and Administrative Expense        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation 858 1,003 2,708 3,650
Research and Development        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation $ 1,215 $ 1,061 $ 3,399 $ 3,734
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Warrants - Additional Information (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Nov. 16, 2022
$ / shares
shares
Sep. 30, 2023
$ / shares
shares
Sep. 30, 2022
$ / shares
Sep. 30, 2023
USD ($)
Tranche
$ / shares
shares
Sep. 30, 2022
$ / shares
Dec. 31, 2022
USD ($)
shares
Dec. 26, 2022
Jun. 15, 2022
Dec. 27, 2017
$ / shares
shares
Jun. 15, 2015
$ / shares
shares
Class Of Warrant Or Right [Line Items]                    
Number of tranches | Tranche       1            
Common stock warrants outstanding   10,719,846   10,719,846   10,719,846        
Common stock warrants expiration date   Jun. 15, 2015   Jun. 15, 2015            
Pre Funded Warrants       1,531,440            
Earnings Per Share, Basic | $ / shares   $ (0.24) $ (0.31) $ (0.82) $ (1.11)          
Tranche 1                    
Class Of Warrant Or Right [Line Items]                    
Common stock warrants outstanding                   1,500
Common stock warrants expiration date   Jun. 15, 2022   Jun. 15, 2022            
Exercise price of common stock warrants | $ / shares                   $ 2.7
Common stock warrants life               7 years    
Tranche 2                    
Class Of Warrant Or Right [Line Items]                    
Common stock warrants outstanding                 882,071  
Common stock warrants expiration date   Dec. 26, 2022   Dec. 26, 2022            
Exercise price of common stock warrants | $ / shares                 $ 9.38  
Common stock warrants life             5 years      
Tranche 3                    
Class Of Warrant Or Right [Line Items]                    
Pre Funded Warrants       1,531,440            
Pre-Funded Warrants [Member]                    
Class Of Warrant Or Right [Line Items]                    
Common stock warrants outstanding 9,188,406                  
Exercise price of common stock warrants | $ / shares $ 3.93                  
Pre Funded Warrants 1,531,440                  
Additional Paid In Capital Warrant Issued | $       $ 4,999,999            
Placement Fees | $           $ 299,999        
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Warrants - Summary of Common Stock Warrant Activity (Details)
9 Months Ended
Sep. 30, 2023
shares
Class Of Warrant Or Right [Line Items]  
Shares remaining to be issued as of December 31, 2022 10,719,846
Issued via cashless exercises 0
Withheld as payment to cover issued shares 0
Expired 0
Issued 0
Shares remaining to be issued as of September 30, 2023 10,719,846
Warrant Issued November Sixteen Two Thousand Twenty Two [Member]  
Class Of Warrant Or Right [Line Items]  
Shares remaining to be issued as of December 31, 2022 10,719,846
Issued via cashless exercises 0
Withheld as payment to cover issued shares 0
Expired 0
Issued 0
Shares remaining to be issued as of September 30, 2023 10,719,846
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Revenue - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 23, 2021
Dec. 07, 2020
May 16, 2019
Dec. 31, 2020
Jun. 30, 2019
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2018
Feb. 22, 2023
Dec. 31, 2022
Nov. 06, 2018
Disaggregation Of Revenue [Line Items]                          
Collaboration revenue           $ 2,100,000 $ 68,000 $ 3,669,000 $ 1,094,000        
Short-term research and development contract liability           2,238,000   2,238,000       $ 0  
Milestone payment associated with contract liability $ 3,000,000 $ 1,250,000 $ 2,500,000                    
Prepaid expenses and other short-term assets           1,165,000   1,165,000       841,000  
Other long-term assets           120,000   120,000       128,000  
Ono Collaboration and Option Agreement [Member]                          
Disaggregation Of Revenue [Line Items]                          
Percentage of right to development and commercialized                     50.00%    
Development and commercial milestone payment payable cuo biopharma                     $ 220,000,000    
One Time Up Front Payment Payable As Consideration RD Activities           3,000,000   3,000,000          
Milestone payments received           $ 3,000,000   $ 3,000,000          
First Research Term Processed Milestone Payment Under Agreement           18 months   18 months          
Collaboration revenue           $ 1,922,000 0 $ 3,426,000 0        
Short-term research and development contract liability           2,238,000   2,238,000          
Ono Collaboration and Option Agreement [Member] | Maximum                          
Disaggregation Of Revenue [Line Items]                          
Full time employe salary payable in first research term           2,100,000   2,100,000          
Collaboration Agreement with LG Chem Life Sciences | LG Chem Life Sciences                          
Disaggregation Of Revenue [Line Items]                          
Milestone payments received 3,000,000 1,250,000 2,500,000         6,750,000          
Collaboration revenue           178,000 $ 68,000 243,000 $ 1,094,000        
Equity investment nonrefundable upfront cash payment                         $ 5,000,000
Equity investment for research collaboration agreement                         5,000,000
Milestone payment associated with contract liability 3,000,000 1,250,000 2,500,000                    
Income tax expense $ 495,000 $ 206,250 $ 412,500                    
Collaboration Agreement with LG Chem Life Sciences | LG Chem Life Sciences | Maximum                          
Disaggregation Of Revenue [Line Items]                          
Additional amount receivable research development regulatory and sales milestones                         $ 400,000,000
Collaboration Agreement with LG Chem Life Sciences | Einstein                          
Disaggregation Of Revenue [Line Items]                          
Prepaid expenses and other short-term assets           $ 0   0       $ 0  
Einstein License And Service Agreement | Einstein                          
Disaggregation Of Revenue [Line Items]                          
Amortization of intangible assets               908,000          
Cost of Goods and Services Sold       $ 157,000 $ 313,000     $ 908,000   $ 438,000      
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Additional Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2015
SupportingTechnology
Commitments And Contingencies [Line Items]          
Type of Cost, Good or Service [Extensible List] us-gaap:LicenseMember   us-gaap:LicenseMember    
Albert Einstein College Of Medicine | Einstein License And Service Agreement          
Commitments And Contingencies [Line Items]          
Milestone payments for each product, process or service     $ 1,850    
Milestone payments for each new indication of licensed product     1,850    
Aggregate amount of additional milestone payments     5,750    
Einstein License          
Commitments And Contingencies [Line Items]          
Number of supporting technologies | SupportingTechnology         2
Patent expenses $ 0 $ 0 $ 0 $ 0  
Type of Cost, Good or Service [Extensible List] us-gaap:CostsAndExpenses us-gaap:CostsAndExpenses us-gaap:LicenseMember us-gaap:LicenseMember  
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Additional Information (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
May 31, 2022
USD ($)
May 03, 2022
USD ($)
Mar. 28, 2022
USD ($)
ft²
Lessee Lease Description [Line Items]                  
Operating lease right-of-use $ 7,060,000     $ 7,060,000   $ 9,203,000      
Total $ 7,254,000     $ 7,254,000          
Operating lease, weighted average discount rate 5.75%     5.75%          
Operating lease liability, current portion $ 3,399,000     $ 3,399,000   3,300,000      
Rent expense 853,000 $ 860,000   2,566,000 $ 3,309,000        
Operating lease liability, net of current portion 3,855,000     3,855,000   6,017,000      
Non-cash interest expense to the lease liability 122,000 146,000   402,000 309,000        
Operating lease cost (in thousands) 853,000     2,566,000          
Gain on right-of-use asset termination 0 $ 0   0 $ (258,000)        
License Agreement                  
Lessee Lease Description [Line Items]                  
Operating lease right-of-use 9,056,000     9,056,000          
Total $ 9,056,000     $ 9,056,000          
Operating lease, weighted average discount rate 8.00%     8.00%          
Security deposit               $ 225,760  
License monthly rental rate               209,700  
License monthly rental rate first year                 $ 200,700
License monthly rental rate remainder of the term               200,700 225,760
License monthly rental rate second year                 208,728
License monthly rental rate third year                 $ 217,077
Increase in security deposit               $ 235,884  
Operating Lease Agreement                  
Lessee Lease Description [Line Items]                  
Total           6,018,000      
Operating lease liability, net of current portion $ 3,855,000     $ 3,855,000          
First Amendment | License Agreement                  
Lessee Lease Description [Line Items]                  
Operating lease right-of-use 369,000     369,000          
Operating lease liability, current portion 100,300     100,300          
Operating lease liability, net of current portion 260,600     260,600          
Additional Laboratory Lease Fourth Amendment                  
Lessee Lease Description [Line Items]                  
Loss on right-of-use asset     $ 258,000            
Adjustment related to right of use asset     8,124,000            
Adjustment related to lease liability     $ 8,382,000            
21 Erie Laboratory and Office Lease                  
Lessee Lease Description [Line Items]                  
Cash collected 0     199,000          
40G Office and Additional Laboratory                  
Lessee Lease Description [Line Items]                  
Security deposit 595,000     595,000   595,000      
Lab Space Lease Member                  
Lessee Lease Description [Line Items]                  
Operating lease right-of-use 945,000     945,000          
Operating lease cost (in thousands)       963,000          
Gain on right-of-use asset termination       19,000          
ASU 2016-02                  
Lessee Lease Description [Line Items]                  
Operating lease right-of-use 7,060,000     7,060,000   9,203,000      
Operating lease liability, current portion 3,399,000     3,399,000   $ 3,300,000      
Cambridge, Massachusetts                  
Lessee Lease Description [Line Items]                  
Office space for lease | ft²                 13,000
Boston, Massachusetts | Operating Lease Agreement For Additional Laboratory Space                  
Lessee Lease Description [Line Items]                  
Operating lease right-of-use $ 1,307,000     $ 1,307,000          
Lessee operating lease monthly rental payments for remaining term             $ 61,519    
Lessee operating lease monthly rental payments             $ 59,152    
Operating lease, weighted average discount rate 10.00%     10.00%          
Operating lease liability, current portion $ 712,000     $ 712,000          
Operating lease liability, net of current portion $ 535,000     $ 535,000          
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Schedule of Future Minimum Lease Payments on Operating Leases (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Leases [Abstract]  
2023 (3 months remaining) $ 835
2024 3,368
2025 2,799
2026 818
Total lease payment 7,820
Less: present value discount (566)
Total $ 7,254
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Schedule of Other Information of Operating Leases (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases (in thousands) $ (709) $ (2,064)
Operating lease cost (in thousands) $ 853 $ 2,566
Weighted average discount rate 5.75% 5.75%
Weighted average remaining lease term 2 years 4 months 20 days 2 years 4 months 20 days
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events (Additional Information) (Details) - shares
Sep. 30, 2023
Dec. 31, 2022
Subsequent Event [Line Items]    
Common stock, shares issued 45,123,281 43,042,548
XML 69 cue-20230930_htm.xml IDEA: XBRL DOCUMENT 0001645460 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001645460 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001645460 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001645460 cue:SiliconValleyBankMember cue:TermLoanAgreementMember 2023-09-30 0001645460 cue:OnoCollaborationAndOptionAgreementMember 2023-02-22 0001645460 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001645460 2023-01-01 2023-09-30 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2021-11-23 2021-11-23 0001645460 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001645460 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001645460 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001645460 cue:ComputerAndOfficeEquipmentMember 2023-09-30 0001645460 us-gaap:RetainedEarningsMember 2021-12-31 0001645460 cue:OnoCollaborationAndOptionAgreementMember 2023-01-01 2023-09-30 0001645460 cue:WarrantTrancheTwoMember 2023-09-30 0001645460 cue:WarrantTrancheOneMember 2022-06-15 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2023-01-01 2023-09-30 0001645460 cue:EinsteinMember cue:EinsteinLicenseAndServiceAgreementMember 2019-06-01 2019-06-30 0001645460 cue:TwentyOneErieLaboratoryAndOfficeLeaseMember 2023-07-01 2023-09-30 0001645460 cue:WarrantIssuedNovemberSixteenTwoThousandTwentyTwoMember 2022-12-31 0001645460 srt:MaximumMember cue:OnoCollaborationAndOptionAgreementMember 2023-09-30 0001645460 us-gaap:OtherIncomeMember us-gaap:EquipmentMember 2023-01-01 2023-09-30 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2018-11-06 0001645460 srt:MinimumMember 2022-01-01 2022-09-30 0001645460 us-gaap:CommonStockMember 2023-09-30 0001645460 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001645460 us-gaap:EquipmentMember 2023-01-01 2023-09-30 0001645460 cue:OperatingLeaseAgreementMember 2022-12-31 0001645460 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001645460 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001645460 us-gaap:RetainedEarningsMember 2023-06-30 0001645460 cue:AdditionalLaboratoryLeaseFourthAmendmentMember 2022-01-01 2022-03-31 0001645460 cue:OnoCollaborationAndOptionAgreementMember 2023-07-01 2023-09-30 0001645460 cue:Agreement2Member cue:TransactionExpenseMember 2021-10-01 2023-09-30 0001645460 cue:WarrantTrancheOneMember 2023-09-30 0001645460 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001645460 2021-12-31 0001645460 us-gaap:AccountingStandardsUpdate201602Member 2022-12-31 0001645460 us-gaap:CommonStockMember 2021-12-31 0001645460 us-gaap:ComputerEquipmentMember 2022-12-31 0001645460 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001645460 us-gaap:ComputerEquipmentMember 2023-09-30 0001645460 srt:MaximumMember cue:SiliconValleyBankMember cue:TermLoanAgreementMember 2023-09-30 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2022-07-01 2022-09-30 0001645460 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001645460 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001645460 cue:LicenseAgreementForPatentRightsMember 2022-07-01 2022-09-30 0001645460 cue:JefferiesLlcMember cue:TransactionExpenseMember 2023-09-30 0001645460 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001645460 us-gaap:AccountingStandardsUpdate201602Member 2023-09-30 0001645460 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001645460 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001645460 cue:TwentyOneErieLaboratoryAndOfficeLeaseMember 2023-01-01 2023-09-30 0001645460 cue:JefferiesLlcMember srt:MaximumMember 2023-01-01 2023-09-30 0001645460 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001645460 cue:SiliconValleyBankMember cue:TermLoanAgreementMember 2023-01-01 2023-09-30 0001645460 cue:LicenseAgreementForPatentRightsMember 2023-01-01 2023-09-30 0001645460 cue:LGChemLifeSciencesMember srt:MaximumMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2018-11-06 0001645460 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001645460 cue:LicenseAgreementForPatentRightsMember 2022-01-01 2022-09-30 0001645460 2023-07-01 2023-09-30 0001645460 us-gaap:CertificatesOfDepositMember 2023-09-30 0001645460 cue:PreFundedWarrantsMember 2022-11-16 0001645460 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001645460 stpr:MA 2022-03-28 0001645460 us-gaap:RetainedEarningsMember 2022-09-30 0001645460 2022-09-30 0001645460 srt:MaximumMember 2022-01-01 2022-09-30 0001645460 2022-01-01 2022-09-30 0001645460 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001645460 us-gaap:EquipmentMember 2022-12-31 0001645460 us-gaap:EquipmentMember 2023-09-30 0001645460 us-gaap:RestrictedStockUnitsRSUMember 2019-10-03 0001645460 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001645460 cue:WarrantTrancheTwoMember 2017-12-27 0001645460 us-gaap:TrademarksMember 2023-01-01 2023-09-30 0001645460 cue:EinsteinMember cue:EinsteinLicenseAndServiceAgreementMember 2018-01-01 2018-12-31 0001645460 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001645460 us-gaap:EquipmentMember 2022-09-30 0001645460 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001645460 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001645460 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001645460 us-gaap:TrademarksMember 2022-07-01 2022-09-30 0001645460 us-gaap:CommonStockMember 2022-06-30 0001645460 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001645460 srt:MaximumMember 2023-01-01 2023-09-30 0001645460 us-gaap:CommonStockMember 2022-09-30 0001645460 2021-11-23 2021-11-23 0001645460 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001645460 cue:FortyGOfficeAndAdditionalLaboratoryMember 2023-09-30 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001645460 cue:PreFundedWarrantsMember 2022-11-16 2022-11-16 0001645460 cue:WarrantTrancheThreeMember 2023-01-01 2023-09-30 0001645460 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001645460 us-gaap:TrademarksMember 2023-07-01 2023-09-30 0001645460 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001645460 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001645460 2022-01-01 2022-12-31 0001645460 us-gaap:CommonStockMember 2022-12-31 0001645460 cue:PreFundedWarrantsMember 2022-01-01 2022-12-31 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001645460 cue:SiliconValleyBankMember 2024-02-15 2024-02-15 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2019-05-16 2019-05-16 0001645460 cue:March2020AwardedAndGrantedMember us-gaap:RestrictedStockUnitsRSUMember 2020-03-01 2020-03-31 0001645460 cue:AlbertEinsteinCollegeOfMedicineMember cue:EinsteinLicenseAndServiceAgreementMember 2023-01-01 2023-09-30 0001645460 cue:OnoCollaborationAndOptionAgreementMember 2022-07-01 2022-09-30 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2020-12-07 2020-12-07 0001645460 cue:CommonStockOptionsMember 2023-01-01 2023-09-30 0001645460 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001645460 us-gaap:RetainedEarningsMember 2022-12-31 0001645460 cue:JefferiesLlcMember cue:TransactionExpenseMember 2023-07-01 2023-09-30 0001645460 2023-09-30 0001645460 us-gaap:LicenseAgreementTermsMember 2023-09-30 0001645460 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001645460 2023-06-30 0001645460 cue:OperatingLeaseAgreementMember 2023-09-30 0001645460 us-gaap:LeaseholdImprovementsMember 2023-09-30 0001645460 cue:EinsteinMember cue:EinsteinLicenseAndServiceAgreementMember 2023-01-01 2023-09-30 0001645460 2022-12-31 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2023-07-01 2023-09-30 0001645460 cue:Agreement2Member cue:TransactionExpenseMember 2023-01-01 2023-09-30 0001645460 2023-11-01 0001645460 cue:Agreement2Member cue:TransactionExpenseMember 2023-07-01 2023-09-30 0001645460 cue:FortyGOfficeAndAdditionalLaboratoryMember 2022-12-31 0001645460 cue:EinsteinMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2023-09-30 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001645460 us-gaap:CommonStockMember 2023-06-30 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001645460 cue:EinsteinMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2022-12-31 0001645460 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001645460 cue:February2020AwardedAndGrantedMember us-gaap:RestrictedStockUnitsRSUMember 2020-02-05 2020-02-05 0001645460 us-gaap:RetainedEarningsMember 2023-09-30 0001645460 cue:FirstAmendmentMember us-gaap:LicenseAgreementTermsMember 2023-09-30 0001645460 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001645460 cue:LGChemLifeSciencesMember cue:CollaborationAgreementWithLGChemLifeSciencesMember 2022-01-01 2022-09-30 0001645460 cue:LicenseAgreementForPatentRightsMember 2015-12-31 0001645460 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-09-30 0001645460 2020-12-07 2020-12-07 0001645460 cue:BostonMember cue:OperatingLeaseAgreementForAdditionalLaboratorySpaceMember 2022-05-31 0001645460 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001645460 cue:SiliconValleyBankMember 2025-02-15 2025-02-15 0001645460 srt:MinimumMember 2023-01-01 2023-09-30 0001645460 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001645460 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001645460 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001645460 cue:EinsteinMember cue:EinsteinLicenseAndServiceAgreementMember 2020-12-01 2020-12-31 0001645460 us-gaap:RestrictedStockUnitsRSUMember 2020-08-21 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001645460 cue:SiliconValleyBankMember 2022-02-15 2022-02-15 0001645460 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001645460 cue:SiliconValleyBankMember cue:TrancheALoanMember 2023-01-01 2023-09-30 0001645460 cue:WarrantIssuedNovemberSixteenTwoThousandTwentyTwoMember 2023-09-30 0001645460 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001645460 cue:BostonMember cue:OperatingLeaseAgreementForAdditionalLaboratorySpaceMember 2023-09-30 0001645460 us-gaap:EquipmentMember 2022-01-01 2022-09-30 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001645460 us-gaap:LicenseAgreementTermsMember 2022-03-28 0001645460 cue:WarrantIssuedNovemberSixteenTwoThousandTwentyTwoMember 2023-01-01 2023-09-30 0001645460 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001645460 us-gaap:OtherIncomeMember us-gaap:EquipmentMember 2022-01-01 2022-09-30 0001645460 cue:OnoCollaborationAndOptionAgreementMember 2023-09-30 0001645460 cue:LabSpaceLeaseMember 2023-01-01 2023-09-30 0001645460 cue:TransactionExpenseMember 2023-01-01 2023-09-30 0001645460 cue:WarrantTrancheOneMember 2015-06-15 0001645460 cue:LicenseAgreementForPatentRightsMember 2023-07-01 2023-09-30 0001645460 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-09-30 0001645460 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001645460 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001645460 cue:SiliconValleyBankMember cue:TermLoanAgreementMember 2022-02-15 0001645460 cue:PreFundedWarrantsMember 2023-01-01 2023-09-30 0001645460 us-gaap:CertificatesOfDepositMember 2022-12-31 0001645460 cue:LaboratoryEquipmentMember 2023-09-30 0001645460 2022-06-30 0001645460 2019-05-16 2019-05-16 0001645460 us-gaap:TrademarksMember 2022-01-01 2022-09-30 0001645460 cue:OnoCollaborationAndOptionAgreementMember 2022-01-01 2022-09-30 0001645460 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001645460 us-gaap:RetainedEarningsMember 2022-06-30 0001645460 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001645460 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001645460 srt:MinimumMember cue:SiliconValleyBankMember cue:TermLoanAgreementMember 2023-01-01 2023-09-30 0001645460 us-gaap:RestrictedStockUnitsRSUMember 2019-10-02 2019-10-03 0001645460 cue:WarrantTrancheTwoMember 2022-12-26 0001645460 cue:LabSpaceLeaseMember 2023-09-30 0001645460 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001645460 cue:CommonStockOptionsMember 2022-01-01 2022-09-30 0001645460 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001645460 2022-07-01 2022-09-30 0001645460 us-gaap:LicenseAgreementTermsMember 2022-05-03 cue:Tranche pure utr:sqft shares iso4217:USD shares iso4217:USD cue:SupportingTechnology false --12-31 0001645460 Q3 http://fasb.org/us-gaap/2023#LicenseMember http://fasb.org/us-gaap/2023#LicenseMember http://fasb.org/us-gaap/2023#CostsAndExpenses http://fasb.org/us-gaap/2023#CostsAndExpenses http://fasb.org/us-gaap/2023#LicenseMember http://fasb.org/us-gaap/2023#LicenseMember 10-Q true 2023-09-30 2023 false 001-38327 Cue Biopharma, Inc. DE 47-3324577 40 Guest Street Boston MA 02135 617 949-2680 Common Stock, par value $0.001 per share CUE NASDAQ Yes Yes Non-accelerated Filer true false false 45123281 54691000 51614000 0 24675000 1661000 57000 1165000 841000 57517000 77187000 1064000 1499000 7060000 9203000 2977000 3116000 150000 150000 120000 128000 68888000 91283000 2480000 2731000 5127000 3554000 2238000 0 3399000 3300000 3963000 1963000 17207000 11548000 3855000 6017000 5160000 8035000 26222000 25600000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 45123281 45123281 43042548 43042548 45000 43000 330376000 316192000 -0 -96000 -287755000 -250456000 42666000 65683000 68888000 91283000 2100000 68000 3669000 1094000 3645000 3528000 12071000 12465000 9874000 7571000 29915000 27246000 0 0 0 258000 13519000 11099000 41986000 39453000 -11419000 -11031000 -38317000 -38359000 700000 200000 1756000 296000 -286000 -124000 -738000 -355000 414000 76000 1018000 -59000 -11005000 -10955000 -37299000 -38418000 5000 -92000 96000 -92000 -11000000 -11047000 -37203000 -38510000 -0.24 -0.24 -0.31 -0.31 -0.82 -0.82 -1.11 -1.11 46358555 46358555 35383430 35383430 45274124 45274124 34471499 34471499 35381743 35000 284630000 -224909000 59756000 2064000 2064000 6667 2828 -9000 -9000 -92000 -92000 -10955000 -10955000 35385582 35000 286685000 -92000 -235864000 50764000 43744414 44000 322715000 -5000 -276750000 46004000 1378867 1000 5588000 5589000 2073000 2073000 5000 5000 -11005000 -11005000 45123281 45000 330376000 -0 -287755000 42666000 32202496 32000 262906000 -197446000 65492000 3117220 3000 16595000 16598000 7384000 7384000 9549 98335 42018 -200000 -200000 -92000 -92000 -38418000 -38418000 35385582 35000 286685000 -92000 -235864000 50764000 43042548 43000 316192000 -96000 -250456000 65683000 1915131 2000 7603000 7605000 6108000 6108000 165602 473000 473000 96000 96000 -37299000 -37299000 45123281 45000 330376000 -0 -287755000 42666000 -37299000 -38418000 443000 719000 6108000 7384000 2142000 507000 0 258000 2000 -4000 -234000 -101000 28000 21000 98000 76000 1603000 -2347000 324000 846000 139000 -395000 -251000 -546000 1573000 -741000 2238000 -645000 -2064000 -397000 0 3000 -29003000 -31292000 0 170000 2000 6000 -25000000 0 0 29445000 25002000 -29609000 7605000 16598000 0 10000000 -1000000 0 473000 0 0 142000 0 200000 7078000 26256000 3077000 -34645000 51764000 64521000 54841000 29876000 768000 354000 0 9057000 0 7119000 <div style="text-indent:0;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and Basis of Presentation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cue Biopharma, Inc. (the "Company") is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s corporate office and research facilities are located in Boston, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is in the development stage and has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2023, the Company had cash and cash equivalents of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Management believes that current cash and cash equivalents on hand at September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are sufficient to fund operations for at least the next twelve months from the date of issuance of these financial statements; however, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations and to fund research and development costs in order to seek approval for commercialization of its drug product candidates. The Company’s failure to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategies as this capital is necessary for the Company to perform the research and development activities required to develop and commercialize the Company’s drug product candidates in order to generate future revenue streams.</span></p> 54691000 <div style="text-indent:0;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited consolidated financial statements as of September 30, 2023, and for the three and nine months ended September 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for financial information, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp., which was incorporated in the Commonwealth of Massachusetts in December 2018. In the opinion of management, these financial statements reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim results for the three and nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future periods.</span></p></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offerings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Company entered into an open market sale agreement (the “October 2021 ATM Agreement”) with Jefferies LLC ("Jefferies"), as agent, to sell shares of the Company’s common stock for aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, from time to time, through an at-the-market equity offering program. The October 2021 ATM Agreement will terminate upon the earliest of (a) the sale of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of the Company’s common stock pursuant to the October 2021 ATM Agreement or (b) the termination of the October 2021 ATM Agreement by the Company or Jefferies. During the three months ended September 30, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,378,867</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,589,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> net of commission paid, but excluding transaction expenses. During the nine months ended September 30, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,915,131</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,605,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> net of commission paid, but excluding transaction expenses. As of September 30, 2023, the Company had sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,508,538</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, net of commission paid, but excluding transaction expenses, since its inception.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has eliminated all intercompany transactions.</span></p></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains its cash balances with financial institutions in federally insured accounts and may periodically have cash balances in excess of insurance limits. The Company maintains its accounts with financial institutions with a high credit rating. The Company has not experienced any losses to date from our deposits with these financial institutions and believes that it is not exposed to any significant credit risk on cash.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company currently invests available cash in money market funds.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities consist of investments with original maturities greater than ninety days and less than one year from the balance sheet date. The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are recognized and determined on a specific identification basis and are included in other comprehensive loss. Realized gains and losses are determined on a specific identification basis and are included in other income on the consolidated statement of operations and other comprehensive loss. Amortization and accretion of discounts and premiums is recorded in interest income. The Company has invested available cash in U.S. Treasury obligations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in restricted cash deposited with separate commercial banks to collateralize a credit card as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is recorded at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from dispositions of property and equipment are included in income and expense when realized. Amortization of leasehold improvements is provided using the straight-line method over the shorter of the lease term or the useful life of the underlying assets. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation of property and equipment is provided using the straight-line method over the following estimated useful lives: </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.24%;"></td> <td style="width:1.94%;"></td> <td style="width:17.82%;"></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Computer and office equipment</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8 years</span></span></p></td> </tr> </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes depreciation and amortization expense in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on how each category of property and equipment is utilized in the Company’s business activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trademark</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trademark consists of the Company’s right, title and interest to the CUE BIOLOGICS Mark, and any derivative mark incorporating CUE, throughout the world, together with all associated goodwill and common law rights appurtenant thereto, including, but not limited to, any right, title and interest in any corporate name, company name, business, name, trade name, dba, domain name, or other source identifier incorporating CUE.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has classified the trademark as a component of other long-term assets, having a useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The Company evaluates the status of this intangible asset for amortization and impairment at each quarter end and year end reporting date. For each of the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022, the Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in amortization expense on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and other comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company’s license and collaboration agreements that are within the scope of Accounting Standards Codification (“ASC”), Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the expected value method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of compensation costs, fees paid to consultants, outside service providers and organizations (including research institutes at universities), facility costs, and development and clinical trial costs with respect to the Company’s drug product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses incurred under contracts are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different pattern of performance is more appropriate. Other research and development expenses are charged to operations as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nonrefundable advance payments are recognized as an expense as the related services are performed. The Company evaluates whether it expects the services to be rendered at each quarter end and year end reporting date. If the Company does not expect the services to be rendered, the advance payment is charged to expense. Nonrefundable advance payments for research and development services are included in prepaid and other current assets on the balance sheet. To the extent that a nonrefundable advance payment is for contracted services to be performed within 12 months from the reporting date, such advance is included in current assets; otherwise, such advance is included in non-current assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the status of its research and development agreements and contracts, and the carrying amount of the related assets and liabilities, at each quarter end and year end reporting date, and adjusts the carrying amounts and their classification on the balance sheet as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is the exclusive worldwide licensee of, and has patent applications pending for, numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development of one or more commercially viable drug product candidates based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal fees, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7b094dd4-b9e7-47d1-af18-eecb9b2c0d72;"><span style="-sec-ix-hidden:F_43d1faa3-f58a-44c5-99bb-17a75e6867cc;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">filing</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fees and other costs are charged to general and administrative expense as incurred. For the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023, patent expenses were approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">503,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,649,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. For the three and nine months ended September 30, 2022, patent expenses were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">395,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,625,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licensing Fees and Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Licensing fees and costs consist primarily of costs relating to the acquisition of the Company’s license agreement (the “Einstein License Agreement”) with the Albert Einstein College of Medicine (“Einstein”), including related royalties, maintenance fees, milestone payments and product development costs. Licensing fees and costs are charged to research and development expense as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. </span></span><span style=""></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for leases under ASC 842,</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases are required.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company periodically issues stock-based awards to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based payments to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values. Stock option grants, which are generally time-vested, are measured at the grant date fair value and charged to operations on a straight-line basis over the service period, which generally approximates the vesting term. The Company also grants performance-based awards periodically to officers of the Company. The Company recognizes compensation costs related to performance awards over the requisite service period if and when the Company concludes that it is probable that the performance condition will be achieved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options and restricted stock units is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading history for its common stock that approximates the expected term of the options, estimated volatility is based on the average historical volatility of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends and has no plans to do so for the foreseeable future. As permitted by Staff Accounting Bulletin No. 107, due to the Company’s limited trading history and option activity, management</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">utilizes the simplified method to estimate the expected term of options at the date of grant. The exercise price is determined based on the fair value of our common stock at the date of grant. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the fair value of stock-based compensation in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on the type of services provided by the recipient of the equity award.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive income (loss) includes net income (loss) as well as changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. The Company’s only element of other comprehensive income (loss) in periods presented was unrealized gain or loss on available-for-sale securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings (Loss) Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s computation of earnings (loss) per share (“EPS”) for the respective periods includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares that would result from the exercise of outstanding stock options and warrants as if they had been exercised at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Basic and diluted loss per common share is the same for all periods presented because all outstanding stock options and warrants are anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,531,440</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants in the denominator of basic EPS at September 30, 2023.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.5%;"></td> <td style="width:5.04%;"></td> <td style="width:1%;"></td> <td style="width:21.5%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:21.96%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock warrants</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">789,358</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock options</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,500,480</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,268,729</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18,220,326</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,058,087</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active exchange-traded securities and exchange-based derivatives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash equivalents as of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in cash equivalents and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in short-term marketable securities that were measured and recorded at fair value on the Company’s balance sheet at December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value of financial instruments (consisting of cash, a certificate of deposit, accounts payable, accrued compensation and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update ("ASU") No. 2016-13</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 326) (CECL). </span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The new standard is effective for annual reporting periods beginning after December 15, 2022, including interim reporting periods within each annual reporting period for smaller reporting companies. T</span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he Company adopted ASU No. 2016-13 but there was no financial impact to the Company’s consolidated financial statements for the year ended December 31, 2022 or for the nine months ended September 30, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.</span></p></div> <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited consolidated financial statements as of September 30, 2023, and for the three and nine months ended September 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for financial information, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp., which was incorporated in the Commonwealth of Massachusetts in December 2018. In the opinion of management, these financial statements reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim results for the three and nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future periods.</span></p> <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offerings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Company entered into an open market sale agreement (the “October 2021 ATM Agreement”) with Jefferies LLC ("Jefferies"), as agent, to sell shares of the Company’s common stock for aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, from time to time, through an at-the-market equity offering program. The October 2021 ATM Agreement will terminate upon the earliest of (a) the sale of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of the Company’s common stock pursuant to the October 2021 ATM Agreement or (b) the termination of the October 2021 ATM Agreement by the Company or Jefferies. During the three months ended September 30, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,378,867</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,589,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> net of commission paid, but excluding transaction expenses. During the nine months ended September 30, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,915,131</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,605,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> net of commission paid, but excluding transaction expenses. As of September 30, 2023, the Company had sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,508,538</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the October 2021 ATM Agreement for proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, net of commission paid, but excluding transaction expenses, since its inception.</span></p> 80000000 80000000 1378867 5589000000 1915131 7605000000 5508538 31200000 <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the Company and its wholly owned subsidiary, Cue Biopharma Securities Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has eliminated all intercompany transactions.</span></p> <p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains its cash balances with financial institutions in federally insured accounts and may periodically have cash balances in excess of insurance limits. The Company maintains its accounts with financial institutions with a high credit rating. The Company has not experienced any losses to date from our deposits with these financial institutions and believes that it is not exposed to any significant credit risk on cash.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company currently invests available cash in money market funds.</span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities consist of investments with original maturities greater than ninety days and less than one year from the balance sheet date. The Company classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are recognized and determined on a specific identification basis and are included in other comprehensive loss. Realized gains and losses are determined on a specific identification basis and are included in other income on the consolidated statement of operations and other comprehensive loss. Amortization and accretion of discounts and premiums is recorded in interest income. The Company has invested available cash in U.S. Treasury obligations.</span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in restricted cash deposited with separate commercial banks to collateralize a credit card as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 150000 150000 <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is recorded at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from dispositions of property and equipment are included in income and expense when realized. Amortization of leasehold improvements is provided using the straight-line method over the shorter of the lease term or the useful life of the underlying assets. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation of property and equipment is provided using the straight-line method over the following estimated useful lives: </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.24%;"></td> <td style="width:1.94%;"></td> <td style="width:17.82%;"></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Computer and office equipment</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8 years</span></span></p></td> </tr> </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes depreciation and amortization expense in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on how each category of property and equipment is utilized in the Company’s business activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation of property and equipment is provided using the straight-line method over the following estimated useful lives: </span><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.24%;"></td> <td style="width:1.94%;"></td> <td style="width:17.82%;"></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Computer and office equipment</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8 years</span></span></p></td> </tr> </table> P5Y P3Y P3Y P8Y <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trademark</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trademark consists of the Company’s right, title and interest to the CUE BIOLOGICS Mark, and any derivative mark incorporating CUE, throughout the world, together with all associated goodwill and common law rights appurtenant thereto, including, but not limited to, any right, title and interest in any corporate name, company name, business, name, trade name, dba, domain name, or other source identifier incorporating CUE.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has classified the trademark as a component of other long-term assets, having a useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The Company evaluates the status of this intangible asset for amortization and impairment at each quarter end and year end reporting date. For each of the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022, the Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in amortization expense on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and other comprehensive loss.</span></p> P15Y 3000 3000 9000 9000 <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company’s license and collaboration agreements that are within the scope of Accounting Standards Codification (“ASC”), Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the expected value method.</span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of compensation costs, fees paid to consultants, outside service providers and organizations (including research institutes at universities), facility costs, and development and clinical trial costs with respect to the Company’s drug product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses incurred under contracts are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different pattern of performance is more appropriate. Other research and development expenses are charged to operations as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nonrefundable advance payments are recognized as an expense as the related services are performed. The Company evaluates whether it expects the services to be rendered at each quarter end and year end reporting date. If the Company does not expect the services to be rendered, the advance payment is charged to expense. Nonrefundable advance payments for research and development services are included in prepaid and other current assets on the balance sheet. To the extent that a nonrefundable advance payment is for contracted services to be performed within 12 months from the reporting date, such advance is included in current assets; otherwise, such advance is included in non-current assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the status of its research and development agreements and contracts, and the carrying amount of the related assets and liabilities, at each quarter end and year end reporting date, and adjusts the carrying amounts and their classification on the balance sheet as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is the exclusive worldwide licensee of, and has patent applications pending for, numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development of one or more commercially viable drug product candidates based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal fees, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7b094dd4-b9e7-47d1-af18-eecb9b2c0d72;"><span style="-sec-ix-hidden:F_43d1faa3-f58a-44c5-99bb-17a75e6867cc;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">filing</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fees and other costs are charged to general and administrative expense as incurred. For the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023, patent expenses were approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">503,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,649,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. For the three and nine months ended September 30, 2022, patent expenses were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">395,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,625,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p> 503000 1649000 395000 1625000 <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licensing Fees and Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Licensing fees and costs consist primarily of costs relating to the acquisition of the Company’s license agreement (the “Einstein License Agreement”) with the Albert Einstein College of Medicine (“Einstein”), including related royalties, maintenance fees, milestone payments and product development costs. Licensing fees and costs are charged to research and development expense as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. </span> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for leases under ASC 842,</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases are required.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company periodically issues stock-based awards to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based payments to officers, directors, employees, Scientific and Clinical Advisory Board members and consultants, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values. Stock option grants, which are generally time-vested, are measured at the grant date fair value and charged to operations on a straight-line basis over the service period, which generally approximates the vesting term. The Company also grants performance-based awards periodically to officers of the Company. The Company recognizes compensation costs related to performance awards over the requisite service period if and when the Company concludes that it is probable that the performance condition will be achieved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options and restricted stock units is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading history for its common stock that approximates the expected term of the options, estimated volatility is based on the average historical volatility of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends and has no plans to do so for the foreseeable future. As permitted by Staff Accounting Bulletin No. 107, due to the Company’s limited trading history and option activity, management</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">utilizes the simplified method to estimate the expected term of options at the date of grant. The exercise price is determined based on the fair value of our common stock at the date of grant. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the fair value of stock-based compensation in general and administrative expenses and in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss, depending on the type of services provided by the recipient of the equity award.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive income (loss) includes net income (loss) as well as changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. The Company’s only element of other comprehensive income (loss) in periods presented was unrealized gain or loss on available-for-sale securities.</span></p> <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings (Loss) Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s computation of earnings (loss) per share (“EPS”) for the respective periods includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares that would result from the exercise of outstanding stock options and warrants as if they had been exercised at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Basic and diluted loss per common share is the same for all periods presented because all outstanding stock options and warrants are anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,531,440</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants in the denominator of basic EPS at September 30, 2023.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.5%;"></td> <td style="width:5.04%;"></td> <td style="width:1%;"></td> <td style="width:21.5%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:21.96%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock warrants</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">789,358</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock options</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,500,480</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,268,729</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18,220,326</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,058,087</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div> 1531440 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.5%;"></td> <td style="width:5.04%;"></td> <td style="width:1%;"></td> <td style="width:21.5%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:21.96%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock warrants</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">789,358</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock options</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,500,480</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,268,729</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18,220,326</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,058,087</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 10719846 789358 7500480 6268729 18220326 7058087 <p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active exchange-traded securities and exchange-based derivatives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash equivalents as of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in cash equivalents and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in short-term marketable securities that were measured and recorded at fair value on the Company’s balance sheet at December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value of financial instruments (consisting of cash, a certificate of deposit, accounts payable, accrued compensation and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.</span></p> 54691000 45423000 24675000 <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update ("ASU") No. 2016-13</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 326) (CECL). </span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The new standard is effective for annual reporting periods beginning after December 15, 2022, including interim reporting periods within each annual reporting period for smaller reporting companies. T</span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he Company adopted ASU No. 2016-13 but there was no financial impact to the Company’s consolidated financial statements for the year ended December 31, 2022 or for the nine months ended September 30, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.</span></p> <div style="text-indent:0;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022, and indicate the level of the fair value hierarchy utilized to determine such fair value:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:25.246%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of December 31, 2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70,098</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, the Company reported approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash equivalents. The Company measures the cash equivalents that are invested in money market funds using Level 1 inputs for identical securities. The Company measures the fair value of marketable securities that are invested in U.S. Treasury securities using Level 2 inputs and primarily relies on quoted prices in active markets for similar marketable securities. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, the Company reported approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash equivalents and marketable securities, respectively. During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the year ended December 31, 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between Level 2 and Level 3.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022, and indicate the level of the fair value hierarchy utilized to determine such fair value:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:25.246%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> <td style="width:1.965%;"></td> <td style="width:1%;"></td> <td style="width:14.724%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54,691</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements as of December 31, 2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,423</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70,098</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 54691000 0 0 54691000 0 0 0 0 54691000 0 0 54691000 45423000 0 0 45423000 0 24675000 0 24675000 45423000 24675000 0 70098000 54691000 45423000 24675000 0 0 <div style="text-indent:0;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had no marketable securities. The Company had marketable securities that consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at December 31, 2022. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the Company's marketable securities at December 31, 2022:</span></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:25.727%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Gross Unrealized<br/>Gains</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Gross Unrealized<br/>Losses</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Treasury Securities</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,771</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,771</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2022, the Company's marketable securities consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,771,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of investments that mature within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company recorded an unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div> 24675000 <span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the Company's marketable securities at December 31, 2022:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:25.727%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> <td style="width:1.544%;"></td> <td style="width:1%;"></td> <td style="width:15.025%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Amortized Cost</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Gross Unrealized<br/>Gains</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Gross Unrealized<br/>Losses</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Treasury Securities</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,771</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,771</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,675</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2022, the Company's marketable securities consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24,771,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of investments that mature within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company recorded an unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 24771000 0 96000 24675000 24771000 0 96000 24675000 24771000 P12M 96000 <div style="text-indent:0;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 consisted of the following:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.573%;"></td> <td style="width:1.737%;"></td> <td style="width:1%;"></td> <td style="width:12.975%;"></td> <td style="width:1%;"></td> <td style="width:1.737%;"></td> <td style="width:1%;"></td> <td style="width:12.975%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30,<br/>2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,205</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,246</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Computer and office equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">296</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">296</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,699</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,741</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less accumulated depreciation</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,635</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,242</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net property and equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,064</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,499</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the three months ended September 30, 2023 and 2022 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">198,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Depreciation expense for the nine months ended September 30, 2023 and 2022 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">434,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">630,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Depreciation expense for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023 excludes trademark amortization expense of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Depreciation expense for the nine months ended September 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> excludes trademark amortization expense of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and amortization of capitalized license expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company sold fully depreciated lab equipment with an acquisition cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41,450</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and collected cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company recorded a gain on the sale of fixed assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is presented in other income on the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consolidated statements of operations and other comprehensive loss. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2022, the Company sold furniture and fixtures with an acquisition cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and collected cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,800</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company recorded a loss on the sale of fixed assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,300</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is presented in other income on the consolidated statements of operations and other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 consisted of the following:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.573%;"></td> <td style="width:1.737%;"></td> <td style="width:1%;"></td> <td style="width:12.975%;"></td> <td style="width:1%;"></td> <td style="width:1.737%;"></td> <td style="width:1%;"></td> <td style="width:12.975%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30,<br/>2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,205</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,246</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Computer and office equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">296</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">296</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,699</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,741</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less accumulated depreciation</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,635</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,242</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net property and equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,064</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,499</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 5205000 5246000 81000 81000 296000 296000 118000 118000 5699000 5741000 4635000 4242000 1064000 1499000 128000 198000 434000 630000 9000 9000 80000 41450000 2000 2000 30000 5800 4300 <div style="text-indent:0;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan with Silicon Valley Bank</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2022 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”), with Silicon Valley Bank, as lender (“SVB”). The Company drew $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in term loans under the Loan Agreement (the "Term Loans") on the Closing Date.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Loan Agreement was amended in April 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loans bear interest at a floating rate per annum equal to the greater of (A) the prime rate (as published in the money rates section of The Wall Street Journal) plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The Term Loans were interest only from the Closing Date through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, after which the Company is required to pay </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal monthly installments of principal. At </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the interest rate was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.75</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> based on the prime rate plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loans may be prepaid in full prior to February 15, 2024 with payment of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.00</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% prepayment premium, on or after which they may be prepaid in full with payment of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% prepayment premium. Upon prepayment or repayment in full of the Term Loans, the Company will be required to pay a one-time final payment fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the original principal amount of any funded Term Loans being repaid. This one-time final payment fee is recorded to interest expense using the effective interest method over the period of the Term Loans in the consolidated statements of operation and other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loans and related obligations under the Loan Agreement are secured by substantially all of the Company’s properties, rights and assets, except for its intellectual property which is subject to a negative pledge under the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary representations, warranties, events of default and covenants, including a requirement that the Company maintain in accounts of the Company at SVB unrestricted and unencumbered cash equal to the lesser of all of the Company’s cash or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20,000,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On March 10, 2023, SVB was closed by state regulators and the Federal Deposit Insurance Company ("FDIC") was appointed receiver for the bank. The FDIC created a successor bridge bank, Silicon Valley Bridge Bank, N.A. (“SVBB”) and all deposits of SVB were transferred to SVBB under a systemic risk exception approved by the U.S. Department of the Treasury, the Federal Reserve and the FDIC. SVBB continues to hold the Company’s Term Loans under the same existing terms and covenants which were in place with SVB.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2023, the Company recognized interest expense related to the Term Loans of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">254,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">848,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in interest expense related to accretion of the final payment. During the three and nine months ended September 30, 2022, the Company recognized interest expense related to the Term Loans of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">183,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">354,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in interest expense related to accretion of the final payment for the three months and nine months ended September 30, 2022, respectively.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the aggregate maturities of long-term and current portion of debt as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.284%;"></td> <td style="width:12.287%;"></td> <td style="width:1%;"></td> <td style="width:15.591000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:28.839%;"></td> <td style="width:1%;"></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Year</span></p></td> <td colspan="3" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Aggregate Minimum Payments</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,000</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,000</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total maturities</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total long-term debt</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td colspan="4" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accretion of final payment</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">207</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less: unamortized debt issuance costs</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td colspan="4" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term debt, net</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,160</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total current portion of long-term debt</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less: unamortized debt issuance costs</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td colspan="4" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current portion of long-term debt, net</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,963</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are deferred and presented as a reduction to long-term debt. Debt issuance costs are amortized using the effective interest rate method over the term of the loan. Amortization of deferred debt issuance costs are included in interest expense in the consolidated statements of operations and comprehensive loss. The Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">141,748</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in debt issuance costs related to the Loan Agreement. For the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023, the Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in amortization of debt issuance costs to interest expense in the consolidated statements of operations and comprehensive loss. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three and nine months ended September 30, 2022, the Company recorded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in amortization of debt issuance costs to interest expense in the consolidated statements of operations and comprehensive loss.</span></p> 10000000 0.0225 0.055 2023-06-30 P30M 10.75 0.0225 0.02 0.01 0.05 20000000 254000 848000 33000 98000 183000 354000 33000 76000 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the aggregate maturities of long-term and current portion of debt as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.284%;"></td> <td style="width:12.287%;"></td> <td style="width:1%;"></td> <td style="width:15.591000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:28.839%;"></td> <td style="width:1%;"></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Year</span></p></td> <td colspan="3" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Aggregate Minimum Payments</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,000</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,000</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total maturities</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total long-term debt</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td colspan="4" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accretion of final payment</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">207</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less: unamortized debt issuance costs</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td colspan="4" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term debt, net</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,160</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total current portion of long-term debt</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,000</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less: unamortized debt issuance costs</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td colspan="4" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current portion of long-term debt, net</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,963</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 1000000 4000000 4000000 9000000 5000000 207000 -46000 5160000 4000000 37000 3963000 141748 9000 28000 9000 21000 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Valuation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For stock options requiring an assessment of value during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023 and 2022, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.715%;"></td> <td style="width:1.9%;"></td> <td style="width:23.385%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.16</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97.03</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected life</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.25</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2022</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.53</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.92</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95.7</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected life</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.25</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023 is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.716%;"></td> <td style="width:1.304%;"></td> <td style="width:1%;"></td> <td style="width:10.763%;"></td> <td style="width:1%;"></td> <td style="width:1.365%;"></td> <td style="width:1%;"></td> <td style="width:10.763%;"></td> <td style="width:1%;"></td> <td style="width:1.325%;"></td> <td style="width:1%;"></td> <td style="width:10.763%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Number of<br/>Shares</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual <br/>Life <br/>(in Years)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options outstanding at December 31, 2022</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,173,867</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.60</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.05</span></span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,576,900</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.65</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">165,602</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.86</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cancelled</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,084,685</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.78</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options outstanding at September 30, 2023</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,500,480</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.40</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.35</span></span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options exercisable at September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,365,960</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.38</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.54</span></span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,073,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,108,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in stock-based compensation expense during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023, respectively, related to stock options activity. As of September 30, 2023, total unrecognized stock-based compensation expense was approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12,141,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is expected to be recognized as an operating expense in the Company’s consolidated statement of operations and other comprehensive loss over the weighted average remaining period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.16</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. During the three months ended September 30, 2023, the Company granted stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,115,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of common stock with a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.17</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. During the nine months ended September 30, 2023, the Company granted stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,576,900</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of common stock with a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.65</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,045,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,537,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in stock-based compensation expense during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2022, respectively, related to stock options activity. As of September 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation expense was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13,856,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is expected to be recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss over the weighted average remaining period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.13</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. During the three months ended September 30, 2022, the Company granted stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12,500</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a weighted average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.45</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. During the nine months ended September 30, 2022, the Company granted stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">828,500</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a weighted average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.99</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The intrinsic value of exercisable but unexercised in-the-money stock options at September 30, 2023 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, based on a weighted average grant date fair value of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.38</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on September 30, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 3, 2019, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> restricted stock units (“RSUs”) with time-based vesting conditions to an executive officer having an average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.53</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The RSUs vested in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter. Compensation expense is recognized on a straight-line basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2020, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSUs with time-based vesting conditions to an executive officer. One-half of the RSUs vested on September 30, 2021, and the balance vested on March 31, 2022. On March 31, 2020, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSUs with time-based vesting conditions to an executive officer. The RSUs vested in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter. Compensation expense is recognized on a straight-line basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 21, 2020, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSUs with time-based vesting conditions to an executive officer. The RSUs vest in three equal installments beginning on the grant date, and annually on each anniversary of the grant date thereafter, subject to the recipient’s continued service on each applicable vesting date. Compensation expense is recognized on a straight-line basis.</span></p><p style="text-indent:7.987%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in stock-based compensation during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 related to RSU activity. As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation was fully recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss. The Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">847,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in stock-based compensation during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2022, respectively, related to RSU activity. As of September 30, 2022, total unrecognized stock-based compensation was fully recognized as an operating expense in the Company’s consolidated statements of operations and other comprehensive loss.<br/><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022 was included in the Company’s consolidated statements of operations and other comprehensive loss as follows:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.847%;"></td> <td style="width:2.872%;"></td> <td style="width:1%;"></td> <td style="width:9.568%;"></td> <td style="width:1%;"></td> <td style="width:2.179%;"></td> <td style="width:1%;"></td> <td style="width:9.568%;"></td> <td style="width:1%;"></td> <td style="width:1.69%;"></td> <td style="width:1%;"></td> <td style="width:9.568%;"></td> <td style="width:1%;"></td> <td style="width:2.179%;"></td> <td style="width:1%;"></td> <td style="width:9.527000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">858</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,003</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,708</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,650</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,215</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,061</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,399</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,734</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,073</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,064</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,108</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,384</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For stock options requiring an assessment of value during the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023 and 2022, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.715%;"></td> <td style="width:1.9%;"></td> <td style="width:23.385%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.16</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97.03</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected life</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.25</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> <tr> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2022</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.53</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.92</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected dividend yield</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95.7</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected life</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.25</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> </tr> </table> 0.034 0.0416 0 0.9703 1.104 P5Y6M P6Y3M 0.0153 0.0292 0 0.921 0.957 P5Y6M P6Y3M <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023 is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.716%;"></td> <td style="width:1.304%;"></td> <td style="width:1%;"></td> <td style="width:10.763%;"></td> <td style="width:1%;"></td> <td style="width:1.365%;"></td> <td style="width:1%;"></td> <td style="width:10.763%;"></td> <td style="width:1%;"></td> <td style="width:1.325%;"></td> <td style="width:1%;"></td> <td style="width:10.763%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Number of<br/>Shares</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual <br/>Life <br/>(in Years)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options outstanding at December 31, 2022</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,173,867</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.60</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.05</span></span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,576,900</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.65</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">165,602</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.86</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cancelled</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,084,685</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.78</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options outstanding at September 30, 2023</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,500,480</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.40</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.35</span></span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options exercisable at September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,365,960</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.38</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.54</span></span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 6173867 9.6 P5Y18D 2576900 3.65 165602 2.86 1084685 4.78 7500480 8.4 P6Y4M6D 4365960 10.38 P4Y6M14D 2073000 6108000 12141000 P2Y1M28D 1115000 4.17 2576900 3.65 2045000 6537000 13856000 P2Y1M17D 12500 2.45 828500 6.99 0 10.38 100000 7.53 150000 50000 20000 0 0 19000 847000 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022 was included in the Company’s consolidated statements of operations and other comprehensive loss as follows:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.847%;"></td> <td style="width:2.872%;"></td> <td style="width:1%;"></td> <td style="width:9.568%;"></td> <td style="width:1%;"></td> <td style="width:2.179%;"></td> <td style="width:1%;"></td> <td style="width:9.568%;"></td> <td style="width:1%;"></td> <td style="width:1.69%;"></td> <td style="width:1%;"></td> <td style="width:9.568%;"></td> <td style="width:1%;"></td> <td style="width:2.179%;"></td> <td style="width:1%;"></td> <td style="width:9.527000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">858</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,003</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,708</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,650</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,215</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,061</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,399</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,734</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,073</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,064</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,108</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,384</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 858000 1003000 2708000 3650000 1215000 1061000 3399000 3734000 2073000 2064000 6108000 7384000 <p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tranche of common stock warrants outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company issued warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,500</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 15, 2015</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.70</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which warrants expired at the end of their </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7-year</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term on</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> June 15, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company issued another tranche of warrants exercisable for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">882,071</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.38</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share when issued on December 27, 2017, which warrants expired at the end of their </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year term on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 26, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On November 16, 2022, the Company issued in a private placement </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,188,406</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.93</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,531,440</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each tranche of warrants was evaluated under ASC 480, Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the Company determined that equity classification was appropriate. The Company determined equity classification for both warrants and pre-funded warrants as they do not embody an obligation for the Company to repurchase its shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Per ASC 815-40-25, the Company accounts for the warrants and pre-funded warrants as equity, as the Company does not provide the holder a fixed or guaranteed return.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded cash received from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,531,440</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants to additional paid in capital in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,999,999</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company recorded placement fees and expenses related to the sale of pre-funded warrants in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">299,999</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a charge to additional paid in capital in the consolidated balance sheet at December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Per ASC 260-10-45-13, shares issuable for little to no consideration should be included in the number of outstanding shares used for basic EPS. The FASB proposed that warrants or options exercisable for little to no cost (sometimes referred to as “penny warrants”) be included in the denominator of basic EPS (and therefore diluted EPS) once there were no further vesting conditions or contingencies associated with them. The Company included </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,531,440</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants in the denominator of basic EPS at September 30, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows common stock warrants outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.04%;"></td> <td style="width:2.52%;"></td> <td style="width:1%;"></td> <td style="width:15.78%;"></td> <td style="width:1%;"></td> <td style="width:2.52%;"></td> <td style="width:1%;"></td> <td style="width:12.14%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:7pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Warrant Issued<br/>November 16, 2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued via cashless exercises</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withheld as payment to cover issued shares</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expired</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div> 1 1500 2015-06-15 2.7 P7Y 2022-06-15 882071 9.38 P5Y 2022-12-26 9188406 3.93 1531440 1531440 4999999 299999 1531440 <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows common stock warrants outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.04%;"></td> <td style="width:2.52%;"></td> <td style="width:1%;"></td> <td style="width:15.78%;"></td> <td style="width:1%;"></td> <td style="width:2.52%;"></td> <td style="width:1%;"></td> <td style="width:12.14%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:7pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Warrant Issued<br/>November 16, 2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued via cashless exercises</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withheld as payment to cover issued shares</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expired</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,719,846</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 10719846 10719846 0 0 0 0 0 0 0 0 10719846 10719846 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Collaboration Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property and research and development services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and if, over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company’s contracts may include options to acquire additional goods and/or services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front payment, and pass through costs related to research activities, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of pass through costs and milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the “most likely amount” method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any development, regulatory or commercial milestones or royalty revenue resulting from any of its collaboration arrangements. Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis, when applicable. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. The Company measures progress toward satisfaction of the performance obligation over time as effort is expended.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with LG Chem</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 6, 2018, the Company entered into a collaboration agreement (the “LG Chem Collaboration Agreement”) with LG Chem Ltd. (“LG Chem”) related to the development of the Company’s Immuno-STATs focused in the field of oncology. Pursuant to the LG Chem Collaboration Agreement, the Company granted LG Chem an exclusive license to develop, manufacture and commercialize the Company’s lead product, CUE-101, as well as Immuno-STATs that target T cells against two additional cancer antigens, in certain Asian countries (collectively, the “LG Chem Territory”). On April 30, 2021, LG Chem’s option pursuant to the Global License and Collaboration Agreement entered into between the Company and LG Chem on December 18, 2019 and as amended on November 5, 2020 (the "Global License and Collaboration Agreement"), expired, and accordingly the Company no longer has any material obligations under the Global License and Collaboration Agreement. In June 2021, after ongoing discussions regarding the selection of the second of the two additional cancer antigens, LG Chem and the Company agreed to let the selection period expire without a second antigen being selected. The Company retains rights to develop and commercialize all assets included in the LG Chem Collaboration Agreement in the United States and in global markets outside of the LG Chem Territory. In exchange for the licenses and other rights granted to LG Chem under the LG Chem Collaboration Agreement, LG Chem made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million equity investment in common stock of the Company and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million nonrefundable up-front cash payment. The Company is also eligible to receive up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research, development, regulatory and sales milestones. In addition, the LG Chem Collaboration Agreement also provides that LG Chem will pay the Company tiered single-digit percentage royalties on net sales of commercialized drug product candidates in the LG Chem Territory.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 16, 2019, LG Chem paid the Company a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment for the U.S. Food and Drug Administration’s (“FDA”) acceptance of the investigational new drug application (“IND”) for the Company’s lead drug product candidate, CUE-101, pursuant to the LG Chem Collaboration Agreement. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment was recorded as a contract liability upon receipt of payment as it requires deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">412,500</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was recognized as tax withholding, shown as income tax expense on the consolidated statement of operations and other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 7, 2020, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.25</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment on the selection of a pre-clinical candidate pursuant to the LG Chem Collaboration Agreement. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.25</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment was recorded as a contract liability upon receipt. Revenue related to this milestone payment was recognized by the Company pursuant to the Company’s revenue recognition policy in relation to the performance of its obligations related to the development of this pre-clinical candidate. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.25</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">206,250</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was withheld as payment of foreign tax withholding and shown as income tax expense on the consolidated statement of operations and other comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 23, 2021, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment for the selection of a clinical product candidate in partnership with LG Chem. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment was recorded as a contract liability upon receipt. Revenue related to this milestone payment was recognized by the Company pursuant to the Company’s revenue recognition policy in relation to the performance of its obligations related to the development of this preclinical candidate. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone payment,</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">495,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was withheld as payment of foreign tax withholding and shown as income tax expense on the consolidated statements of operations and comprehensive loss. Cash was collected in relation to this milestone payment in February 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aside from the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.75</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in milestone payments earned to date, the Company does not believe that any variable consideration should be included in the transaction price as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur. For the three months ended September 30, 2023 and 2022, the Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognized revenue of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">178,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the LG Chem Collaboration Agreement. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">243,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,094,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the LG Chem Collaboration Agreement. The Company did not record short- or long-term research and development liabilities on its balance sheet dated </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022 as the performance obligation was met and completed. Research and development cost sharing provisions under the agreement expired on March 31, 2022.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration and Option Agreement with Ono</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 22, 2023, the Company entered into a strategic collaboration agreement (the "Ono Collaboration and Option Agreement") with Ono Pharmaceutical Co., Ltd. ("Ono") to further develop CUE-401 a</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nd provide dedicated resources and capabilities to help advance CUE-401 toward the clinic. Under the terms of the Ono Collaboration and Option Agreement, Ono paid the Company an upfront payment and agreed to fully fund all research activities related to CUE-401 through a specified option period. During this option period, the Company will be responsible for the research and development of CUE-401. Upon Ono’s exercise of its option to license CUE-401, the Company will receive an option exercise payment and be eligible for development and commercial milestone payments up to an aggregate of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">220</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, as well as tiered royalties on sales. Upon any such exercise, Ono will receive worldwide rights to develop and commercialize CUE-401, with the Company retaining a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% co-development and co-commercialization right in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Ono Collaboration and Option Agreement, the Company will perform research activities related to CUE-401 through a specified option period of 24 months (the “Research Term”). During this Research Term, the Company will be responsible for the execution of scientific investigation, nonclinical, preclinical, and clinical drug research and development activities designed to progress CUE-401 toward a potential IND and regulatory approval (such activities, collectively referred to as “R&amp;D”). Ono is responsible for the funding of R&amp;D activities performed by the Company. Per the agreement, as consideration for the R&amp;D activities performed by the Company, Ono (i) made a one-time, non-refundable, non-creditable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Company and (ii) will reimburse the Company for all costs incurred in conducting research, including (a) pass through costs from third party contractors and (b) full time employee salaries capped at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the first </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 </span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">months of the Research Term. The term of the Ono Collaboration and Option Agreement extends until the expiration of the Research Term which cannot exceed a 24-month period. The Company has forecasted that it will be able to complete the R&amp;D activities in 18 months based on the initial research and development plans it has established. The Company received the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront payment in March 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aside from the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront payment and funding related to pass through costs, the Company does not believe that any variable consideration should be included in the transaction price as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur. For the three months ended September 30, 2023 and 2022, the Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognized revenue of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,922,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ono Collaboration and Option Agreement. For the nine months ended September 30, 2023 and 2022, the Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognized revenue of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,426,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ono Collaboration and Option Agreement. The Company recorded short-term research and development liabilities on its balance sheet dated September 30, 2023, of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,238,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company did not recognize short or long-term research and development liabilities on its balance sheet as of December 31, 2022, as the agreement was executed in February 2023.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalization of Contract Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considered the capitalization of contract costs under the guidance in ASC 340-40, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Assets and Deferred Costs: Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As it related to the LG Chem Collaboration Agreement, the Company capitalized license expenses of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">908,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">paid to Einstein pursuant to the Einstein License Agreement which requires the Company to pay a percentage of sublicenses related to the Company’s patent rights for components of its core technology that is</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">licensed </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from Einstein. This amount is comprised of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">438,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of capitalized license expenses related to the up-front payment received from LG Chem in December 2018, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">313,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in capitalized license expenses related to the milestone payment received in June 2019, and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">157,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in capitalized license expenses related to the milestone payment received in December 2020, net of accumulated amortization</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on all capitalized license expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">908,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> capitalized license expenses net of accumulated amortization were included in prepaid expenses and other short-term assets related to the LG Chem Collaboration Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> 5000000 5000000 400000000 2500000 2500000 2500000 412500 1250000 1250000 1250000 206250 3000000 3000000 3000000 495000 6750000 178000 68000 243000 1094000 220000000 0.50 3000000 2100000 P18M 3000000 3000000 1922000 0 3426000 0 2238000 908000 438000 313000 157000 908000 0 0 <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Einstein License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2015, the Company entered into the Einstein License Agreement with Einstein for certain patent rights relating to the Company’s core technology platform for the engineering of biologics to control T cell activity, precision, immune-modulatory drug product candidates, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> supporting technologies that enable the discovery of costimulatory signaling molecules (ligands) and T cell targeting peptides. The Company entered into an amended and restated license agreement on July 31, 2017, as amended on October 2018, which modified certain obligations of the parties under the Einstein License Agreement. For each of the three months ended September 30, 2023 and 2022, the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f9ae109b-8f59-43ae-a21f-45f688059daf;"><span style="-sec-ix-hidden:F_13ebdb4b-55ed-428e-bdbd-75de4af8bb2a;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company incurred</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in fees and expenses to Einstein related to this license. For each of the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_eaf3a0ee-7c7e-4944-82f4-9d2f2fb60857;"><span style="-sec-ix-hidden:F_419ea3d6-3012-4518-be41-0780d8288eac;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company incurred</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in fees and expenses to Einstein related to this license.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s remaining commitments with respect to the Einstein License Agreement are based on the attainment of future milestones. The aggregate amount of milestone payments made under the Einstein License Agreement may equal up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.85</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each product, process or service that use the patents covered by the Einstein License Agreement, including certain technology received from Einstein related thereto (the "Licensed Product"), and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.85</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each new indication of a Licensed Product. Additionally, the aggregate amount of one-time milestone payments based on cumulative sales of all Licensed Products may equal up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company is also party to a material transfer agreement with Einstein focusing on infectious disease and assessing the application of the Company's Neo-STAT asset for the treatment of infectious disease.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with LG Chem</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See discussion of the LG Chem Collaboration Agreement in Note 9.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with Ono</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See discussion of the Ono Collaboration and Option Agreement in Note 9.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accrues contingent liabilities to the extent that the liability is probable and estimable. There are no accruals for contingent liabilities in the Company’s consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may be subject to various legal proceedings from time to time as part of its business. As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company was not a party to any legal proceedings or threatened legal proceedings, the adverse outcome of which, individually or in the aggregate, would have a material adverse effect on its business, financial condition or results of operations.</span></p> 2 0 0 0 0 1850000 1850000 5750000 <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Leases</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 28, 2022, the Company entered into a License Agreement (the “License”) with MIL 40G, LLC (the “Licensor”), pursuant to which the Company leases approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office, research and development and laboratory space located at 40 Guest Street, Boston, Massachusetts 02135 (the “Premises”). The Company relocated its corporate headquarters to the Premises in April 2022. On March 28, 2022, the Company terminated its office and lab space lease in Cambridge Massachusetts (the “Laboratory and Office Lease”) effective April 30, 2022. The Company performed an analysis of the accounting implications of this termination based on ASC 360 Impairments and Abandonments guidance. At March 31, 2022, the Company recorded an adjustment to decrease the right-of-use asset and lease liability of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,124,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,382,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and recorded a gain on right-of-use asset termination included in the consolidated statement of operations and other comprehensive loss of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">258,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized a right of use asset of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,056,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an operating lease liability of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,056,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which were recorded as of the Term Commencement Date (as defined below) related to the License.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the License commenced on April 15, 2022 (the “Term Commencement Date”) and expires on April 14, 2026 (the “Term”). The License has a monthly rental rate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">200,700</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the first year of the Term, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">208,728</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the second year of the Term, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">217,077</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the third year of the Term and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">225,760</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the remainder of the Term. Pursuant to the License, the Company prepaid two months of rent and a security deposit. The Licensor is obligated under the License to provide certain services to the Company, including providing certain gases, chemicals and equipment to the Premises’ laboratory space, IT support, security, office support and health and safety training. The Licensor has the right to terminate the License for Cause (as defined in the License).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 3, 2022, the Company entered into the First Amendment to the License ("First Amendment”) with the Licensor, pursuant to which the License was expanded to include an additional room effective July 15, 2022. In consideration of the First Amendment, the security deposit was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">225,760</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">235,884</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> effective July 15, 2022. Upon execution of the First Amendment, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. Effective July 15, 2022, the monthly rental rate under the First Amendment increased to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">209,700</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">200,700</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company recognized a right of use asset of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">369,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a short- and long-term operating lease liability of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100,300</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">260,600</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, using the weighted average discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, which were recorded as of the Term Commencement Date related to the License.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 31, 2022, the Company entered into an operating lease for additional laboratory space at 40 Guest Street, Boston, Massachusetts for the period from December 1, 2022 through December 1, 2024 (the “40G Additional Laboratory Lease”). The 40G Additional Laboratory Lease contains escalating payments during the lease period. The monthly rental rate under the 40G Additional Laboratory Lease is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59,152</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the first 12 months and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61,519</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the remainder of the term. Under the terms of this lease agreement, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. The Company recognized a right of use asset of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,307,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a short- and long-term operating lease liability of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">712,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">535,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, using the weighted average discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, which were recorded as of the Term Commencement Date related to the 40G Additional Laboratory Lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 9, 2022, the Company terminated its lab space lease in Cambridge, Massachusetts with MIL 21E, LLC with an effective termination date of December 6, 2022. The Company performed an analysis of the accounting implications of this termination based on ASC 360 Impairments and Abandonment guidance. The Company recorded an entry to remove the remaining lease liability and right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">963,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">945,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The difference between the carrying amounts of the right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was recorded at termination in September 2022, to gain on right of use asset and included in the consolidated statements of operations and other comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three and nine months ended September 30, 2023, the Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">402,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in non-cash interest expense to the lease liability. For the three and nine months ended September 30, 2022, the Company recorded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">146,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">309,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in non-cash interest expense to the lease liability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023, the Company recorded approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,060,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to operating lease right-of-use asset, and approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,399,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,855,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the short-term and long-term operating lease liability, respectively. At December 31, 2022, the Company recorded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,203,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to operating lease right-of-use asset, and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,300,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,018,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to short-term and long-term operating lease liability, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and December 31, 2022, a security deposit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">595,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was included in deposits on the Company’s consolidated balance sheet related to the 40G Additional Laboratory Lease. Cash was collected in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">199,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the Company's former Cambridge 21 Erie Laboratory space during the three and nine months ended </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the leases in effect at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.048%;"></td> <td style="width:2.101%;"></td> <td style="width:1%;"></td> <td style="width:15.852%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Year</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 (3 months remaining)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">835</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,368</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,799</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">818</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,820</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less: present value discount</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">566</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,254</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total rent expense of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">853,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">860,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was included in the consolidated statements of operations and other comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended September 30, 2023 and 2022, respectively. Total rent expense of approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,566,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,309,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was included in the consolidated statements of operations and other comprehensive loss for the nine months ended September 30, 2023 and 2022, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information pertaining to the Company’s operating leases for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 is summarized in the table below.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:68.602%;"></td> <td style="width:1.802%;"></td> <td style="width:1%;"></td> <td style="width:13.277999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:12.317%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Other information</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;text-indent:15pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating cash flows from operating leases (in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">709</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,064</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease cost (in thousands)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">853</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,566</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted average discount rate</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted average remaining lease term</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.39</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.39</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table></div> 13000 8124000 8382000 258000 9056000 9056000 200700 208728 217077 225760 225760 235884 209700 200700 369000 100300 260600 0.08 59152 61519 1307000 712000 535000 0.10 963000 945000 -19000 122000 402000 146000 309000 7060000 3399000 3855000 9203000 3300000 6018000 595000 595000 0 199000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the leases in effect at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.048%;"></td> <td style="width:2.101%;"></td> <td style="width:1%;"></td> <td style="width:15.852%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Year</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 (3 months remaining)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">835</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,368</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,799</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">818</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,820</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less: present value discount</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">566</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,254</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 835000 3368000 2799000 818000 7820000 566000 7254000 853000 860000 2566000 3309000 <span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information pertaining to the Company’s operating leases for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 is summarized in the table below.</span><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:68.602%;"></td> <td style="width:1.802%;"></td> <td style="width:1%;"></td> <td style="width:13.277999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:12.317%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Other information</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended<br/>September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended<br/>September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;text-indent:15pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating cash flows from operating leases (in thousands)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">709</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,064</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease cost (in thousands)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">853</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,566</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted average discount rate</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted average remaining lease term</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.39</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.39</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table> 709000 2064000 853000 2566000 0.0575 0.0575 P2Y4M20D P2Y4M20D EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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